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Metal-based compounds have been utilised as chemotherapeutic agents for the last four 
decades due to their well-documented and clinically relevant anti-tumour properties. Acquired 
resistance is a challenge for the clinical use of these compounds and there is a continuing need 
to search for potential new therapeutic agents. Herein, the potential of two metal-based 
compounds containing chelated 1,10-phenanthroline (1,10-Phen), one manganese-based 
(CMPD 73) and one copper-based (CMPD 74), to act as novel therapeutic agents is explored. 
 
CMPD 73 displayed high micromolar (IC50 >100µM) cytotoxic properties against various cell 
systems but interestingly displayed increased cytotoxicity against ovarian (A2780), lung 
(A549) and cisplatin resistant mesothelioma cells (IC50 40-50 µM). CMPD 74 was equally 
cytotoxic against all cell lines tested (IC50 <6µM), with this activity also preserved in the face 
of cisplatin resistance. In a cellular context, each compound was capable of generating reactive 
oxygen species (ROS) and through the use of small molecule ROS specific scavengers, 
superoxide was identified as the key mediator of compound cytotoxicity in both compounds. 
Several different modes of cell death were investigated for these compounds, with the apoptotic 
cell death pathway identified as the primary mechanism of cytotoxicity. Interestingly, evidence 
was uncovered of a direct involvement of superoxide in the effects of 1,10-Phen.   
 
Nuclease mimetic activity is common in 1,10-Phen based compounds, with DNA assumed as 
a primary target. Excellent nuclease mimetic activity against both DNA and RNA were 
observed for both studied compounds. However, no significant enhancement of cytotoxic 
action was observed following co-treatment with compounds known to enhance accessibility 
of genomic DNA. RNAse mimetic effects were visible under both in vitro and in cellulo 
conditions, where we explored a number of different PCR-based approaches to capture impacts 
 ii 
on RNA expression and integrity under sub-toxic conditions. The novel compounds also appear 
to activate ER-stress response pathways to a modest degree. Taken together these data are 
consistent with an impact of the compounds on cellular RNA, which – via the ER stress 
pathway - may represent a critical initiating factor in the cell death process.  
 
This work thus provides important insights into the potential molecular targets of metal-based 
compounds incorporating 1,10-phen, uncovers potential novel mechanisms of action and 
provides evidence that the observed effects are likely mediated by a broad ensemble of 
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1. Chapter 1 
 General introduction 
 Global Rates of cancer 
Fundamentally cancer is a disease which is a result of uncontrolled division of abnormal 
cells in a part of the body (Stratton, Campbell and Futreal, 2009). It affects millions of people 
globally and is one of the most intensely studied diseases of the modern age (Bray et al., 
2018). The Global Cancer Incidence, Mortality and Prevalence study (GLOBOCAN) 
estimated that in 2018, 9.6 million people died and 18.1 million new cases of cancer were 
diagnosed (ibid.). This number is expected to increase by 11.4 million new cases by 2040 to 
29.5 million (International Agency for Research on Cancer, 2019). The World Health 
Organisation estimates that 1 in 8 men and 1 in 11 women will die due to the disease (WHO, 
2018). Of the 18.1 million new cases, a list of the ten most diagnosed cancers can be seen in 
Table 1.1, with lung, colorectal, and breast most prevalent. Of the 9.6 million global fatalities 
recorded in 2018, lung cancer will be responsible for 1.8 million deaths (18.4%), colorectal 
cancer 881,000 deaths (9.2%), and breast cancer 627,000 deaths (6.6%)(WHO, 2018). 
 
Table 1.1-Top 10 cancers of 18.1 million new incidences  (International Agency for Research on 
Cancer, 2019) 












As highlighted in Table 1.2 and Figure 1.1, global cancer incidence and mortality vary 
significantly between developed and developing areas of the world. Much of this variation 
 2 
is explained by the population per region and, as a result of specific cultural and lifestyle 
practices, the prevalence of specific cancers, and the availability of sufficient treatment.  
 
Figure 1.1 Global incidence, mortality and 5-year survival rates per continental population. Self-
generated figure using data from (European Commission, 2018; GLOBOCAN-WHO, 2018b) and 
images widely available online. 
 
Despite only containing 9% of the global population, Europe accounts for 23.4% of cancer 
incidences and 20.3% global mortality (European Commission, 2018; GLOBOCAN-WHO, 
2018b). This is likely a result of sedentary lifestyle and poorer diet associated with western 
cultures (Deepa, 2016; Eschke et al., 2019).   
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Table 1.2-Global incidence, mortality and 5-year prevalence rates of cancer of both sexes 
Global incidence and mortality (%) of cancers 
Region Incidence Mortality 5-year Survival % of global population 
Europe 23.4 20.3 17.7 9.94 
North 
America 
13.2 7.3 18.5 7.79 
LAC* 7.8 7.0 7.6 5.68 
Asia 48.4 57.3 39.7 59.69 
Africa 5.8 7.3 4.4 16.36 
Oceania 1.4 0.73 2.1 0.54 
(*Latina America and Caribbean) (Ferlay et al., 2019) 
 
However the mortality rates among European countries are much lower when compared to 
more developing regions such as Asia or Africa, both of which have higher mortality rates 
compared to incidence. This is believed to be a result of higher rates of detection among 
European countries, compared to the frequency of cancers with poorer prognosis and limited 
access to cancer appropriate healthcare in developing regions of the world such as Africa 
and Asia (WHO, 2018).   
 
In Ireland, 30% of deaths (some 9,000 annually) are caused by cancer, with over 30,272 new 
cases reported in 2018. Ireland thus ranks third on the global scale of cancer with 373.7 per 
100,000, with men also ranking third for global cancer rates at 430.8 per 100,000, and 
women ranking seventh at 322.9 per 100,000 (Cancer statistics | Irish Cancer Society, 2018). 
The most common cancers diagnosed in both Ireland and in women and men are shown in 
Table 1.3, with skin cancers the most prevalent cancer diagnosed among the Irish population. 
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Table 1.3-Cancer statistics for the island of Ireland (2016-2018) 
Most common cancers in Ireland (2016-2018) 
Cancer Type Cases Deaths 
Skin  10,816 228 
Prostate 3,550 533 
Breast 3,244 659 
Bowel 2,767 942 
Lung 2,561 1,693 
Most common cancers in Irish Women  
Skin (Non-melanoma) 4,632 26 
Breast  3,215 649 
Gynaecological  1,321 502 
Lung 1,170 716 
Skin (melanoma) 581 60 
Most common cancers in Irish Men  
Skin (Non-melanoma) 6,184 57 
Prostate 4,976 585 
Bowel  1,752 535 
Lung 1,391 911 
Skin (melanoma) 529 85 
(Cancer statistics | Irish Cancer Society, 2018; GLOBOCAN-WHO, 2018a; HSE.ie, 2018). 
 
 Risk factors contributing to cancer development  
The loss of cell cycle control in response to oncogenic mutations is the main cause of cancer 
and can arise from various different stimuli, such as genetic predisposition and family 
history, infection, environmental factors and age (Blackadar, 2016; Aunan, Cho and Søreide, 
2017). Certain people can be born with various familial mutations that confer a 
predisposition to develop different cancers. A prime example is colon cancer linked with 
Adenomatous polyposis coli (APC) mutation. APC is a gene whose mutation is associated 
with a rare, hereditary form of colorectal cancer known as familial adenomatous polyposis 
(Schell et al., 2016).  
 
Age is one of the most significant factors for increasing the risk of developing cancer. Age 
and longevity increase the exposure time of a person to many of the carcinogenic factors 
described above, increasing the risk of DNA damage and mutations within the cell (Aunan, 
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Cho and Søreide, 2017). Further to this, the ends of chromosomes possess strands of DNA 
known as telomeres, which serve to protect from deterioration and fusion with neighbouring 
chromosomes and which are known to shorten after each cell division (Mcnally, Luncsford 
and Armanios, 2019). The progressive shortening of telomeres can result in loss of genomic 
integrity and chromosome instability, resulting in chromosomal fusions, translocations and 
mutations. As such age-associated telomere shortening has been associated as one of the 
primary risk factors for the development of oncogenesis and neoplasia (Jafri et al., 2016).   
 
Many different infectious agents are responsible for the development of cancers. Two of the 
best known are Helicobacter pylori (H. pylori) and Human Papilloma Virus (HPV). 
Helicobacter pylori, a gastric bacterial pathogen, is the strongest known risk for gastric 
cancer. H. pylori causes gastric ulcers stimulating chronic inflammation (Wroblewski, Peek 
and Wilson, 2010). Chronic inflammation has been identified as a major cause of cancer and 
metastatic cancer development (Todoric, Antonucci and Karin, 2016). Another form of 
carcinogenic infection is infection by HPV and the generation of cervical cancers (Brianti, 
De Flammineis and Mercuri, 2017). HPV infection has been strongly associated with the 
development of squamous cell carcinomas of the cervix (Chan et al., 2019). 
 
A multitude of environmental factors have been associated with the prevalence of cancer via 
the chronic entry, ingestion, or inhalation of carcinogenic agents into the body, as well as 
exposure to high levels of radiation e.g. UV radiation from the sun (Parsa, 2012). Many are 
associated with poor lifestyle choices, such as colorectal cancer and its link to poor diet and 
low physical activity (Thanikachalam and Khan, 2019). Poor diet and low levels of exercise 
are also strongly associated with obesity, with obesity being identified as a significant risk 
of developing many different cancers (e.g. colorectal, breast, and oesophageal cancers) 
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(Stone, McPherson and Gail Darlington, 2018). Further to this the link between smoking and 
lung cancer (O’Keeffe et al., 2018), and high alcohol consumption and liver cancer (Testino, 
Leone and Borro, 2014) has been known for decades.   
 
Other environmental factors include occupational exposure to carcinogens such as asbestos 
in the development of mesothelioma in construction workers (discussed in detail in Chapter 
4 page 123) (Matsuzaki et al., 2012) or exposure to dichlorodiphenyltrichloroethane (DDT) 
in pesticides and the development of breast cancer (Alavanja and Bonner, 2012). Exposure 
to high levels of UV radiation is a well-established risk factor for a variety of different skin 
cancers (Narayanan, Saladi and Fox, 2010).  
 
 These various genetic, pathogenic, environmental and age-related factors described will 
result in the accumulation of multiple mutagenic alterations capable of changing normal cell 
processes and initiating cancer development. These alterations are known as the hallmarks 
of cancer.  
 
 Hallmarks of cancer 
The primary hallmarks of cancer are genetic and epigenetic reprogramming to facilitate 
sustained proliferative signalling and enabling replicative immortality; evasion of growth 
suppressors and resisting cell death; induction of angiogenesis and metastasis; metabolic 
reprogramming and alteration of the surrounding microenvironment; and evading the host 
immune system (Hanahan and Weinberg, 2011; Fouad and Aanei, 2017).  
 
Cells maintain homeostasis by tightly regulating and coordinating the expression and release 
of growth promoting signals and the expression and release of regulatory proteins controlling 
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cell proliferation(reviewed by Lee & Young, 2013). It has been established that oncogenic 
cells alter these regulatory pathways through accumulation of somatic mutations, causing 
hyper activation of growth promoting signals and silencing of regulatory networks, allowing 
dysregulated and uncontrolled growth outside the confines of homeostasis (Sanchez-Vega 
et al., 2018).  
 
A classic example of this form of gene dysregulation is seen in the over activation of the 
oncogene coding for the Ras GTPase family (HRas, KRas, NRas) , which serves as a 
signalling protein to activate downstream mitogen-activated protein kinases (MAPK) and 
phosphoinositide-3 kinase (PI3K) pathways, regulating genes involved in cell growth, 
differentiation and survival (Fernández-Medarde and Santos, 2011). The Ras protein has 
been shown to be chronically active in 30% of cancers, due to an activating mutation in the 
Ras coding sequence or a deactivating mutation in its suppressive protein NF1 (Csermely, 
Korcsmáros and Nussinov, 2016). MAPK and PI3K pathways have also been seen to be 
dysregulated in many cancers as a result of a somatic mutation (see review Zenonos, 2013). 
Cancer cells also hijack Telomerase enzymes to become immortalised and replicate 
endlessly (Jafri et al., 2016). Telomerase activity is almost non-existent in non-immortalised 
cells but is significantly upregulated in almost 90% of human tumours. The increase in the 
expression of telomerases liberates cancer cells from the confines of regulation mediated by 
telomere length  (reviewed Hanahan & Weinberg, 2011).  
 
To maintain this sustained growth signalling, inhibition of tumour suppressor proteins which 
regulate oncogenes and cell proliferation is required to maintain sustained pro-growth 
signalling (Wang et al., 2019). Commonly inactivated TSPs include the Retinoblastoma 
(RB1) protein, APC and Tumour Protein 53 (TP53) (Sun and Yang, 2010). RB1 inhibits the 
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transcription of mitotic genes by forming inhibitory complexes with transcription factors 
such as E2F, which positively regulates cyclins and cyclin-dependent kinases promoting G1-
S phase transitions (Burke, Hura and Rubin, 2012). Inactive RB1 leads to uncontrolled 
expression of cell cycle activating genes ultimately leading to the development of 
retinoblastoma, a rare form of hereditary eye cancer predominantly diagnosed in children 
(Pandey, 2014).  
 
The APC protein negatively regulates the Wnt signalling pathway which is responsible for 
cell proliferation and differentiation in the gastrointestinal tract (Flanagan et al., 2018). Wnt 
signalling causes downstream transcriptional expression of cyclin D1 and the oncogenic 
Myc proteins and aberrant regulation of the Wnt signalling pathway can result in increased 
mitotic activity and neoplasia (reviewed by Zhang & Shay, 2017). Similar to RB1 
inactivation, inactivation of the APC gene by germline mutation is responsible for hereditary 
APC, while somatic mutations of the gene are found in more than 80% of sporadic colorectal 
cancers.  
 
TP53, also known as the guardian of the genome, has been seen to be mutated or altered in 
almost 50% of all tumours (Ozaki and Nakagawara, 2011). The p53 protein acts as a master 
TSP by regulating dozens of target genes responsible for regulating DNA repair such as 
GADD45 (Salvador, Brown-Clay and Fornace, 2013), cell cycle arrest via p21 and apoptosis 
by upregulating the expression of pro-apoptotic proteins such as Bax, Apaf1, PUMA and 
Noxa (Aubrey et al., 2018). As p53 is so intrinsically linked with maintaining cell growth 
and apoptotic homeostasis, its inactivation via deletion or overexpression of regulatory 
inhibitors such as MDM2, would naturally lead to dysregulated cell growth and reduced 
regulatory mechanisms (Lozano, 2019). Conversely, cancer cells can increase the expression 
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of anti-apoptotic proteins, reducing the capacity of apoptotic control over the cell, favouring 
growth and division  (Timucin, Basaga and Kutuk, 2019). 
 
Epigenetic reprogramming refers to the chemical signature found on genes and their 
associated histones which can rapidly regulate gene expression. This is a process heavily 
implicated in cancer initiation, progression, and development of chemotherapy resistance, 
and is discussed in further detail in Chapter 3. 
 
In addition, for cancer cell subpopulations to continue growing and proliferate, cells must 
develop new vascular networks to facilitate the continually growing mass of cells, a process 
known as angiogenesis (Rajabi and Mousa, 2017). Angiogenesis is regulated by oxygen 
sensitive angiogenic factors which are harnessed by cancer cells to drive the formation of 
new endothelial cells from existing vasculature to support the growth of the tumour (Fraisl 
et al., 2009).  One of the predominant pro-angiogenic signalling pathways is regulated by 
the hypoxia-inducible transcription factor (HIF) family (Krock, Skuli and Simon, 2011). The 
tumour microenvironment (TME) is generally hypoxic in nature as a result numerous cancer 
cells forming a thick three-dimensional tumour structure (Watnick, 2012). HIF proteins are 
normally activated by hypoxic conditions to maintain homeostasis in the wound healing 
process, however the hypoxic conditions of the TME can also trigger its activation. This then 
triggers the transcription of pro-angiogenic factors such a Vascular Endothelial Growth 
Factor (VEGF) and genes involved in cell survival, metabolism and inflammation 
(Hashimoto and Shibasaki, 2015). VEGF has been identified as the most potent factor 
initiating angiogenesis, and is overexpressed in most metastatic tumours (Carmeliet, 2005). 
VEGF stimulates angiogenesis by promoting proliferation and survival of nearby endothelial 
cells, increasing the permeability of surrounding blood vessels and recruiting vascular 
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precursor cells form the bone marrow (Yang, Yan and Liu, 2018). Permeable or ‘’leaky’’ 
blood vessels are capable of irrigating solid tumour cells promoting survival (Azzi, Hebda 
and Gavard, 2013), as well as promoting metastasis by providing an accessible framework 
for the entry of metastatic cells into the blood stream (Bielenberg and Zetter, 2015). 
 
The ability of cancer to metastasise and invade surrounding tissue, forming secondary sites 
of growth, is a defining feature of malignancy. Metastatic disease is responsible for over 
90% of cancer associated deaths (Seyfried and Huysentruyt, 2013). To metastasise cancer 
cells must first penetrate the extracellular matrix (ECM) of surrounding tissue, intravasate 
tumour vasculature, extravasate the blood vessels of distant organs and tissues, and 
sufficiently proliferate and grow to form new tumour colonies and reform the TME (Seyfried 
and Huysentruyt, 2013).  
 
For immotile and tightly adherent epithelial and carcinoma cells to escape the ECM, they 
must undergo the Epithelial-Mesenchymal Transition (EMT). This entails the transition of 
an epithelial like cell into that of a mesenchymal cell by replacing epithelial associated 
proteins such as the cell surface protein E-Cadherin for mesenchymal N-Cadherin resulting 
in detachment of the cell from the basal membrane (Mallini et al., 2014). In addition, the 
expression of matrix metalloproteases (MMPs), which are increased in almost all cancers, 
facilitates the degradation of the ECM and allows metastatic cells to escape from their site 
of origin into blood vessels (Gialeli, Theocharis and Karamanos, 2011).  
 
Extravasation of cells from the circulation into tissue(s) requires reversal of the EMT process 
which permits re-expression of the proteins needed to anchor the tumour cells to the new 
tissue site (Cominetti, Altei and Selistre-De-araujo, 2019). Some organs such as the liver or 
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bone marrow possess highly permeable vessels, and as such may explain the high rates of 
metastatic cancer that migrates to these tissues (Lorusso and Rüegg, 2012). Once the 
invading tumour cells have colonised a foreign tissue, they either enter a state of quiescence 
to allow adaptation to their new environment or initiate angiogenesis to facilitate growth and 
survival and establish a new TME (Fouad and Aanei, 2017). 
 
To facilitate the high-energy requirements that these hallmarks demand, cancer cells rewire 
their metabolic and epigenetic programming to quickly adapt to multiple new stimuli and 
provide a selective advantage during the initiation and progression of oncogenesis. Much of 
these metabolic changes are a result of selective pressure by the relatively harsh TME and 
hypoxia (Pavlova and Thompson, 2016). Cancer cell metabolism is adapted to the specific 
tumour microenvironment and a broad number of metabolic alterations have been described 
(Pinheiro et al., 2015; Liberti and Locasale, 2016; Camara et al., 2017; Waldhart et al., 
2017). However, reliance on aerobic glycolysis is a commonly encountered feature of cancer 
cells, and is known as the Warburg effect (DeBerardinis and Chandel, 2016). The Warburg 
effect, first proposed by Otto Warburg in the 1920’s, is the effect whereby cancer cells alter 
their metabolic state to favour anaerobic glycolysis as its main source of ATP production 
over that of oxidative phosphorylation and the Tricarboxylic Acid Cycle (TCA), despite the 
presence of available oxygen (Epstein, Gatenby and Brown, 2017).  
 
Altered metabolic pathways in cancer cells can also generate what are known as 
oncometabolites, metabolic intermediates which further oncogenic processes. An example 
of this is the production of 2-hydroxyglutarate (2HG) via a mutation in Succinate 
Dehydrogenase (SDH) (Wong, Qian and Yu, 2017). 2HG is a competitive inhibitor of many 
α-Keto Glutarate (α-KG) dependent enzymes. α-KG is an essential co-factor for DNA 
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demethylases, epigenetic enzymes involved in the removal of gene silencing methyl 
modifications on DNA and gene promoters (Tran, Lowman and Kong, 2017). The loss of 
demethylase activity results in hypermethylated gene promoters, with hyper methylation of 
TSP gene promoters seen as a hallmark of epigenetic cancer progression (Lewandowska and 
Bartoszek, 2011).  
 
Metabolic reprogramming can also influence the survival of surrounding cells in the TME 
as well as cancer cells themselves (Sun et al., 2018). The TME is both a consequence and 
driver of oncogenesis, with both acting in regulatory loops influencing the other (Ribeiro 
Franco et al., 2020). As previously noted, a hallmark of the TME for solid tumours is hypoxia 
and the initiation of HIF and VEGF mediated angiogenesis (Carmeliet, 2005; Krock, Skuli 
and Simon, 2011). Fluctuating hypoxic conditions can also stimulate oxidative stress, which 
may induce further genetic mutations in cancer cell DNA, facilitating further oncogenic 
transformations (Wang, Zhang and Chen, 2019). 
 
The TME consists of tumour cells, non-tumour cells such as cancer associated fibroblasts 
CAFs), endothelial cells and pericytes (contractile capillary associated cells), immune and 
inflammatory cells, bone marrow derived cells, and the ECM (Belli et al., 2018). The 
interactions between the cells of the TME contribute to oncogenesis through the release of 
paracrine signals such as growth factors, chemokines, cytokines and matrix remodelling 
enzymes, facilitating the initiation, propagation and progression of cancer cells (Balkwill, 
Capasso and Hagemann, 2012). For further reviews on the TME, see Peltanova, Raudenska, 
& Masarik, (2019), Balkwill et al., (2012), and Belli et al., (2018). 
 
 13 
Finally in order to ensure the survival of tumour cells, the evasion of the host immune system 
is required (Nicolini et al., 2018). The innate and the adaptive immune systems can recognise 
and eradicate developing tumour cells in response to the expression of certain extracellular 
markers or induction of functional apoptotic signalling (Swann and Smyth, 2007). 
Circulating cancer cells which have metastasised are particularly susceptible to immune 
surveillance and clearance (Leone, Poggiana and Zamarchi, 2018). However constant 
immune surveillance can confer selective pressure on tumour cells and generate 
subpopulations capable of immune evasion, a process termed cancer immune-editing (Mittal 
et al., 2014). Cancer immune-editing allows cancer cells to escape immunosurveillance by 
reducing the expression of antigenic receptors required for T-cell recognition, resistance to 
cell death, and induction of immuno-tolerance via expression and secretion of 
immunosuppressive cytokines by tumour cells themselves, or stromal cells from the 
surrounding TME (Fouad and Aanei, 2017).  
 
Macrophages recruited into the TME are known as Tumour Associated Macrophages 
(TAMs) (Dehne et al., 2017). TAMs favour tumour growth by further suppression of the 
immune system via cytokine release and through the promotion of angiogenesis via VEGF 
secretion (Ostuni et al., 2015). High levels of TAMs in the TME have been associated with 
poor prognosis and survival rates in breast cancer (Zhao et al., 2017). For further reading on 
tumour immune evasion, see reviews by Chen et al., 2019, Hinshaw and Shevde, 2019, Lin, 




To combat the vast numbers of different cancers, clinicians have developed multiple 
treatment regimens targeting various oncogenic pathways, using chemical, radiological and 
immunological strategies.  
 
One of the most effective chemotherapeutic drugs identified to date is cis-dichloro-
diammineplatinum (II), commonly known as cisplatin (reviewed by McKeage, Higgins and 
Kelland, 1991). Cisplatin was first synthesised in 1844 by the Italian chemist Michele 
Peyrone, however its potential as an anti-bacterial and anti-cancer agent would not be 
realised for another 120 years (Peyrone, 1844; Rosenberg, Van Camp and Krigas, 1965; 
Desoize and Madoulet, 2002).  
 
In 1965 it was first identified as an antibacterial agent by Barnett Rosenberg who 
inadvertently discovered that cisplatin as a complex was generated by electrolysis of 
platinum electrodes and that it was capable of inhibiting cell division in Escherichia coli 
bacteria (Rosenberg, Van Camp and Krigas, 1965; Rosenberg et al., 1967). Rosenberg then 
hypothesised that cisplatin would have similar effects in cancer cells. This was indeed the 
case with cisplatin demonstrating anti-tumour activity against sarcoma and leukaemia 
tumours generated in mice (Rosenberg et al., 1969; Rosenberg, 1971).  
 
Cisplatin showed great success in the treatment of testicular cancer, which until then had 
extremely limited treatment options (Einhorn and Donohue, 1977). Following approval by 
the Food and Drug Administration (FDA) in 1978, it was quickly deployed as a cancer 
therapy (reviewed by Kelland, 2007). In 1979 cisplatin was granted approval in the UK and 
several other EU countries (Ghosh, 2019). Following initial clinical success cisplatin was 
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granted further FDA approval to be used in the treatment of advanced ovarian and bladder 
cancer (Higby et al., 1974; Carter, 1984; Lambert and Berry, 1985). In contemporary clinical 
practice, cisplatin remains effective as a frontline chemotherapeutic against a broad spectrum 
of cancers, including head and neck, colorectal, lymphomas, ovarian, mesothelioma and lung 
cancers (reviewed by Galluzzi et al., 2014). Until the discovery of cisplatin as an anti-cancer 
agent in 1965 most anti-cancer treatments used were organic based compounds (Rosenberg, 
1971). The discovery of cisplatin prompted wide-spread investigation into other metal-
containing and inorganic compounds as potential anti-cancer drugs (Makovec and Makovec, 
2019).  
 
 Biochemistry of cisplatin – the canonical metal-based chemotherapeutic 
Cisplatin is a metallic coordination compound consisting of a doubly charged platinum core 
with four ligands – two cis chloride ligands and two amino ligands (Figure 1.2).  
 
 
Figure 1.2-The structure of Cisplatin and Transplatin.  The cis and trans configuration of the 
chloride ligands is evident 
 
In the extracellular space where chloride concentration is high (100mM), the chloride ligands 
are considered to be stable for cisplatin chemistry (Makovec and Makovec, 2019). However, 
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upon entry into the cell where chloride concentration is relatively low (2-10mM), cisplatin 
undergoes two important steps of hydrolysis, whereby the chloride ions are sequentially 
replaced with two water molecules (see Figure 1.3 below)(reviewed Galluzzi et al., 2014). 
These hydrolytic steps are important for the activation of cisplatin, as each water molecule 
can, in turn, be lost. This process leads to the formation of a potent electrophile which can 
attack various biomolecules, including the purine bases of DNA (Goodsell, 2006). Upon 
interaction with DNA, the formation of both intra- and inter-strand cross-links can cause 
double strand breaks (DSB), interfering with both cell division and transcriptional processes 
(reviewed Rocha, Silva, Quinet, Cabral-Neto, & Menck, 2018). DBSs induce cellular DNA 
damage response (DDR) pathways which ultimately culminate in the induction of apoptosis 
(Ghosh, 2019). 
 
Cisplatin has also been seen to target mitochondrial DNA (mtDNA), disrupting 
mitochondrial integrity further capable of activating apoptosis (Yimit et al., 2019). Cisplatin 
is thus more effective in cells that have less efficient DNA repair mechanisms (e.g. 
testis)(Rocha et al., 2018). Although the exact mechanism of cisplatin has not been fully 
defined and is still actively studied, apoptosis secondary to DNA damage is thought to play 
a central role (Makovec and Makovec, 2019). Cisplatin has also been observed to generate 
reactive oxygen species which are capable of triggering apoptosis, likely further contributing 





Figure 1.3-Activation of cisplatin.  Stepwise hydrolysis of structural chloride ions facilitates DNA 
attack. Self-generated figure using Microsoft PowerPoint and images widely available online. 
 
However, treatment with cisplatin does have its limitations - nephrotoxicity, hepatotoxicity 
and ototoxicity are seen in most cases. In addition, high rates of cancer relapse due to the 
development of acquired resistance is common (Ferreira et al., 2016). Similar effects are 
seen with cisplatin derivatives carboplatin and oxaliplatin, which offer only limited variation 
in their mechanistic scope (Deo et al., 2016). 
 
 Mechanisms of Cancer resistance 
Despite many major advances in treating a multitude of cancers, the prevalence of cancer 
resistance and cancer relapse is still a major cause of mortality worldwide (Butow et al., 
2018). As such determining the mechanisms driving the development of cancer resistance 
has been the focus of many studies over the last few decades (Wang et al., 2017). The 
primary hallmarks of cancer resistance are the presence of intrinsically resistant and 
quiescent cell populations, tumour heterogeneity, increased drug efflux, overexpression and 
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activation of anti-oxidant systems and drug inactivation, alteration of drug target, increased 
DNA repair and decreased cell death mechanisms, influence of the TME, and epigenetic 
alterations (Housman et al., 2014; Mansoori et al., 2017; Wang, Zhang and Chen, 2019). 
 
Resistant phenotypes exist intrinsically within the tumour population or are acquired 
following therapy driven alterations (Wang, Zhang and Chen, 2019). Intrinsic resistance to 
chemotherapy is generally associated with a sub-population of tumour cells, known as 
Cancer Stem Cells (CSC) (Vinogradov, Wei and Thor, 2013).  
 
CSCs are cancer cells with stem cell like features such as the capacity for self-renewal and 
differentiation (Shukla and Meeran, 2014). These are considered to be tumour initiating 
cells, feeding the generation of new tumour bulk cells for long term population and are 
typically intrinsically resistant to chemotherapy (Borovski et al., 2011). In addition to 
possessing efficient DNA repair mechanisms and resistance to apoptosis, CSC appear to 
have slow cell cycle kinetics and thus exist in a state of quiescent dormancy. This reduces 
the cytotoxic capacity of chemotherapy drugs such as cisplatin which relies on cell cycle 
checkpoints to detect damaged DNA and initiate cell death (Chen, Huang and Chen, 2013).  
 
The current consensus is that treatment with chemotherapeutic drugs (e.g. cisplatin) is 
efficient at initially killing sensitive tumour bulk cells, but the inherently resistant CSC sub-
populations survive this initial treatment. This leads to an enrichment of CSC and propagates 
a resistant phenotype (Ayob and Ramasamy, 2018). Indeed both lung and ovarian CSCs 
were seen to be enriched following treatment with cisplatin, increasing overall tumour 
burden (Jiang et al., 2013; Wang, Jin and Wang, 2014). 
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Tumour heterogeneity confers different degrees of drug sensitivity across the different cell 
populations that make up the tumour. Four levels of heterogeneity exist among tumour cells: 
genetic, cell type (e.g. tumour bulk cells, CSCs, TAMs), metabolic and temporal (Chen, Qian 
and Wu, 2015). Genetic heterogeneity is well documented in ovarian, breast and renal cell 
carcinoma (see reference 100, 101, 102 X. Wang et al., 2019).  The varying degrees of drug 
sensitivity and resistance against chemotherapeutic agents makes killing all sub-populations 
of tumour cells quite difficult using a single chemotherapy agent (Baxevanis, Perez and 
Papamichail, 2009). As such tumour heterogeneity has prompted the development of 
combinatorial drug therapies to target multiple sub-populations of tumour cells (Al-
Lazikani, Banerji and Workman, 2012). 
 
The effective concentrations in which cisplatin and other chemotherapeutics are required for 
cytotoxicity are highly dependent on the intracellular concentrations of the drug. Both the 
influx and efflux of cisplatin can be altered in cisplatin resistant cells (Mansoori et al., 2017). 
Uptake of cisplatin into the cell appears to be mediated by Copper Transporter Protein 1 
(CTR1). Cisplatin resistant cells have been shown to downregulate the expression of CTR1 
and so decrease cellular uptake of cisplatin (Ibrahim, Srivenugopal and Rasul, 2013).  
 
Increased efflux of cisplatin and other chemotherapy agents via overexpression of the ATP-
Binding Cassette (ABC) transmembrane transporter superfamily is another mechanism 
through which intracellular cisplatin concentration can be reduced (Zahreddine and Borden, 
2013). The ABC family is made up of ABC transporters ranging from ABC A-G (Sodani et 
al., 2012). Much of this superfamily has been implicated with intrinsic resistance in kidney, 
lung, liver, colon, rectal and ovarian cancers, while overexpression in response to acquired 
 20 
cisplatin resistance has been associated with lung, breast and prostate cancers (Holohan et 
al., 2013).  
 
Specific members of the ABC transporter family namely the ABCB family have been termed 
Multi-Drug Resistant proteins (MDR). MDR1 has been shown to be responsible for 
removing a wide variety of anticancer agents from the cell, such as camptothecin, 
carboplatin, cisplatin, doxorubicin and methotrexate (Katayama, Noguchi and Sugimoto, 
2014). MDRs 1, 2, 3, and 5 have specifically been implicated in the resistance towards 
cisplatin. MDR1 is also capable of pumping out compounds conjugated to glutathione 
antioxidant peptides, such as glutathione-conjugated chemotherapy agents (Chen and 
Tiwari, 2011). Other members of the ABC transporter family such as ABCG2 are found to 
be overexpressed in certain cancer cells such as breast CSCs, potentially contributing to their 
inherent resistance (Westover and Li, 2015). 
 
Cancer cells may also inactivate chemotherapy drugs via increased expression of antioxidant 
mechanisms. Platinum compounds such as cisplatin or carboplatin have been demonstrated 
to have a high affinity towards thiol groups, with many antioxidant defence peptides, 
enzymes and metallothioneins possessing cysteine rich thiol groups (Wong and Stillman, 
2018). As such platinum compounds are subject to antioxidant deactivation by glutathione, 
glutathione-S-transferase and metallothionein overexpression (De Luca et al., 2019). As 
noted above, glutathione conjugated compounds are susceptible to efflux from the cell via 
MDR family proteins. Indeed MDR overexpression has been seen to correlate with 
significantly enhanced expression of glutathione and antioxidant proteins (Lopes-Rodrigues 
et al., 2017). Antioxidant defence overexpression can also reduce the cytotoxic potential of 
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drugs that utilise the generation of reactive oxygen (ROS) or reactive nitrogen (RNS) species 
(discussed section 1.2.4). 
 
Chemotherapy can promote the survival of cancer cells via selective pressures to increase 
the number of cancer cells capable of altering the intracellular drug targets. Resistance 
generating mutations have been seen with the use of topoisomerase inhibitors such as 
doxorubicin, or human epidermal growth factor receptor 2 inhibitors, such as Herceptin (Cox 
and Weinman, 2016; Luque-Cabal et al., 2016). Following long term use, resistant cells are 
selected which carry structural mutations in the targets of these inhibitors or display reduced 
expression of the drug target to favour an alternate oncogenic pathway. This results in loss 
of drug target specificity and the development of resistance (Housman et al., 2014).   
 
The initiation of cancer can be a consequence of defective, or epigenetically/genetically 
silenced DNA repair mechanisms (Lahtz and Pfeifer, 2011). Cancer cells can increase their 
DNA repair capacity by increasing the expression of DNA repair enzymes (Salehan and 
Morse, 2013). However, following chemotherapeutic intervention, some cancer cells can 
induce epigenetic or genetic reversion and re-express DNA repair proteins in order to repair 
damage from DNA targeting chemotherapy drugs, such as cisplatin (Ashworth, 2008). 
Genetic reversion of BRCA1 and BRCA2 genes has been seen in the development of cisplatin 
resistant cells, which were originally cisplatin sensitive as a result of BRCA1/2 silencing 
(Afghahi et al., 2017). BRCA1 overexpression has also been documented in cisplatin 




The overexpression of Nucleotide Excision Repair (NER) proteins has been associated with 
reduced sensitivity to cisplatin, as NER is the most efficient DNA repair system to remove 
cisplatin-DNA adducts and crosslinks. The mismatch repair (MMR) proteins MSH2 and 
MSH3 can also recognise cisplatin-DNA lesions, which if too numerous can signal apoptotic 
proteins to kill the cell. Thus inactivation of the MMR machinery (e.g. via mutations) has 
been seen in cisplatin resistance (Drummond et al., 1996). 
 
Epigenetic alterations promote cancer resistance by facilitating rapid adaptation to cytotoxic 
agents through dynamic alterations in gene expression (Easwaran. Hariharan, 2014). 
Epigenetic alterations and cancer resistance are discussed in further detail in Chapter 3. 
 
The TME of solid tumours plays a pivotal role in mediating cisplatin and chemotherapy 
resistance. Primarily it acts as a physical barrier protecting the tumour initiating cells found 
at the core of most solid tumour masses (Son et al., 2017). The vasculature surrounding the 
TME mediated by dysregulated angiogenesis is generally poorly differentiated and truncated 
in nature, delivering suboptimal concentrations of chemotherapy drugs to the tumour bulk 
(Narang and Varia, 2011). 
 
Overexpression of HIF family of transcription factors, particularly HIF1α, has also been 
associated with cisplatin and chemotherapy resistance. HIF1α can induce mitophagy, 
mitochondrial degradation via autophagy to adapt to hypoxic stress (Zhang et al., 2008). As 
the mitochondria is essential for the intrinsic apoptotic pathway, reduced mitochondrial 
presence results in reduced apoptotic capacity of cisplatin (ibid.). HIF1α-associated cisplatin 
resistance has been reported in ovarian and colon cancer (Lv et al., 2015; Bu et al., 2019). 
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 The use of transition metals in anti-cancer treatments: 
Metal-based drugs have been essential to chemotherapy since the development of cisplatin 
as a clinically effective therapeutic and the generation of its platinum analogues carboplatin 
and oxaliplatin (Garbutcheon-Singh et al., 2011). The prevalence of cisplatin resistance and 
limited effectiveness of carboplatin and oxaliplatin have led to the development of novel 
metal-based complexes to bolster current therapies (Johnstone, Park and Lippard, 2014). 
 
Metal complexes offer unique therapeutic potential in cancer therapy as they exhibit many 
advantageous characteristics, such as redox activity, variable coordination modes and 
reactivity towards multiple organic substrates. These attributes make metal-based drugs an 
attractive probe for development of novel compounds targeting specific cellular pathways, 
such as DNA, mitochondria and cell proliferation pathways (Ndagi, Mhlongo and Soliman, 
2017). As metal homeostasis is tightly regulated detrimental effects typically occur upon 
disruption. As such targeting metal homeostasis using metal-based chemotherapeutics is a 
lucrative target. 
 
A plethora of potential metal-based drugs have been synthesised over recent decades, many 
of which show promise as anti-cancer agents and have undergone clinical trials. For a full 
list of these novel metal compounds see Ndagi, Mhlongo and Soliman, 2017. Compounds 
utilising redox active transition metals such as iron have gained significant interest. However 
research into other redox active metals such as copper and manganese has also gained 
traction  (Kellett et al., 2011; Prisecaru et al., 2012; Slator et al., 2017, 2018; Zhang et al., 
2017; Rochford, 2018). A full understanding of the current understanding of the potential 
modes of action of metal-based drugs is only possible in the context of their redox activities. 
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 Cellular redox homeostasis 
Reactive Oxygen and Reactive Nitrogen Species (ROS, RNS) are important molecules in 
both physiological and pathophysiological cell processes (Ortega, Mena and Estrela, 2010). 
They can come in either free radical or non-radical forms and possess strong oxidising 
properties or the potential to generate strong oxidant properties. Free radicals are atoms or 
molecules with a single unpaired electron, which are highly reactive and unstable (Rahman, 
2007), and can react with many biomolecules such as proteins, lipids or nucleic acids 
(Sharma et al., 2012). Free radicals are by-products of cell metabolism in both the normal 
and disease states, and metabolites of xenobiotic compounds (Ray, Huang and Tsuji, 2012). 
Organisms utilising oxygen metabolism must, therefore, contend with the potential side 
effects of reactive radical species. Oxygen itself is a bi-radical and can react with various 
metal ions and biological molecules resulting in almost certain oxidation (Cadet and Davies, 
2017).  
 
Interaction between ROS and biomolecules found within a cell such as DNA, proteins or 
lipids will result in their oxidation. Such oxidation can alter molecular structure of proteins 
inhibiting enzymes, compromise cell integrity through lipid peroxidation of cell and 
organelle membranes, or lead to single or double strand lesions in DNA, potentially leading 
to deleterious gene mutations (Phaniendra, Jestadi and Periyasamy, 2015). Sophisticated 
antioxidant defence systems (including both small molecules and enzymes) are employed 
by cells to maintain redox homeostasis (Basria S.M.N. Mydin and Okekpa, 2019). Oxidative 
stress is defined as the imbalance of these two systems, resulting in cell damage, death and 
disease  (Betteridge, 2000; Ghosh et al., 2018). Indeed, oxidative stress has been implicated 
as a driving factor in many diseases such as cancer, diabetes, atherosclerosis, hypertension, 
and neurological disorders such as Parkinson’s disease, dementia, and Alzheimer’s disease 
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(Liguori et al., 2018). The production of such radicals in disease can act as a double-edged 
sword however, as the utilisation of radical generating compounds as anti-cancer agents has 
been implemented for many decades (Takeshima, Kuroda and Yumura, 2019). 
 
As noted above, sources of free radicals can be biological, generated as by-products of both 
normal and abnormal metabolism, immune cell generated, or exogenous agents such as 
xenobiotic compounds with high oxidising potential (Tiwari, Hasan and Islam, 2013). Cell-
based sources of free radicals are predominantly generated by the oxidation of molecular 
oxygen, generating ROS and or RNS. ROS or RNS can be either radical or non-radical, with 
non-radical forms still possessing the potential to later form free radicals (Kehrer and 
Robertson, 2010). During normal cell metabolism, molecular oxygen is used by the Electron 
Transport Chain (ETC) to generate adenosine triphosphate (ATP), whereby oxygen is 
reduced into water as the end-point reaction. As the ETC does not operate with 100% 
efficiency small amounts of electrons can leak out of the chain where it can oxidise oxygen 
and form ROS (Li et al., 2013). Alongside the ETC, another predominant source of 
ROS/RNS are the phagocytic immune cells such as neutrophils or macrophages, which 
generate ROS and RNS as part of a respiratory burst, to eliminate phagocytosed pathogens 
such as bacteria or virally infected cells (Thomas, 2017).  
 
The forms of ROS produced in the cell that are of interest for this study are hydrogen 
peroxide (H2O2), the hydroxyl radical (OH
•), the superoxide anion (O2
•-), singlet oxygen 
(1O2), and the peroxyl radical (ROO
•) (Tiwari, Hasan and Islam, 2013). The main forms of 
RNS relevant to this study and are produced intracellularly are nitric oxide (NO•) and 
peroxynitrite (ONOO-) (Adams, Franco and Estevez, 2015). 
 
 26 
 Hydrogen Peroxide (H2O2) 
H2O2 is a diffusible non-radical form of ROS formed by the spontaneous or enzymatically 
catalysed dismutation of two O2




•- + 2H+ → H2O2 + O2 
 
It is considered to be one of the most unreactive ROS species, with little oxidative potential 
on its own (Valverde et al., 2018). However, its longevity compared to other forms of ROS 
(milliseconds versus microseconds) and high diffusibility facilitates H2O2 to move further 
through the cell than other, shorter-lived ROS (Bienert, Schjoerring and Jahn, 2006). 
Critically in the context of metal-based drugs, upon reaction with transition metals such as 
copper or iron, H2O2 can be oxidised into the more reactive O2
•- or the highly reactive OH• 
species via the Fenton reaction (Sies, 2017): 
 
Fe2+ + H2O2 → Fe
3++ OH•+ OH- 
OH•+ H2O2→ O2
•-+ H+ + H2O 
 
 It is through these secondary processes that H2O2 ultimately exerts its cytotoxic effects.  
 
At low physiological levels, H2O2 is utilised by the cell as a classical intracellular signalling 
molecule regulating kinase driven pathways involved in diverse signalling processes, such 
as cell proliferation (Arnold et al., 2001), differentiation and survival, stem cell renewal 
(Goudarzi et al., 2018), immune responses (Wittmann et al., 2012), antioxidant defence, and 
autophagy. During redox signalling, H2O2 oxidizes the thiolate anion to sulfenic form (Cys-
SOH) causing allosteric changes within the target kinase protein that alters its function (van 
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Bergen, Roos and De Proft, 2014). The sulfenic form can be subsequently reduced to thiolate 
anions by disulfide reductases (and other antioxidant proteins) restoring the protein to its 
original, functional state (Gough and Cotter, 2011; Schieber and Chandel, 2014). H2O2 also 
reversibly oxidises specific cysteine sulfhydryl (SH) groups in certain tyrosine kinases, 
causing conformational changes and activation of the enzymes (Chadwick et al., 2011). 
Finally, a  number of transcription factors are susceptible to oxidation for either their 
activation or inactivation, such as NF-κB, AP-1, H1F-1a, p53 and Nrf2 (all activation) and 
upstream stimulatory factor (USF) (inactivation) (Wang et al., 2018). 
 
In contrast, pathological levels of H2O2 and the initiation of oxidative stress have been 
implicated in the initiation of oncogenesis, due to high levels of mutations associated with 
DNA damage caused by oxidative injury and the prolonged activation of pro-survival 
transcription factors (Huang et al., 1999). Furthermore, sustained activation of these 
pathways is associated with overall tumour cell survival and proliferation, metastasis and 
angiogenesis, and induction of acquired resistance (Vilema-Enríquez et al., 2016).  
 
 Hydroxyl radical 
The hydroxyl radical, OH•, is formed by the three-electron reduction of molecular oxygen 
and is the most reactive form of ROS, with reactivity close to the theoretical diffusion rate 
(109–1010 M-1.s-1). Moreover, it has essentially no target specificity and a lifespan of 
nanoseconds (Takeda et al., 2017). It is capable of severing the sugar-phosphate backbone 
of DNA or RNA, causing significant increases in oxidised nucleotide bases (Dizdaroglu and 
Jaruga, 2012), as well as oxidising amino acids significantly altering the function of proteins 
(Liu et al., 2017). However, the high reactivity of OH• limits its damaging potential to within 
50 molecular diameters, as a consequence of its high reactivity and thus short lifespan 
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(Lipinski, 2011). Due to its highly toxic nature, the OH• is not believed to play any part in 
normal cell processes. 
 
OH• may be formed via the Fenton reaction, where H2O2  reacts with redox active metals 
such as Cu2+ of Fe2+, producing OH•(Pham et al., 2013): 
 
H2O2 + Cu
+/Fe2+ → OH• + OH- + Cu2+/Fe3+ 
 
In addition, the Haber Weiβ reaction may produce OH•, via reaction of H2O2 with O2
•- (Kanti 
Das, Wati and Fatima-Shad, 2014): 
 
H2O2 + O2
•-→ OH• + OH- + O2 
 
  Superoxide O2•- radical  
The O2
•- radical is formed through the donation of a single electron to oxygen (Hayyan, 




While slightly more reactive than H2O2 it is not considered as a strong oxidant in its own 
right and generally interacts with molecules close to its source of origin (Clément and 
Pervaiz, 2001). Although it is poorly diffusible through the plasma membrane, it can pass 
through via ion and chloride channels (Ramírez et al., 2016).  
 
Within the cell O2
•- is produced as a by-product of metabolism and by specific enzymes 
including ETC transport chain complexes (ATP synthesis) (Murphy, 2009), xanthine 
oxidases (purine catabolism) (Lee et al., 2014), lipoxygenases (lipid metabolism) (Zuo et 
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al., 2004), cyclooxygenases (prostaglandin synthesis) (Gao et al., 2014) and NADPH 
oxidases (immune cell respiratory bursts) (Panday et al., 2015). O2
•- generally exerts its 
intracellular cytotoxic effects by dismutation into H2O2 via auto-dismutation or a result of 
Superoxide Dismutase (SOD) enzymes, where both Fenton and Haber Weiβ chemistry may 
produce the more reactive OH• (Collin, 2019). O2
•- plays a major role in phagocytic 
respiratory bursts and has been seen to play a role in epigenetic post-translational 
modifications such as DNA methylation, and histone methylation and acetylation (reviewed 
by Afanas’ev, 2015; Wang et al., 2018). It has also been identified as the main ROS involved 
in the regulation of autophagy (Chen, Azad and Gibson, 2009).  
 
 Singlet oxygen (1O2) 
Singlet oxygen (1O2) is a highly reactive and electrophilic non-radical form of ROS and is 
the electronically excited state of molecular oxygen (Agnez-Lima et al., 2012). It possesses 
no unpaired electrons leaving an empty orbital to allow reaction with other molecules and 
has a half-life of in water of 1µs. This, however, may drop down to as low as 100ns in 
biological systems as a result of its ability to react with most biomolecules (Kalyanaraman, 
2013). Sources of 1O2 include ultraviolet radiation, endogenous enzymes (i.e. those involved 
in immunity or metabolic processes) or via chemical cascades secondary to the reaction of 
hydroperoxides and other forms of ROS with each other and/or other biomolecules (Agnez-
Lima et al., 2012; Kalyanaraman, 2013; Onyango, 2016; You, 2018).  
 
UVA radiation can excite photosensitising compounds, such as porphyrins, vitamins, 
bilirubin, flavins, melanin and melanin precursors (found in skin), which can transfer energy 
to triplet oxygen (3O2) generating 
1O2 (Baier et al., 2007; Knak et al., 2014). This form of 
1O2 generation is exploited in Photodynamic Therapy (PDT), a combination of both chemo 
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and radiotherapy used in the treatment of certain cancers, such as oesophageal and non-small 
cell lung cancer. 
 
The core enzymatic source of 1O2 is in relation to bactericidal respiratory bursts in 
phagocytic cells such as neutrophils, eosinophils or macrophages (Nishinaka et al., 2011). 
This is mediated by the enzyme myeloperoxidase (MPO) which catalyses the formation of 
hypochlorous acid (HOCl) from H2O2 (Figure 1.4 scheme 1). This in turn reacts with the 
hydrogen peroxide anion (HO2
-), producing 1O2  (Figure 1.4 scheme 2) (Onyango, 2016).  
 
 1O2 may also be produced as a by-product of the spontaneous dismutation of superoxide into 
hydrogen peroxide and the reaction of nitric oxide with superoxide or H2O2 (Figure 1.4, 
schemes 3-6) (Onyango, 2016, Agnez-Lima et al., 2012). 
 
 
Figure 1.4-Schematic of 1O2 generation from other sources of ROS or RNS (adopted from 
Onyango, 2016). 
 
 Nitric oxide (NO•) 
RNS are nitrogen centred oxidants capable of both oxidising and nitrosylating the same 
biomolecules as oxygen centred radicals (Ozcan and Ogun, 2015). Despite its status as a free 
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radical gas, NO• is an important intracellular second messenger molecule that activates the 
soluble guanylyl cyclase (sGC) at nanomolar concentrations and is a key modulator of 
smooth muscle relaxation (Adams, Franco and Estevez, 2015). It is generated by specific 
nitric oxide synthases (NOS)s which convert L-arginine to L-citrulline (Figure 1.5) 
(Phaniendra, Jestadi and Periyasamy, 2015), consisting of three isoforms: neuronal, 
endothelial and inducible NOS (Förstermann and Sessa, 2012).  
 
 
Figure 1.5- Synthesis of Nitric oxide 
 
NO• is both aqueous and lipid soluble and readily diffuses through the cytoplasm and across 
cell membranes. The estimated biological half-life and diffusion distances are on the order 
of 1–10 sec and 50–1,000 μm, respectively (Radi, 2018).  
 
NO• shares many similarities with O2
•-. High concentrations of NO• are generated as part of 
the immune response in phagocytic immune cells and is free radical but is not particularly 
reactive on its own. Like O2
•-, it usually exerts its cytotoxic effects through generating more 
reactive intermediates, such as the peroxynitrite anion, which is utilised alongside H2O2 and 
OH• to execute its bactericidal properties (Habib and Ali, 2011). 
 
 Peroxynitrite (OONO-) 
Peroxynitrite (OONO-) is a highly toxic cellular oxidant with a half-life of ≈ 10 ms. It can 
cause direct protein oxidation, forming amino acid/nitrogen products such as nitrotyrosine 
and can initiate conformational changes in protein structure, thus inhibiting protein function 
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(Radi, 2018). DNA base oxidation and single strand breaks have also been attributed to 
OONO-, and are thought to be a result of the generation of a “hydroxyl radical-like” oxidant 
(ONOOH•) (Kennedy et al., 1997; Ozcan and Ogun, 2015). OONO- can form other highly 
toxic radicals as well as ONOOH•, resulting from its own decomposition. Decomposition 
can happen spontaneously and can produce the nitrogen dioxide radical (NO2
•) which is 
capable of further initiation of lipid peroxidation and nitrosylation of amino acids (Depayras 
et al., 2018).  
 
As it is capable of crossing cell membranes, it can exert an influence on surrounding cells 
within 1-2 cell diameters from its site of origin. OONO- thus appears to be an important 
tissue-damaging species generated at the sites of inflammation (Pacheco-Yepez et al., 2014). 
It has been shown to be involved in various neurodegenerative disorders and several kidney 
diseases (Seija et al., 2012; Yuste et al., 2015).  
 
 Iron homeostasis and applications in cancer therapy 
Iron is an essential trace element required for many cellular redox-dependent signalling 
pathways, such as oxygen transport, DNA synthesis and repair, lipid metabolism, oxidative 
phosphorylation and ROS signalling.  Iron is highly redox active and can exist in ferrous 
(Fe2+) or ferric (Fe3+) oxidation states. The oxidation of Fe2+ to Fe3+ is capable of generating 
ROS, as such free state  Fe2+ can be highly cytotoxic resulting in uncontrolled production of 
ROS through Fenton like chemistry and Haber Weiβ reactions (Kanti Das, Wati and Fatima-
Shad, 2014). As such, iron metabolism is tightly controlled to maintain bodily and cellular 
homeostasis through the sequestration of iron to carrier proteins such as haem or transferrin, 
or in iron sulfur clusters (ISCs) (reviewed by Camaschella and Pagani, 2018).  
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Iron is absorbed through enterocytes in the small intestine. Once inside enterocytes iron is 
bound by ferritin, the iron storage protein. Ferritin stores iron in the ferric form and can store 
4,500 iron atoms bound to oxygen. Ferritin can act as both an iron carrier and an intracellular 
source of bioavailable iron (Chiou and Connor, 2018).  
 
Once it has been imported and bound to ferritin, iron may be transported to metabolic 
enzymes where it acts as an essential co-factor, such as lipoxygenases involved in lipid 
metabolism and heme dependent enzymes such as catalases and peroxidases (Poulos, 2014) 
Iron can also be sequestered in the mitochondria for haem synthesis or storage (Andreini et 
al., 2018). The mitochondria has its own form of ferritin, known as mitochondrial ferritin, 
and is thought to play a protective role to deal with iron overload (Rouault, 2016). Iron can 
also be incorporated into ISCs in the mitochondria to be used as co-factors in iron metabolic 
signalling (Rouault, 2012). Iron can also be exported into the blood stream where it binds an 
iron transport protein called apo-transferrin forming transferrin. Approximately 75% of 
transferrin bound iron is transported to the bone marrow to facilitate erythropoiesis and the 
synthesis of haemoglobin in red blood cells (Silva and Faustino, 2015). 
 
Iron may also exist in what are termed labile iron pools, poorly defined non-protein bound 
and redox active intracellular iron. The exact function of these labile iron pools is unclear. It 
is thought to exist as a form of readily available and exchangeable iron and is mediated by 
both antioxidant defence systems and protein carriers such as ferritin. However, during 
oxidative stress or periods of iron overload the iron buffering capacity of the cell may 
become overwhelmed and labile iron pools may propagate oxidative stress (reviewed 
Cabantchik, 2014). A form of iron and lipid mediated necrotic cell death is known as 
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Ferroptosis, which involves the accumulation of toxic lipid and phospholipid peroxides 
leading to necrotic cell death. This is discussed in detail in Chapter 5.  
 
Due to its significant role cell signalling and maintaining cell homeostasis, iron has been 
implicated in tumour progression by metastasis. Tumour cells physiologically alter DNA 
synthetic and repair mechanisms, cell cycle regulation, and epigenetic remodelling, as well 
as facilitating metastasis and angiogenesis through dysregulated iron metabolism (Yafang 
Wang et al., 2018). As such tumour cells have increased iron metabolic pathways such as 
pathways responsible for iron import, storage and export in order to fuel metabolic iron 
demands of proliferating and metastasising cells (Jung et al., 2019). Iron has been recognised 
as an important target for chemotherapeutic intervention. Bleomycin, an antibiotic 
repurposed as an anti-cancer agent, is an example of a frontline chemotherapeutic which 
utilises iron chelation and the generation of ROS to exert anti-cancer effects (Reinert et al., 
2013). 
 
Iron based chemotherapeutic strategies utilise iron chelation therapy or treatment using iron 
based ionophores. Several iron chelative drugs have been developed (Derasirox and 
Desferal®) and have entered clinical trials, however poor pharmacokinetics and serious off 
target side effects have severely limited their development into clinically effective drugs 
(Bedford et al., 2013). However some progress has been made using combinatorial 
treatments with current chemotherapy drugs such as cisplatin, carboplatin, or doxorubicin, 
decreasing adverse side effects while supressing tumour growth (see references 182 and 183 
Wang et al., 2018).  
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Iron complex ionophores have also demonstrated promise as anti-cancer agents. Iron 
complex anti-cancer activity was first demonstrated using ferrocenium picrate and 
ferrocenium trichloroacetate, with cytotoxicity attributed to formation of ROS and oxidative 
DNA damage (Köpf-Maier, Köpf and Neuse, 1984). Research into the synthesis and 
development of novel iron anti-complexes as anti-cancer agents has therefore gained 
interest. Multinuclear complexes with variable side chains and derivatives have been 
designed with the aim of potentially enhancing the anti-cancer effects and increasing cancer 
cell specificity  (reviewed Wani et al., 2016).    
 
 Copper homeostasis and applications in cancer therapy 
Copper (Cu) is an essential trace element within the body, which plays significant roles in 
multiple cellular pathways (Lutsenko, 2010). As a transition metal, Cu is an essential co-
factor in many redox dependant pathways, such as antioxidant defence (Cu-Zn Superoxide 
Dismutase), iron metabolism and transport (Ceruloplasmin), respiratory pathways 
(cytochrome-c oxidase, methionine synthase) and connective tissue synthesis (lysyl oxidase) 
(Hilton et al., 2018).  
 
Cu is highly redox active, shifting between cuprous (Cu+) and cupric (Cu2+) valence states 
facilitating its redox activity, with Cu2+ the most biologically relevant state. In similarity 
with iron, redox capabilities of Cu make it essential for life but also renders it potentially 
toxic. Dysregulation of Cu homeostasis has been associated with heart, liver and CNS 
dysfunction, as well as in inflammation, cancer and resistance to chemotherapy. As such Cu 
activity and availability is tightly regulated in the body (reviewed by Gaetke, Chow-Johnson, 
& Chow, 2014). 
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Cancer cells have been seen to possess elevated levels of copper, which has been seen to 
contribute to increased cell survival, proliferation, angiogenesis, metastasis and 
chemotherapy resistance, particularly in platinum-based therapies (Wang et al., 2010). 
Patients with resistant breast, lung or colon cancers demonstrated serum copper levels of 
130-160% of normal (Majumder et al., 2009). As such, the potential of copper-based 
therapies has gained much attention in recent years. Copper can be used to target cancer cells 
either through the use of copper chelators to reduced essential copper levels mediating 
proliferative, angiogenic or metastatic processes, or through the use of copper complex 
ionophores (Helsel and Franz, 2015). Limited success has been reported with the 
implementation of copper chelators as anti-cancer agents, with cytostatic mechanisms more 
prevalent than cytotoxic ones. Copper chelators (such as disulfiram and trientine) have 
therefore been recommended to be used as a strategy to inhibit the progression of copper 
dependent angiogenesis and metastatic processes (reviewed by Lopez, Ramchandani, & 
Vahdat, 2019).  
 
The use of copper complex ionophores has therefore seen the most promise as cytotoxic anti-
cancer agents, as the high levels of copper associated with cancer signalling and resistance 
could predispose cancer cells to copper overload (Denoyer et al., 2015). The ability of copper 
to bind to DNA, inducing conformational change and DNA damage indicates the 
chemotherapeutic potential of copper (Govindaraju et al., 2013). The primary mechanisms 
of copper induced anti-cancer cytotoxicity documented to date are DNA interactions, ROS 
production, mitochondrial dysfunction, proteasome inhibition and induction of apoptosis 
(Denoyer et al., 2015; McGivern, Afsharpour and Marmion, 2018).  
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Utilising copper as an anti-cancer agent may also impact iron regulation. Many regulatory 
proteins controlling copper (e.g. Ceruloplasmin) also regulate iron, while copper has been 
seen to regulate the iron sensing hormone Hepcidin (Gulec and Collins, 2014). Studies into 
patients suffering from Wilson’s disease, a genetic disease-causing toxic accumulation of 
copper in the vital organs, demonstrated that patients also experience iron overload (Shiono 
et al., 2001). As such targeting copper homeostasis in cancer cells may further disturb iron 
regulation increasing cytotoxic capabilities and there is likely a complex interplay between 
different metals under in vivo conditions.   
 
 Manganese homeostasis and applications in cancer therapy 
Manganese, also an essential trace metal, plays a similar critical role to copper as an essential 
redox active co-factor to multiple cell pathways, such as mitochondrial antioxidant defence, 
and the metabolism of lipids, carbohydrates and amino acids to name a few (Li and Yang, 
2018). Manganese has 11 potential oxidation states, ranging from Mn-3 to Mn7+, Mn7+ having 
the highest oxidative potential, however biologically relevant oxidation states of manganese 
are Mn2+ and Mn3+ (O’Neal and Zheng, 2015).  
 
Manganese shares many chemical and structural similarities with iron, sharing identical 
biological oxidation states, and both being transferred throughout the body bound to 
transferrin in the Mn3+ oxidation state, with Mn2+ primarily transported by albumin 
(Martinez-Finley et al., 2013; Smith et al., 2017). While both share redox capabilities, 
manganese is not thought to undergo ROS generating Fenton reactions seen in reactions 
involving copper or iron, as a result of its high reduction potential (Aguirre and Culotta, 
2012). Manganese transport is inversely related to iron storage implying coregulatory 
mechanisms of each divalent cation (DeWitt, Chen and Aschner, 2013). 
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Intracellular manganese is found mostly in the Mn2+ state, where it is primarily located in 
the mitochondria and the nucleus (O’Neal and Zheng, 2015). The mitochondria is generally 
seen as the main target for manganese uptake where mitochondrial manganese is generally 
incorporated into Superoxide Dismutase 2 (SOD2), also known as Mn-SOD. SOD2 is a 
highly conserved antioxidant enzyme tasked with detoxifying superoxide anions into 
hydrogen peroxide as part of its antioxidant and cytoprotective role (Azadmanesh and 
Borgstahl, 2018). High levels of manganese have been seen to be cytotoxic, and mainly 
targets the brain and liver causing severe dysfunction (Harischandra et al., 2019). 
 
As the primary target of intracellular manganese is the mitochondria, Mn2+ mediated toxicity 
has been demonstrated to inactivate mitochondrial complexes I, II, III and IV, causing severe 
disruption to the electron transport chain and the Krebs cycle (Harischandra et al., 2019). It 
has also been shown to increase mitochondrial superoxide, hydrogen peroxide and ROS 
production, further exacerbating mitochondrial dysfunction and decreasing mitochondrial 
membrane potential (ibid). The main species of manganese responsible for cytotoxicity is 
Mn2+. While Mn3+ is a significantly stronger oxidising agent, it is not as readily soluble in 
aqueous solution as Mn2+, and disproportionates into Mn2+ in the presence of oxygen 
(reviewed by Gunter, 2017). However, Mn3+ is the oxidation state present in SOD2 
(Azadmanesh and Borgstahl, 2018). 
 
The cytotoxic potential of Mn2+ has been further implicated via effects on calcium 
homeostasis, glutathione depletion and impairment of antioxidant processes, and oxidative 
stress, culminating in the activation of apoptosis and cell death (reviewed by Smith et al., 
2017). Mn2+ disrupts calcium homeostasis as it shares spherical symmetry with Ca2+, and so 
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is capable of binding and substituting multiple Ca2+ binding sites involved in many 
biologically processes such as ATP production (see references 160 and 161 in Martinez-
Finley et al., 2013). Mn2+ can also competitively bind to Mg2+ and Fe2+ binding sites, further 
disrupting metal ion mediated signalling and enzymatic processes (Gunter, 2017). 
 
In addition, manganese has been demonstrated to bind both DNA and RNA and has also 
been seen bound to ribosomes, resulting in disruption of transcription and translation (see 
references 149 and 150 Smith et al., 2017). The disruption of these process could result in 
endoplasmic reticulum (ER) stress, which can further activate apoptosis. Indeed it has been 
shown that manganese can trigger ER stress but it is not yet known if this directly results in 
ER stress mediated apoptosis or through other manganese-dependent activities (Seo, Li and 
Wessling-Resnick, 2013; Smith et al., 2017). Stephenson et al., (2013) demonstrated Mn2+ 
could induce oxidative DNA damage and single strand breaks in SH-SY5Y neuroblastoma 
cells, a process which was attenuated by Glutathione (GSH) and N-acetyl cysteine 
antioxidant molecules, indicating this Mn2+ dependent nuclease mimetic activity was 
mediated by ROS. Apoptosis was confirmed as the mechanism of cell death (Stephenson et 
al., 2013). 
 
Despite many studies implicating manganese in DNA damage and the induction of oxidative 
stress, it is generally considered to have a low mutagenic or carcinogenic potential compared 
with other redox active metals such as copper or iron. There is no clear evidence of a link 
between manganese exposure and cancer (Gerber, Léonard and Hantson, 2002; Assem, 
Holmes and Levy, 2011; Zhang et al., 2014). However, manganese associated toxicity may 
be a useful tool to harness in the fight against cancer. Stephenson et al., (2013) demonstrated 
the cytotoxic mechanism of manganese in neuroblastoma cells. These data were supported 
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by later observations made by Hernroth and collaborators which demonstrated similar 
apoptotic mechanisms in three different prostate cancer cells (PC3, DU145 and LNCaP) 
exposed to manganese (Hernroth et al., 2018). This demonstrates the potential of ROS 
mediated, manganese dependent nuclease mimetic activity as a novel anti-cancer strategy.    
 
 Current and novel metal-based drugs as chemotherapeutic agents 
Many novel compounds utilising many different metal ions have been developed over the 
last few decades (e.g. gold, silver, copper, manganese and ruthenium), with some showing 
potent DNA binding and anti-cancer activity (Deegan et al., 2007; Tan et al., 2010; Ndagi, 
Mhlongo and Soliman, 2017). While many variations of compounds containing these metals 
have been investigated, of note are compounds possessing 1,10-phenanthroline (1,10-Phen) 
or its derivatives as ligands.  
 
1,10-Phen is a polycyclic aromatic hydrocarbon used for its strong chelative properties in 
both industrial and therapeutic synthetic processes (Natarajan, 2018). 1,10-phen has many 
properties which make it useful in synthetic and coordinate chemistry, including rigidity, 
planarity, aromaticity, basicity and the ability to chelate a variety of different metals (Accorsi 
et al., 2009). These properties provide great versatility in binding with metal ions, allowing 
the synthesis of a broad range of metal-phenanthroline based compounds (Bencini and 
Lippolis, 2010; Bonacorso et al., 2015). Echoing the discovery of cisplatin, therapeutic 1,10-
Phen and associated chelates were first noted for their bacteriostatic and bactericidal 
proprieties (Butler et al., 1969; Dwyer et al., 1969).  
 
As a result of its planar structure (Figure 1.6) 1,10-phen is an avid intercalator of DNA 
capable of strong DNA groove binding (Accorsi et al., 2009). This ability to intercalate with 
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DNA coupled with its strong chelative properties are generally considered to be the key 
drivers of the strong cytotoxic effects against bacterial, fungal and mammalian cells seen to 
date (Sammes and Yahioglu, 1994; McCann et al., 2012). These properties of 1,10-Phen 
give it the potential to inhibit many other biological pathways, such as intermediate 
metabolism (Carver et al., 1988), transcription (Grigull et al., 2004), and a variety of metallo-
enzyme dependent pathways (Abebe et al., 2018). 1,10-Phen has also been seen to sequester 
essential trace metals such as zinc or redox active copper or iron further adding the its 
cytotoxic potential (McCann et al., 2012; Viganon et al., 2017). 
 
 
Figure 1.6 - Chemical structure of 1,10-phenanthroline with 2-9 representing numbering for 
substituents for coordination with other compounds (Viganor et al., 2017).  
  
Following the initial discovery of antimicrobial capabilities of 1,10-Phen, copper based 
phenanthroline compounds were discovered to possess synthetic chemical nuclease 
capabilities via oxidative cleavage of the deoxyribose sugar backbone (Sigman et al., 1979). 
This discovery has sparked massive interest in synthesising and developing novel artificial 
metallo nucleases (McGivern, Afsharpour and Marmion, 2018), with copper based 
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phenanthroline chelates the most extensively studied to date (Kuwabara et al., 1986; 
Murakawa et al., 1989; Pitié, Boldron and Pratviel, 2006; Roy et al., 2008; Anbu et al., 2013; 
Molphy et al., 2015). DNase mimetic activity is therefore considered a primary mechanism 
for both copper and metal-based phenanthroline compounds, and has been seen to operate 
via oxidative scission of deoxyribose residues or hydrolysis of the phosphodiester sugar 
backbone (Bonacorso et al., 2015; Molphy et al., 2015). Indeed, the DNase mimetic 
capabilities of Cu-phenanthroline based compounds can be used as a tool for DNA foot 
printing studies (Papavassiliou, 1995).  
 
The use of 1,10-Phen may also further facilitate the uptake of metal-based drugs into cancer 
cells. Zhang et al., (2013) demonstrated that the uptake of 1,10-Phen ternary copper 
complexes into cancer cells was facilitated by the presence of 1,10-Phen compared to free 
copper, and that the increased Cu-Phen concentration was capable of potent proteasome 
inhibition and apoptosis induction in breast cancer cells. The observation of proteasome 
inhibition by copper-phen compounds has been further supported by recent work from 
Zhang et al. (2017).   
 
While much attention has been given to copper-phen compounds, manganese based 
phenanthroline drugs have also been developed alongside copper-phen compounds 
demonstrating comparable potency  (McCann et al., 1997; Kellett et al., 2011; Gandra et al., 
2017; Slator et al., 2017). Eskandari & Suntharalingam (2019) demonstrated a Mn-Phen 
compound to possess significantly greater potency towards breast CSCs than cisplatin or a 
structurally similar Cu-Phen compound. The Mn-phen compounds was seen to produce 
significantly higher intracellular ROS than that of the copper-phen compound, with ROS 
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generation speculated to be the key cytotoxic mechanism in play (Eskandari and 
Suntharalingam, 2019). 
 
A number of such derivatives, based on copper, manganese and silver have been synthesised 
and characterised as part of ongoing medicinal chemistry research at Technological 
University Dublin (Thornton et al., 2016; Gandra et al., 2017; Rochford, 2018). In recent 
years, compounds which contain multiple 1,10-phenanthroline moieties and organic 
carboxylic acids of various lengths have been developed. Many of these compounds, in line 
with previous generations, display strong DNA binding affinities, cancer cell cytotoxicity, 
the ability to induce reactive oxygen species (ROS) and thus oxidative stress (Kellett et al., 
2011). 
 
Kellet et al. (2011) investigated the cytotoxicity, DNA binding/cleavage capacity, and 
capacity for reactive oxygen species generation of the binuclear, water soluble Cu2+  and 
Mn2+ bis-phenanthroline octanedioate compounds – [Cu2(2-oda)(phen)4](ClO4)2 and 
{[Mn2(2-oda)(phen)4(oda)2]
2-[Mn2(2-oda)(phen)4(H2O)2]
2+}, hereafter CMPD22 and 
CMPD19, respectively. Both complexes displayed high affinity for binding DNA and were 
shown to be capable of relaxing supercoiled plasmid DNA under in vitro conditions. 
CMPD22 was also capable of DNA cleavage in the absence of O2 and an added reductant 
(ascorbate), in contrast to CMPD19. In addition, CMPD22 was capable of double strand 
scission of plasmid DNA whereas CMPD19 was not. In studies with in vitro cell systems, 
both complexes exhibited cytotoxic properties greater than cisplatin and metal-free 1,10-
phenanthroline in colorectal cancer cell lines but were significantly less toxic towards a non-
cancerous HaCaT keratinocyte line. ROS production was tested using 2’,7’-
dichlorofluorescin diacetate (DCFDA) which demonstrated CMPD19 to be a robust ROS 
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generator (>25-fold increase in ROS production) at concentrations of 0.25-1 µM in HT29 
colorectal cancer cells. CMPD22 displayed little activity in comparison to CMPD 19 and 
metal-free 1,10-Phen (Kellett et al., 2011).  
 
The mimetic SOD-like activity (dismutation of superoxide anion into hydrogen peroxide) 
and mimetic catalase activity (breakdown of hydrogen peroxide into H2O and O2) were also 
investigated. As noted above, SOD and catalase like activity are important catalytic reactions 
for the cleavage of the DNA phosphodiester backbone, as both superoxide and hydrogen 
peroxide (H2O2) can play an important role in hydroxyl radical formation via Fenton like 
redox chemistry involving copper and iron (Pham et al., 2013).  Both complexes show potent 
mimetic SOD activity when exposed to superoxide anions, with CMPD 19 appearing to 
possess exceptional activity (Kellett et al., 2011). However, CMPD 19 was the only 
compound to display catalase like activity. CMPD 19 was further tested by (Slator et al., 
2017), and was found to induce autophagic cell death, apparently utilising mitochondrial 
superoxide generation as a key autophagic regulator to induce the intrinsic apoptotic 
pathway in the later stages of cytotoxicity. Double stranded breaks in cellular DNA were 
also detected via γH2AX and COMET assays. However, the authors attributed this damage 
to be a product of the natural increase in ROS production associated with both autophagic 
and intrinsic apoptotic cell death, as opposed to direct DNA damage caused by the compound 
itself. 
 
While these compounds have seen preliminary successes, optimisation of efficacy and 
properties (e.g. solubility, selectivity) are required. Recently a new series of 1,10-Phen based 
compounds containing copper or manganese at their cores and with trioxaundecanedioic acid 





Figure 1.7- Chemical structure of trioxaundecanedioic acid 
 
Trioxaundecanedioic acid contains three ethereal oxygens, theoretically increasing the 
possibilities for interaction with water leading to an anticipated enhancement of water 
solubility of the overall complex (McCann et al., 1997; Bartos, Hudecz and Uray, 2009). 
The chemical structures of Mn (CMPD 73) and Cu (CMPD 74) containing 
trioxaundecanedioic acid dicarboxylic acids can be seen in Figure 1.8. These compounds are 
analogues of CMPD19 and 22 respectively and have demonstrated potential antifungal 





Figure 1.8- Chemical structures of CMPD 73 and 74 
 
However, there is currently very limited data available about potential anti-cancer activity 
of these compounds. Both novel compounds would be expected to share many biochemical 
properties with compounds based on an octanedioate linked compound, i.e. ROS generation, 
DNA intercalation, DNA cleavage capabilities.  
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 Hypothesis:  
If novel metal-TDDA-phenanthroline compounds possess biological activities which lead to 
cell death, then characterisation of these activities will lead to identification of strategies to 
rationally enhance their activities for potential therapeutic benefit. 
 
 Aims 
The general cytotoxic capacity of metal-based phenanthroline compounds is well known. 
The biological characteristics (e.g. cytotoxic action) or mechanism(s) of action (e.g. nucleic 
acid cleavage) of the novel compounds under study here are not yet known. The broad aim 
of this thesis is to characterise the biological action(s) of these novel compounds with a view 
towards identifying approaches to maximise their cytotoxic activity and revealing 
underlying mechanisms of action. 
 
The specific objectives are: 
-To characterise the baseline cytotoxic capacity of the compounds (Chapter 2) 
-To determine if DNA compaction plays a key role compound activity (Chapter 3) 
-To define the role of ROS generation in mediating the activity of the compounds (Chapter 
4) 
-To clarify if these compounds induce iron-mediated cell death (i.e. ferroptosis) (Chapter 5)  
-To define the capacity of these compounds to cleave nucleic acids, both DNA and RNA 
(Chapter 6) 
-To define the capacity of these compounds to induce ER stress and interact with the 
Unfolded Protein Response (Chapter 7) 
Taken together these objectives will enable the realisation of the overall aim and identify 
both approaches to maximise activity as well as revealing the mechanistic basis for their 
action. 
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2. Evaluation of the cytotoxicity profiles of novel 
compounds 
 Introduction  
Cytotoxicity is the quality of an agent to be toxic towards the cell. Cytotoxicity can present 
in many different forms, with two of the most characterised being apoptotic cell death and 
necrotic cell death. These differ in how they are regulated and their effects on surrounding 
cells and their physiological roles. Apoptosis is a highly regulated process with minimal 
collateral damage to the surrounding area. In contrast, necrosis has minimal regulation and 
causes high collateral damage to cells in the surrounding area  (D’Arcy, 2019). However, 




Apoptosis is a naturally occurring process involved in development and maintenance of 
cellular homeostasis (Gavrilescu and Denkers, 2003). Apoptosis removes old cells and cells 
that are stressed or injured. Apoptosis is regulated by the delicate balance of pro and anti-
apoptotic signals, capable of responding to different stimuli, whereupon a threshold of pro-
apoptotic signals must be reached in order to overcome anti-apoptotic pathways (reviewed 
Singh, Letai, & Sarosiek, 2019).  
 
Morphological changes initiated by apoptosis are cell shrinkage where the cytoplasm and 
cell organelles are tightly condensed and pyknosis where chromatin becomes highly 
condensed and disintegration of the nuclear membrane occurs. Apoptotic cells appear round 
with dense nuclear fragmentation when observed microscopically (Saraste, 2000). Early and 
advanced apoptotic cells can be seen in Figure 2.1, taken from Balvan et al., (2015). 
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Figure 2.1-Characteristic apoptotic cells as seen under holographic, fluorescent (using AnnexinV 
PI staining) and contrast microscopy.  Early stage apoptotic cells appear as typically round-shaped 
cells, which undergo extensive membrane blebbing and compartmentalisation into apoptotic bodies 
(Balvan et al., 2015). 
 
Extensive membrane blebbing results in the separation of cell fragments and the formation 
of small apoptotic bodies, which are then engulfed by phagocytic cells, with little to no 
inflammatory response initiated (reviewed by Elmore, 2007). The compartmentalisation of 
cell organelles protects surrounding cells from the release of potentially toxic metabolic 
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intermediates or degradative enzymes involved in intracellular recycling, such as 
proteasomal or lysosomal proteins (Aits and Jäättelä, 2013).  
 
Apoptosis relies on the activation of a family of proteases called cysteine-aspartic proteases 
(Caspases) which, once activated, are responsible for initiating apoptosis through the 
degradation of DNA and cell organelles. Cells that experience sustained forms of injury or 
insult, generally xenobiotic compounds (such as chemotherapy agents, viral infection, 
oxidative stress, DNA damage, or dysfunctional organelles like the endoplasmic reticulum 
or mitochondria) initiate pro-apoptotic proteins which further activate executioner Caspases 
present within the cell, as seen in Figure 2.2 (reviewed Czabotar, Lessene, Strasser, & 
Adams, 2013).  
 
 
Figure 2.2-Activation of pro-apoptotic signalling cascade in response to initiating stimuli and the 
subsequent activation of apoptotic caspases. 
 
Caspases can be divided into initiator (caspases 2, 8, 9, 10) and executioner (3, 6, and 7) 
caspases. Another category of caspases (1, 4, 5 and 12L) are involved in the inflammatory 
response (McIlwain, Berger and Mak, 2013).  Caspases are synthesised as inactive 
procaspases which require either dimerization (initiator caspases) or cleavage (executioner 
caspases) to become activated. As such caspases exist as dormant proteins capable of rapid 
activation of apoptosis in response to apoptotic stimuli, bypassing the slower traditional 
protein transcription and translation processes (Patel et al., 2015). Initiator caspases become 
activated in response to upstream signalling events, which in turn cause proteolytic cleavage 
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of executioner caspases (Shi, 2004). Caspases are responsible for the characteristic 
morphological changes seen in apoptotic cells, primarily cell shrinkage and membrane 
blebbing, nuclear fragmentation, chromatin/chromosomal condensation and fragmentation, 
and global mRNA decay (Parrish, Freel and Kornbluth, 2013). 
 
Apoptotic stimulus can be either external or internal. External stimuli (e.g. immune cells 
detecting oncogenic extracellular membrane markers or virally infected cells) initiate the 
extrinsic apoptotic pathway that operates through membrane bound death receptors that 
initiate caspase activation. Both pathways converge through the activation of executioner 
caspases to carry out programmed cell death (Loreto et al., 2014). 
 
The extrinsic apoptotic pathway is regulated by death receptor ligands such as the Tumour 
Necrosis Factor (TNF) superfamily (e.g.TNFα) or FasL, and their corresponding death 
receptors, TNFR for TNF and FasR for FasL. TNFs are cytokines secreted by inflammatory 
cells, whereas FasL is a transmembrane protein expressed on cytotoxic T-cells (Nair et al., 
2014). Upon ligand binding the cognate receptors TNFR and FasR undergo homo-trimeric 
clustering, whereby they recruit their corresponding intracellular adapter proteins to 
potentiate the death signal. TNFR recruits TNFR1-associated death domain protein 
(TRADD) and FasR recruits Fas-associating protein with death domain (FADD) 
(Pobezinskaya and Liu, 2012).  
 
Homo-trimeric death receptor binding following ligand activation allows for the formation 
of a multi-protein complex to form on the intracellular domain of the death receptor and is 
known as the Death Inducing Signal Complex (DISC). DISC functions as a molecular 
platform for the regulation and activation of Caspase 8 or Caspase 10 (Yang, 2015).  
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Activated caspase 8 can then go on to activate executioner caspases 3, 6 and 7, or pro-
apoptotic proteins such as BH3 family (BH3 Interacting Death agonist (BID), Bcl-2 Agonist 
of cell Death (BAD) and Bcl-2 Associated X (BAX)) proteins which can in turn activate the 
intrinsic apoptotic pathway, demonstrating crosstalk between both pathways (Mariño et al., 
2014). The extrinsic apoptotic pathway is demonstrated in Figure 2.3. 
 
 
Figure 2.3-Extrinsic Death receptor apoptotic pathway.  FasL and TNF-α death ligands bind FasR 
and TNFR1 death receptors causing homo-trimeric ligation, recruiting FADD and TRADD adaptor 
proteins forming the DISC complex. DISC can then catalytically cleave procaspase 8 causing its 
activation. This in turn can catalytically activate pro-executioner caspases (3, 6 or 7) initiating 
apoptosis. This figure was self-generated using Microsoft PowerPoint based on the current 
understanding of knowledge from a multitude of sources. 
 
Internal stimuli (oxidative stress, DNA damage, hypoxia, growth factor deprivation or 
organelle dysfunction) initiate the intrinsic apoptotic pathway through activation of the pro-
apoptotic family of BH3 proteins, such as BAX and BAK, and the inhibition of anti-
apoptotic proteins such as the Bcl-2 family of proteins (Martin and Henry, 2013). Once the 
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apoptotic threshold of pro apoptotic BH3 proteins has been reached, activated BAX and 
BAK oligomerise and attach to the outer mitochondrial membrane. Here they simultaneously 
inhibit mitochondrial membrane bound anti-apoptotic Bcl-2 proteins such as Bcl-xL, and 
initiates Mitochondrial Outer Membrane Permeabilisation (MOMP) (Suhaili et al., 2017).  
 
MOMP results in the release of pro-apoptotic intermembrane space proteins such as 
cytochrome c, which once released into the cytosol, binds to and activates Apoptotic protease 
activating factor 1 (Apaf1). Apaf1 is an inactive cytosolic pro-apoptotic protein which is 
synthesised in a dormant state similar to that of procaspases (Kalkavan and Green, 2018). 
Activated Apaf1 then forms an oligomeric complex known as the apoptosome, a large wheel 
like quaternary protein assembly which serves to activate initiator caspase 9, which then 
goes on to cleave and activate executioner caspases 3, 6, and 7, initiating apoptosis (Shakeri, 
Kheirollahi and Davoodi, 2017). MOMP and activation of the intrinsic apoptotic pathway 




Figure 2.4-Intrinsic mitochondrial apoptotic pathway.  Intracellular stress signals (xenobiotics, 
oxidative stress) disrupt mitochondrial signalling activating pro-apoptotic Bax and Bad forming 
MOMP complex and releasing mitochondrial bound cytochrome-c. Released cytochrome-c binds 
with Apaf-1 forming apoptosome which catalytically cleaves pro-initiator caspases (2, 8, 9, and 10) 
which in turn activate pro-executioner caspases (3, 6, or 7) initiating apoptosis. This figure was 
self-generated using Microsoft PowerPoint based on the current understanding of knowledge from 
a multitude of sources. 
 
Other pro-apoptotic intermembrane space proteins released in response to MOMP are 
Apoptosis inducible factor (AIF) and endonuclease G (eG). AIF and eG are part of what is 
known as caspase independent apoptosis, as both translocate to the nuclease causing 
significant DNA degradation and induction of apoptosis, but are not activated by or cause 
the activation of caspases (Yang et al., 2017). 
 
 ROS signalling apoptosis: 
ROS has been seen to play a dual role in regulating apoptosis, serving as both an inhibitor 
and an inducer in a concentration dependent manner. Low levels of H2O2 have been seen to 
inhibit apoptosis through signalling cell survival pathways and activation of the tumour 
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suppressor p53 (Redza-Dutordoir and Averill-Bates, 2016). Low levels of oxidative stress 
causes p53 induced cell cycle arrest, DNA repair and senescence, allowing the cell to repair 
any damage and survive (He and Simon, 2013). However prolonged p53 signalling in 
response to high levels of ROS and oxidative stress results in p53 inhibition of anti-apoptotic 
Bcl-2 protein, and upstream regulation of both extrinsic and intrinsic apoptotic pathways 
(Aubrey et al., 2018). Procaspases and caspases also possess redox sensitive cysteine 
residues in their active sites, facilitating redox regulation. Theses cysteine residues can 
become activated upon oxidation by ROS initiating the apoptotic pathway, or in some 
circumstances can experience inhibitory irreversible inactivation (Izeradjene et al., 2005). 
Pro-caspases-3 and -9 are also available to undergo S-Glutathionylation, reducing the 
accessibility for proteolytic cleavage and activation. This process occurs during low levels 
of oxidative stress where antioxidant defences attempt to repair oxidative damage before 
apoptotic signalling kills the cell (Huang et al., 2008). However if this damage is irreparable 
or levels of oxidative stress are increased then apoptotic mechanisms will become activated. 
 
ROS signals the intrinsic apoptotic pathway by targeting mitochondrial DNA and RNA, and 
by causing disruption to the electron transport chain and ATP production, leading to the loss 
of mitochondrial membrane potential and MOMP formation, initiating apoptosis (Wu and 
Bratton, 2013). P53 activation has also been implicated as an upstream regulator of 
mitochondrial apoptosis by directly inhibiting Bcl-2 anti-apoptotic proteins (Bcl-2, Bcl-XL 
and Mcl-1) and directly activating pro-apoptotic proteins (Bax and Bak) facilitating MOMP 
(Pietsch et al., 2008; Aubrey et al., 2018).  
 
ROS has been seen to be an activator of TNFR1, initiating the death receptor pathway 
through activation of DISC and caspase 8 activation (Wajant and Siegmund, 2019). Many 
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components of the death receptor pathway consist of redox sensitive proteins, such as 
Apoptosis signal-regulating kinase 1 (ASK1) and JNK. ASK1 is a downstream component 
of TNFR signalling, and under normal conditions is kept inactive by bound reduced Trx 
(Hattori et al., 2009). However under high levels of oxidative stress Trx becomes oxidised 
releasing ASK1 which serves to activate JNK, initiating apoptosis (Soga, Matsuzawa and 
Ichijo, 2012). JNK itself is activated by ROS, promoting apoptosis (Shi et al., 2014). Finally, 
FasL is seen to be both transcriptionally upregulated and catalytically activated by H2O2, 




In contrast to apoptosis, necrosis is generally associated with cell injury and premature death 
as a result of autolysis of the plasma membrane (reviewed Golstein & Kroemer, 2007). It is 
associated with pathologic processes such as exposure to bacterial/viral infection, 
toxins/venoms, and compounds capable of attacking the cell membrane (Escobar, Echeverría 
and Vázquez-Nin, 2015). Unlike apoptosis which is the controlled disintegration of the cell, 
necrosis is associated with the sudden and uncontrolled release of intracellular contents into 
the surrounding area (Escobar, Echeverría and Vázquez-Nin, 2015). This release is 
detrimental to surrounding cells, and necrosis is significantly associated with initiation of 
the inflammatory response, while apoptosis is seen to be significantly less inflammatory 
(Martin and Henry, 2013).  
 
However while initially thought to be a form of uncontrolled cell death, necrosis has in some 
instances been seen to be mediated by multiple highly regulated intracellular signalling 
pathways (Festjens, Vanden Berghe and Vandenabeele, 2006). This form of regulated 
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necrosis is often referred to as necroptosis, and demonstrates shared morphological features 
of both necrosis and apoptosis (Dhuriya and Sharma, 2018).  
 
Necrosis often refers to the un-programmed swelling and rupture of the cell in response to 
severe injury, such as physical damage, heat, or toxins (Jog and Caricchio, 2014). 
Necroptosis shares similar features as necrosis such release of cytoplasmic content and 
initiating an inflammatory response, however necroptosis is seen to be regulated by many 
signalling pathways in a caspase independent manner (Karch and Molkentin, 2015), and can 
be inhibited at the molecular level by necroptotic specific inhibitors (Hou et al., 2019). 
Necroptosis is heavily regulated by Receptor Interacting Protein Kinase 1 and 3 (RIPK1 and 
RIPK3), which in turn are regulated predominantly by three signal transduction cascades, 
TNFR, Toll-like Receptor (TLR) and poly-(ADP-ribose) polymerase 1 (PARP1) (Berghe et 
al., 2014), as seen in Figure 2.5. PARP1 is an enzyme involved in DNA repair such as single 
and double strand breaks. Its primary role is to catalyse the formation of poly ADP-ribose 
chains to both itself and to target proteins using NAD+ as a cofactor to recruit further DNA 
repair mechanisms (Ray Chaudhuri and Nussenzweig, 2017).  
 
Interaction of RIPK1 with activated death receptors (e.g. TNFR) leads to the activation of 
RIPK1 which subsequently activates RIPK3 (He et al., 2009). However RIPK1 activation 
can only take place when caspase 8 is inactive which may occur in response to viral, bacterial 
or pharmacological factors (Tummers and Green, 2017). Caspase 8 thus acts as a molecular 
switch between apoptosis and necroptosis (Tonnus et al., 2019). Activated RIPK3 in turn 
phosphorylates a pseudo kinase called Mixed Lineage Kinase Like (MLKL) protein. 
Phosphorylated MLKL then oligomerises and translocates to the plasma membrane. Here it 
forms a transmembrane pore, compromising membrane integrity, resulting in necrosis and 
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induction of the inflammatory response through the release of damage associated molecular 
patterns (DAMPs) (Dhuriya and Sharma, 2018). 
 
TLR regulated necroptosis follows a similar pathway to TNFR mediated signalling. TLR 3 
or TLR 4 use the adaptor molecule TIR domain-containing adapter-inducing interferon-β 
(TRIF), to directly activate RIPK3, which initiates the downstream necroptotic signalling 
cascade involving MLKL and loss of plasma membrane integrity (Kaiser et al., 2013). 
 
Following extensive DNA damage by ROS or DNA damaging agents, the DNA repair 
enzyme PARP1 becomes hyper activated (Shin et al., 2015). PARP1 catalyses the hydrolysis 
of NAD+ into nicotinamide in order to catalyse the addition of  poly-ADP-ribose side chains 
to itself and target proteins, and so hyper activation results in a severe drop in NAD+  and 
ATP levels, and induction of cell energy failure death mechanisms (Alano et al., 2010). This 
signals the activation of RIP1K which can initiate RIPK3 mediated necrosis, or activates c-
Jun N-terminal Kinase (JNK) which then translocates to the mitochondria where it induces 
mitochondrial membrane depolarisation, resulting in loss of membrane integrity and 
membrane rupture, initiating necrosis (Baines, 2010). The three main necroptotic pathways 
are represented in Figure 2.5. 
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Figure 2.5-Necroptotic cell death pathways.  TNFR1/TLR3 and 4 death receptor activation results 
in the activation of RIPK1, which in turn activates RIKP3. RIPK3 then activates MLKL which 
dimerizes and migrates to the cell membrane, where it forms membrane pores resulting in a loss of 
membrane integrity and the release of pro-inflammatory DAMPs. Intracellular ROS can induce 
DNA damage which activates PARP1. PARP1 hyper activation depletes the cell of NAD+ and 
ATP, resulting in RIPK1 activation. RIPK1 can then active the RIKP3/MLKL pathway or activate 
JNK which can target the mitochondria for membrane depolarisation and induction of 
mitochondrial necrosis. This figure was self-generated using Microsoft PowerPoint based on the 
current understanding of knowledge from a multitude of sources. 
 
As well as apoptosis and necroptosis, many other distinct variations of cell death exist. 
Examples of these and corresponding reviews detailing these processes are shown in Table 
2.1. Ferroptosis is an iron regulated form of necrotic cell death and is discussed in detail in 







Table 2.1-Alternate forms of cell death 
Form of Cell death: Mechanism: Review: 
Pyroptosis Regulated osmotic swelling 
and necrosis of infected 
macrophages 
(Robinson et al., 2019) 
Oncosis  Non-regulated ischemic cell 
death 
(Weerasinghe and Buja, 
2012) 
Entosis  Regulated invasion of a 
living/malignant cell into 
neighbouring viable cell 
(Galluzzi et al., 2018) 
Ferroptosis Iron regulated necrotic cell 
death 
(Xie et al., 2016) 
Lysosomal cell death Regulated release of 
cathepsins causing necrotic 
or apoptotic cell death 
(Aits and Jäättelä, 2013) 
 
 
 ROS signalling and necrosis/necroptosis: 
ROS can signal necrosis/necroptosis through many different pathways, for example via 
induction of PARP1, mediated necrosis secondary to ROS induced DNA damage. During 
times of sustained oxidative stress calcium homeostasis can become dysregulated. 
Disruption of calcium homeostasis and influx of calcium into the ER increases the activity 
of NOS enzymes and thus nitric oxide production and oxidative stress. Elevated nitric oxide 
can disrupt mitochondrial stability and thus lead to the release of ROS such as superoxide. 
Superoxide can react with nitric oxide forming peroxynitrite, which in turn can cause 
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significant levels of DNA damage therefore activating PARP1. The loss of mitochondrial 
integrity would significantly reduce the cells ATP producing capacity, which when coupled 
with energy deficiency from PARP1 activation, will initiate necroptosis. Nitric oxide has 
also been seen to inhibit caspases through nitrosylation, therefore reducing the apoptotic 
capacity of the cell, further favouring necrosis (Festjens, Vanden Berghe and Vandenabeele, 
2006; Berghe et al., 2014; Karch and Molkentin, 2015; Tonnus et al., 2019).  
 
 Dysregulation of cell death mechanisms and cancer: 
The ability of cancer cells to evade cell death has been discussed as a primary hallmark of 
cancer cells and the oncogenic process. As such the manipulation and dysregulation of both 
apoptotic and necrotic/necroptotic pathways to favour unrestrained cell growth is a primary 
mechanism of this hallmark. 
 
 Apoptosis and Cancer:  
Cancer cells arise from the imbalance of regulatory mechanisms controlling the expression 
of cell cycle control genes and apoptotic regulatory genes. Cancer cells evade apoptotic 
mechanisms through the dysregulation of Bcl-2 family proteins and increased expression of 
Inhibitors of Apoptosis Proteins (IAPs), reduced caspase activity, defective or mutated p53 
signalling, and impaired receptor signalling pathways (Hassan et al., 2014). Cancer cells 
utilise dysregulated apoptotic protein signalling pathways to confer distinctive survival 
advantage and escape cell death mechanisms. This is done via downregulation of pro-
apoptotic genes (Bax, Bak, Bid, Bim, Puma, and Noxa), or the overexpression of anti-
apoptotic genes (Bcl-2, Bcl-xL, Mcl-1, BF-1) or IAPs (XIAP, cIAP1, cIAP-2, survivin) 
(Chen, Zeng and Zhou, 2018). Increased anti-apoptotic Bcl-2 proteins serve to inhibit their 
BH3 containing pro-apoptotic Bcl-2 counterparts by preventing them from forming MOMP 
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and initiating intrinsic apoptotic pathways (Campbell and Tait, 2018). IAPs are endogenous 
inhibitors of apoptosis which serve to inhibit caspase activity by marking them for 
degradation (Pluta et al., 2015). The disruption of the balance between expression of pro and 
anti-apoptotic genes and proteins has been demonstrated in many different cancers, reducing 
overall survival rates and has been implicated in the prevalence of acquired resistance to 
chemo or radiotherapies (Wong, 2011).  
 
Reduced caspase activity can be initiated in response to reduced signalling of pro-apoptotic 
signals previously mentioned or through direct downregulation of caspase genes, further 
reducing the apoptotic capacity of the cell (Jakubowska et al., 2016). P53, referred to as the 
guardian of the genome and one of the most studied tumour suppressor proteins, has been 
seen to be mutated in almost 50% of all cancers (Rivlin et al., 2011). As discussed p53 is a 
major regulator of apoptosis, cell cycle regulation, differentiation, DNA repair and cellular 
senescence. Loss of p53 signalling would result in further dampening of apoptotic signalling 
(Aubrey et al., 2018).  
 
Finally, many cancers have been seen to possess several abnormalities in many of their death 
receptor signalling pathways. Other members of the death receptor family, such as Death 
Receptor 3 (DR3), Death Receptor 4 (DR4), and TNF‐related apoptosis‐inducing ligand 
(TRAIL), have been seen to be altered in different cancers (Oikonomou and Pintzas, 2013). 
Many cancer cells have been seen to either reduce the expression of these receptors or their 
ligands, or impair their function through downregulation of surface receptors by generating 
receptors without an intracellular death domain (decoy receptors) capable of propagating the 
extracellular death signal from the death ligand (Shirley, Morizot and Micheau, 2011). 
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 Necroptosis and cancer: 
Necroptosis has been implicated in all three stages of cancer, initiation, progression and 
metastasis (Najafov, Chen and Yuan, 2017). However it is seen to have dual roles in whether 
it acts as an oncogenic factor or tumour suppressor, and does so in a cancer type specific 
manner (Seifert and Miller, 2017). RIPK3 has been seen to be targeted by the epigenetic 
machinery of cancer cells for genetic silencing through hyper methylation of its promoter 
region, in multiple cancers (breast, colorectal, Acute Myeloid Leukaemia (AML)) and has 
been associated with poor prognosis and survival rates (see references 7 and 65, Gong et al., 
2019 ). MLKL has also been seen to be downregulated in AML, with both RIPK3 and MLKL 
being downregulated in T-cell Lymphomas (Höckendorf, Yabal and Jost, 2017; Van Hoecke 
et al., 2018). As most cancer cells have escaped the control of apoptotic processes, reducing 
the necroptotic fail safe cells have for such an event may provide a survival advantage to 
certain cancer cells (Gong et al., 2019).  
 
However many cancers have been seen to have increased RIPK3 expression (glioblastoma, 
lung, and pancreatic adenocarcinoma) which has also been associated with poor prognosis 
and overall survival rates (see references 10, 72, 64 and 73, Gong et al., 2019). Much of the 
role necroptosis plays in promoting tumour progression and metastasis comes from its 
regulation of the surrounding microenvironment and immune cell suppression (Qin et al., 
2019). The release of pro-inflammatory cytokines and DAMPs may stimulate proliferation 
in surrounding cells, further promoting neoplasia through increased levels of ROS or RNS 
(Gong et al., 2019). It has also been demonstrated that the release of certain cytokines can 
promote an immunosuppressive microenvironment by downregulating Tumour Associated 
Macrophages, a phenomena demonstrated in pancreatic adenocarcinoma cells (Seifert et al., 
2016). 
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Cancer cells appear to hijack RIPK3 and necroptotic signalling to induce necroptosis in 
surrounding endothelial cells in order to facilitate metastasis and extravasation in order to 
invade foreign tissues. This has been demonstrated by Strilic et al., (2016), using co cultures 
of human and murine endothelial and tumorigenic cells in the presence of necroptotic 
inhibitors, demonstrating that tumorigenic cells utilise Death Receptor 6 (DR6) expressed 
on endothelial cells to initiate necroptosis as part of the metastatic process (Strilic et al., 
2016).  
 
As cancer cells generally possess inherent resistance towards apoptosis and with the 
prevalence of acquired resistance, the necroptotic pathway may be a lucrative alternative for 
potential chemotherapeutic intervention (Wu, Dong and Sheng, 2020). 
 
The mechanism through which the novel compounds initiate cell death is therefore of high 
importance, with apoptotic induced cytotoxicity being favoured over necrosis in order to 
minimise inflammation and collateral damage to surrounding cells. To determine the 
cytotoxic capabilities of the novel phen compounds CMPD 73 and CMPD 74, a panel of 
different cancer cell lines, and one cell line of non-cancerous origin were exposed to both 
compounds for 24 hours and cell viability was measured using the Alamar Blue assay, and 
cell cytotoxicity using the LDH assay and the AnnexinV-FITC/PI Dead cell assay for 
apoptosis.  As a point of comparison, known chemotherapeutic agents cisplatin and 





As a first step in the characterisation of these new compounds, we evaluated their 
cytotoxicity in a panel of different cell lines, including several cancer lines of different origin 
and one of non-cancerous origin. To determine compound efficiency alongside a mainstream 
anti-cancer drug, cisplatin was also tested in parallel in some experiments.  
 
 Materials 
Compounds 73, 74 as well as all precursors were synthesised in house according to standard 
procedures (McCann et al., 1997; Gandra et al., 2017) and dissolved in sterile water as 
10mM stocks. The characterisation data for both compounds can be seen in the Appendix 
page 271. The following cell lines were used: A2780 (ovarian cancer), A549 (alveolar 
adenocarcinoma), HT-29 (colonic adenocarcinoma), PC3 (prostatic carcinoma), U373MG 
(glioblastoma), CS and CR P31 cells (isogenic cisplatin sensitive and cisplatin resistant 
mesothelioma cells, respectively). BeaS2B (SV40/adenovirus 12 transformed bronchial 
epithelium) were used as a non-cancer origin cell system. Cells were cultured in RPMI 1640, 
supplemented with 10% foetal bovine serum and 1% L-glutamine, with the exception of 
BeaS2B and U373MG, which were cultured in DMEM with supplements as above. Cells 
were incubated in a humidified atmosphere of 5% CO2 in air at 37°C. A solution of 0.44mM 
Resazurin salt in PBS (pH 7.4) was prepared in house. This is equivalent to the commercial 
Alamar Blue reagent (O’Brien et al., 2000).  
 
The Lactate Dehydrogenase (LDH) cell cytotoxicity assay was conducted as per 
protocol (Chan, Moriwaki, & De Rosa, 2013). The preparation of the LDH reagent was 
conducted in house on the day of experimentation and was prepared as follows: 200µl of 
INT (2-p-iodophenyl-3-p-nitrophenyl-5-phenyl tetrazolium chloride, 3.3mg/ml stock 
prepared in DMSO), 200µl of PMS (N-methylphenazonium methyl sulfate, 0.9mg/ml stock 
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in H2O), 98mg of Lithium Lactate (Sigma), and 17.4mg of NAD (nicotinamide adenine 
dinucleotide) were added to 10mls of H2O and 5mls of 200mM Tris pH 8. Reagent was 
stored in the dark at four degrees until use. All reagents were purchased from Sigma Aldrich 
Ireland. 
 
The Annexin V FITC/PI Dead Cell apoptosis Kit (V13242 Thermo Fisher) was prepared as 





 Cell Viability Assay 
Cells were plated in octuplet wells (1x104 cells/well in 100L of media) of Greiner 96 well 
flat-bottomed, black-walled plates and allowed to acclimatise over-night before exposure to 
the different compounds. Following drug exposure for the specified time (typically 24 hours) 
cell viability was then investigated using the Resazurin reduction assay, also known as the 
Alamar Blue assay, described in section 2.4. 10µl of resazurin reagent was added to each 
well (i.e. 10% of final well volume) and incubated for optimised, cell-specific time periods 
(2-4 hours). The fluorescence at the end of the incubation period was detected using a Spectra 
Max M3 spectrophotometer (Molecular Devices) at excitation 530 nm and emission 590 nm. 
Cisplatin was used as a drug of comparison in A2780 cells for 24 hours and in the isogeneic 
mesothelioma cell lines for 72 hours, in accordance with the timescale in which cisplatin 
became active within the cells. Data was expressed as a percentage of the non-treated control.  
 
A549 cells were selected as a model to investigate the cytotoxicity of compounds compared 
to constituent components and so were seeded at a density of 10,000 cells, allowed to attach 
overnight, and then exposed to test compounds. To fully map the molecular entity 
responsible for the biological activity, all complex components were tested individually or 
in combination.  Pilot studies of some combinations e.g. CuCl2/MnCl2 combined with TDDA 
(0.1%) did not elicit any cytotoxic response and so were not exhaustively investigated. The 
highest concentration of TDDA used was 4.5mM as higher concentrations resulted in 
artefactual resazurin reduction, leading to false positive results (result not shown). 
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 Cell cytotoxicity assay 
LDH Assay: A549 cells were plated in quadruplet wells (1x104 cells/well in 100L of media) 
of Greiner 96-well flat-bottomed clear plates and allowed to acclimatise over-night before 
exposure to the different compounds. Following drug exposure for the specified time 
(typically 24hours), 50L of cell supernatant was removed from each test well and dispensed 
into fresh wells of the same plate. 150L of LDH reagent was then added to each well and 
incubated for 45mins in the dark. Absorbance was measured at 490nm using a 
MULTISKANGO spectrophotometer (ThermoFischer) and data was expressed as a 
percentage of full lysis control (1% v:v of Triton-X 100). 
 
Annexin V FITC PI Flow Cytometry: A2780 cells were plated at 5x105 cells/well in a 6 well 
plate and allowed to acclimatise over-night before exposure to the different compounds. 
A2780 cells were used as A2780 cells were seen to be more sensitive to chemotherapeutic 
controls (cisplatin, doxorubicin) than A549 cells, allowing 24hr incubation periods over 
72hr. Cells were then exposed to approximate IC50 concentrations of CMPD 73 (45µM), 74 
(3µM) and 1,10-Phen (200µM) for 24hrs. Doxorubicin (3µM) was also used as a positive 
inducer of apoptosis, and is reported to have a very low IC50 value when used in A2780 cells 
(Altaf et al., 2019). Following 24hr treatment, A2780 cells were then stained with Annexin 
V FITC/PI for 15mins as per protocol, and read in a BD Accuri C6 Flow cytometer, using 
FITC FL1 channels and PI FL3 channels. Compensation between FL1 and FL3 channels 
was conducted as per the BD Accuri C6 cytometer manual in order to remove spectral 
overlap between FITC and PI. Dead cells and cellular debris were removed by selective 
gating based on forward and side scatter data, and a positive response was selected by gating 
events with a higher fluorescent intensity than that of the non-treated control. Levels of 
apoptosis were determined using quadrant-based gating strategies. Lower Left (LL) 
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quadrants contained low FITC/PI expressing cells and were determined to be viable cells. 
Lower Right (LR) quadrant contained high FITC expression but low PI and were determined 
to be early apoptotic cells with bound AnnexinV but without membrane permeabilization. 
Upper Right (UR) quadrants contained cell populations expressing both high FITC and PI 
levels and were determined to be late stage apoptotic cells with high levels of bound 
AnnexinV and instances of membrane permeabilization allowing entry of PI. Upper Left 
(UL) quadrants were determined to be cell populations with high levels of PI but low levels 
of FITC and were therefore determined to be predominantly necrotic cells with high levels 
of membrane permeabilization.  
 
 Statistical analysis  
All data including calculation of IC50 values was analysed using GraphPad Prism Version 
8.3. Statistical analysis was conducted using Two-way ANOVA, multiple T-Test or students 
T-Test where applicable. Significant differences were expressed as a P Value < 0.05, 0.01, 
0.001. Where multiple T-test analysis was used, Figure 10.1 and Figure 10.2 in the 
appendices provides an example of output of the comparisons made by GraphPad Prism 
Version 8.3.   
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 Results:  
 Cytotoxic effects of metal-based drugs 
To investigate the cytotoxic effects of metal-based drugs and identify suitable cell models 
for future experiments a variety of cancer cell lines were tested. Cell lines which 
demonstrated the highest cytotoxic effect following exposure to test compounds were 
investigated further. As shown in Table 2.2, CMPD73 shows cancer cell cytotoxicity against 
A2780 ovarian (IC50 45 µM), A549 alveolar (IC50 45 µM) and Cisplatin Resistant (CR Meso, 
IC50 49 µM), but not Cisplatin Sensitive mesothelioma (CS Meso, IC50 306 µM). IC50 values 
for the other cell lines ranged from 250-430 µM. CMPD 73 is seen to be comparable with 
cisplatin following 24hr treatment in ovarian cancer cells (IC50 27 µM) and following 72hr 
treatment with Cisplatin Sensitive mesothelioma (Table 2.3). 1,10-Phen demonstrated a 
similar high micro-molar range (329-580 µM) across all cell lines. PC3 cells were not 
available for treatment with 1,10-Phen.  
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Table 2.2 Cytotoxic effect of novel compounds and 1,10-Phen on cultured human cancer cells 
following 24 hrs. 
Cell Line  
IC50 µM 
(95% CI) 
CMPD73  CMPD74  1,10-Phen 























































N.A- Not available 
 
Interestingly, CMPD 73 is seen to overcome cisplatin resistance in the Resistant 
Mesothelioma cell line when compared to cisplatin (Table 2.3, Figure 2.6) following 72hr 
treatment, indicating applicability as a novel treatment for acquired chemotherapeutic 
resistance.  
 
A direct comparison with the data described by Gandra et al., (2017) regarding the effects 
of CMPD 73 against A549 cells demonstrates some variability with the results from Table 
2.2. Gandra et al., (2017) determined the CC50 of CMPD 73 to be 261.7mg/L (calculated to 
356 µM) which is significantly higher than the IC50 value of 45µM seen in Table 2.2. 
However the method Gandra et al., (2017) used to determine this value was the MTT assay, 
whereas the Alamar Blue assay was used to determine the IC50 values in Table 2.2. While it 
would be expected that both assays should provide comparable results these inconsistencies 
 72 
can likely be explained by differences in sensitivity between the MTT and Alamar Blue 
assays (Hamid et al., 2004; Damiani et al., 2019), batch variability among the synthesised 
compounds or slight differences in the A549 cells themselves. Variability among compounds 
used for cancer cell screening is also a common obstacle in modern cancer research (He et 
al., 2016).  
 
Table 2.3-Effectiveness of CMPD 73 and CMPD 74 is not impacted by the presence of cisplatin 
resistance following 72 hr incubation  (Data generated from two independent experiments)  
Cell Line  
IC50 µM  
(95% CI) 
CMPD73  CMPD74  Cisplatin 







CR Meso.  
4.1 a 
(3.6-4.6) 
2.4 a  
(1.2-3.5) 
59.1 b  
(43.1-75.0) 
(a Significantly different from Cisplatin control P<0.05, b Significantly different from CS Meso P<0.05 
calculated using students t-test). 
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Figure 2.6 Cytotoxic effects of Cisplatin, CMPDs 73 and 74 against CS Meso (A) and CR Meso 
(B) cells following 72hr incubation.  (± 1 Standard Deviation of two independent experiments 
using 8 technical replicates). 
 
CMPD 73 and its constituent components were tested using A549 cells. As an intact 
compound CMPD73 is moderately more cytotoxic towards A549 cells than either 1,10-Phen 
or 1,10-Phen combined with free manganese (Figure 2.7). CMPD 69 (precursor to CMPD73 
lacking the 1,10-Phen moiety) displayed limited activity with high micro-molar/milli-molar 





Figure 2.7 Cytotoxic profiles of CMPD 73, and its constituent components CMPD 69 (Mn-TDDA), 
MnCl2, 1,10-Phen, and combinations of each constituent in A549 cells. (±1 Standard deviation of 
three independent experiments using 4 technical replicates). 
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Table 2.4-P Values of manganese and phen components and combinations compared to CMPD 73 
at each concentration tested.  






500nM N.S N.S N.S N.S N.S N.S 
5M P<0.001 P<0.001 P<0.001 N.S N.S P<0.01 
50M P<0.001 P<0.001 P<0.001 N.S N.S P<0.01 
500M P<0.001 P<0.001 P<0.001 P<0.001 P<0.01 P<0.001 
1mM P<0.001 P<0.001 P<0.001 P<0.001 P<0.001 P<0.001 
(Calculated using multiple T-Tests) (N.S= not significant) 
 
CMPD 74 is seen to be significantly more cytotoxic than CMPD73, with IC50 Values in the 
low M range (2-6M, Table 2.2) However the compound did not appear to possess either 
cancer cell specificity or cancer cell selectivity, as it is equally as effective against all cell 
lines, cancerous and non-cancerous (Table 2.2). In time course studies it is observed that 
potent cytotoxic action of CMPD74 is readily observable in short time courses – the IC50 
against A549 cells is 6.3M within 6 hours and that against CS Meso. is 6.5M within 8 
hours. This is very similar to the value following 24 hours. The IC50 value of CMPD 74 was 
also seen to be comparable with the data described in Gandra et al., (2017), where a value 
of 1.06mg/L (1.4M) was obtained.  
 
Compound 74 (CMPD74) and its constituent components were tested using A549 cells 
(Figure 2.8). These data indicate that both copper and 1,10-Phen are required to generate 
potent cytotoxic effects in this cell model with effects most obvious at 5M (Figure 2.8 light 
grey columns). A slight additive effect of CMPD74 compared to a mix of components is 
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noted. No significant effect is observed under conditions lacking copper and 1,10-Phen 
together.  
 
Figure 2.8 Cytotoxic profiles of CMPD 74, and its constituent components CMPD 70 (Cu-TDDA), 
CuCl2, 1,10-Phen, and combinations of each constituent in A549 cells (±1 Standard Deviation of 
three independent experiments using 4 technical replicates). 
 
Table 2.5-P Values of copper and phen components and combinations compared to CMPD 74 at 
each concentration tested  






50nM N.S N.S N.S N.S N.S N.S 
500nM N.S P<0.001 N.S N.S N.S N.S 
5M P<0.001 P<0.001 P<0.001 N.S N.S P<0.001 
50M P<0.001 P<0.001 P<0.001 P<0.001 P<0.001 P<0.001 
(Calculated using multiple T-Tests) (N.S= not significant) 
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 Membrane Integrity- LDH assay 
To examine if necrosis is the key mode of cell death, we employed the LDH assay, which is 
based on the release of LDH from cells which lyse during necrosis and is thus a measure of 
the integrity of the plasma membrane (Chan, Moriwaki and De Rosa, 2013). Surprisingly, 
treatment of cells with CMPD73 resulted in a paradoxical reduction in LDH activity (Figure 
2.9), with measured LDH activities in the presence of higher concentrations of the 
compound actually less than that of the negative control. Addition of EDTA before the assay 
procedure eliminates the inhibitory effect on LDH activity, suggesting that free metal ions 
are involved in the process (compare lanes 9 and 10 in Figure 2.9). These data are consistent 
with findings in the literature where Cu2+ has been reported to markedly inhibit LDH 
activity in brain homogenates at a concentration of 10µM, while Mn initially induced 
activity and subsequently markedly decreased it (Heron et al., 2001). Raw absorbance values 
were zero following blank subtraction compared with 1.11 absorbance values in wells where 
0.1% triton was used. Treatment with EDTA in wells treated with 1mM CMPD 73 gave 
average absorbance units of 0.39. 
 
Similar results were obtained for CMPD74, although the effect is not as potent (Figure 2.10). 
Again, EDTA eliminates the inhibitory effect. Raw absorbance values were also zero 
following blank subtraction, however 10M of CMPD 74 did appear to elicit a response 
giving an absorbance value of 0.483, which is comparable with EDTA-treated wells using 
CMPD 74 at 100µM (absorbance of 0.432). 1, 10- Phen (data not shown) did not appear to 




Figure 2.9 Inhibition of LDH activity in A549 cell supernatant by CMPD73. Visualization of LDH 
enzyme inhibition with increasing concentration of CMPD 73 as seen by loss of colour change of 
LDH assay reagent, when compared to triton control and EDTA control preserving LDH activity. 




 Mode of cell death – Annexin/PI flow cytometry staining  
To determine whether CMPD 73 and 74 were capable of initiating apoptosis as the 
mechanism through which they kill cancer cells, A2780 ovarian cancer cells were stained 
with AnnexinV-FITC and PI following 24hr treatment with IC50 concentrations of test 
compounds and Doxorubicin control. AnnexinV-FITC/PI staining utilises a FITC 
conjugated AnnexinV protein which has a strong affinity towards a plasma membrane 
phospholipid phosphatidylserine (PS). During apoptosis, PS is flipped from the cytosolic 
domain of the plasma membrane to the extracellular side of the plasma membrane, where it 
acts as a recognition marker for phagocytes to engulf apoptotic cells. FITC bound AnnexinV 
is therefore a useful biomarker for cells undergoing apoptosis. Counter staining with PI, a 
DNA intercalating fluorescent dye which can only enter the cell upon plasma membrane 
1 2 3 4 5 6 7 8 9 10 
Figure 2.10 Inhibition of LDH activity in A549 cell supernatant by CMPD74.Visualization of LDH enzyme 
inhibition with increasing concentration of CMPD 74 as seen by loss of colour change of LDH assay reagent, 
when compared to triton control and EDTA control preserving LDH enzymatic activity in A549 cells. 
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permeabilization, can determine whether the cell is in late stage apoptosis where breakdown 
of the cell membrane is taking place if it is detected alongside AnnexinV-FITC expression. 
Cells expressing only PI are generally considered to be undergoing necrosis, as lysis of the 
plasma membrane by necrosis allows entry of PI without the expression of the apoptotic 
marker PS (Logue, Elgendy and Martin, 2009). 
 
CMPD 73 is seen to significantly induce the apoptosic pathway, as seen in Figure 2.11 (D) 
and Figure 2.12 demonstrating an increase (22.1%) in cells expressing both AnnexinV-FITC 
and PI (UR quadrant). Minimal amounts of early stage apoptosis were detected (2.2% LR 
quadrant), likely a result of longer exposure times to the compound, with shorter exposure 
times possibly increasing this percentage. Low levels of necrosis were detected (9.8% UL 
quadrant) indicating that CMPD 73 may induce low levels of necrosis. However this may 
also be a result of extreme late stage apoptosis owing to the presence of highly permeable 
apoptotic bodies. It is likely that apoptosis is the main form of cell death through which 
CMPD 73 exerts its cytotoxic effects.  
 
Similarly, CMPD 74 appears to significantly induce apoptosis over necrosis as its primary 
mechanism of cytotoxicity, however higher levels of necrosis were detected in CMPD 74 
(19.1%) (UL quadrant) when compared to CMPD 73 (9.8%), hinting at induction of necrosis 
(Figure 2.11E). However, this may again be indicative of very late-stage apoptosis rather 
than necrosis owing to 24 hr exposure time, as significant detection of late stage apoptosis 




1,10-Phen is demonstrated to have similar results to CMPD 73 (Figure 2.11 F, Figure 2.12) 
albeit with a slightly lower level of necrotic cells (4% UL quadrant). Near identical 
expression of late stage apoptotic cells (21% UR quadrant) is also seen compared to CMPD 
73. 
 
Surprisingly doxorubicin, used as an inducer of apoptosis demonstrated higher levels of 
necrosis (70% UL quadrant) than apoptosis (18% UR quadrant) in A2780 cells (Figure 2.11 
C, Figure 2.12), even when used at 0.3µM (55.8% necrosis vs 17.4% late apoptosis, 1-2% 
apoptosis) Figure 2.11 B). This effect is also seen at concentrations of 0.5 and 1µM (data 
not shown), further demonstrating that doxorubicin may favour necrosis over apoptosis in 
the A2780 cell model. 
 
Non-treated control cells (Figure 2.11 A, Figure 2.12) did not demonstrate any significant 
increases in either apoptosis or necrosis (91.5% viability as seen in LL quadrant). High levels 
of background fluorescence were detected in non-treated control cells regarding AnnexinV-
FITC (up to 104 -105 fluorescence units), resulting in normalisation of the x-axis. 
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Figure 2.11-Representative data (of three independent experiments) of Annexin-FITC/PI staining 
of A2780 cells to doxorubicin (0.3µM and 3µM) and CMPDs 73 (45µM), 74 (3µM) and 1,10-Phen 
(200µM).   A) Negative control cells showing no significant increase in Annexin-FITC/PI 
expression. B) Doxorubicin control showing an increase in expression of late apoptosis (UR 
quadrant) and necrosis markers (UL quadrant). C) Doxorubicin at higher concentrations showing a 
similar increase in late apoptosis markers and a significant increase in necrotic markers. D) CMPD 
73 displaying an increase in late apoptotic and a moderate increase in necrotic markers. E) CMPD 
74 displaying a significant increase in late apoptotic markers and an increase in necrotic markers. 





































Figure 2.12-Expression of non-apoptotic, apoptotic, late apoptotic and necrotic markers following 
flow cytometric analysis of A2780 cells exposed to Doxorubicin (3µM), CMPD 73 (45 µM), 
CMPD 74 (3 µM) and 1,10-Phen (200 µM) stained with Annexin-FITC/PI. (± 1 Standard deviation 
of three independent experiments using duplicate technical replicates) points of significance 
calculated using multiple t-test (a= P<0.01 compared to control) (b=P<0.05 compared to control) 




The cytotoxic properties of two new coordination compounds, which incorporate a 
trioxaundecanedioate rather than an octanedioate acid linker to enhance aqueous solubility, 
were evaluated. CMPD73 incorporated manganese as a coordinating metal, while CMPD74 
incorporated copper. Importantly for cell experiments, these new compounds were found to 
be readily water soluble, particularly the copper-based compound, in contrast to its 
octanedioate-based analogue, which is only partially soluble in aqueous media, even 
following sonication (Kellett et al., 2011).  
 
Both compounds were seen to be effective against a panel of cancer cell lines including cells 
with a cisplatin resistant phenotype, with CMPD 73 observed to be more active against 
ovarian, lung and the cisplatin resistant mesothelioma cell line than all other cell systems 
tested. Apoptosis was identified as the primary mechanism of cell death activated by both 
compounds, with evidence for compound dissociation as an active part of compound 
cytotoxicity also observed.  
 
CMPD74 is observed to be significantly more active than CMPD73 in the reduction of 
resazurin (i.e. the Alamar Blue) assay. Estimated IC50 values (24-hour exposure) for 
CMPD74 were in the low (2-7) micro molar range across all cell types tested, while those 
for CMPD73 were approximately 45 µM for A2780 (ovarian) and A549 (lung epithelia) 
cells, and greater than 200µM for the remaining cells lines. Inclusion of HT29 (colonic) cells 
allowed comparison of the novel compounds described here with their saturated analogues.  
 
The current results were comparable with data previous reported for the octanedioate 
analogue (Kellett et al., 2011). IC50 values for CMPD74 were estimated at 6, 8, 24, and 72 
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hrs after treatment. Almost identical values for IC50 were obtained, indicating that its mode 
of action is very rapid and intracellular activation, if any, proceeds very rapidly.  Use of 
isogenic cisplatin sensitive and resistant cells revealed an intriguing observation for 
CMPD73 – in cisplatin resistant cells only, the estimated IC50 value (49 µM with 24 hours 
exposure) were observed to be in the same range as the estimates for A2780 and A549 cells, 
significantly lower than the IC50 for cisplatin sensitive cells. This selectivity disappeared 
when these cells were exposed to the compounds for 72 hours. The reason(s) for the 
selectivity towards these cells during short incubations are unclear and warrant further 
investigation.  
 
Using A549 cells as a model, we combinatorically evaluated the cytotoxic effects of each of 
the precursors of the coordination compounds. As Figure 2.7 and Figure 2.8 show, the 
presence of 1,10-phenanthroline is necessary to generate the cytotoxic effects. However, it 
did not seem to be critical if metal-trioxaundecanedioate complexes or free metals were 
present. Compared to the presence of free 1,10-Phen there is a modest increase in efficacy 
for the CMPD73, with a greater magnitude of effect as the concentration of CMPD73 
increases. Similar findings were observed for CMPD74, although the increase in efficacy, 
and concentration effect, were more pronounced. It is interesting to note that CMPD73 is 
only more effective than 1,10-Phen in the three cell models noted above - A2780, A549 and 
cisplatin resistant mesothelioma.    
 
Treatment with different coordination complexes has been reported to lead to cell death by 
a variety of different mechanisms, such as necrosis and apoptosis (Ndagi, Mhlongo and 
Soliman, 2017).  Initial attempts to assess if necrosis is the principal mode of cell death were 
unsuccessful due to the impact of the compounds on the LDH assay, which assesses 
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membrane integrity. It has been reported that LDH activity may be reduced by various toxic 
compounds including menadione (a known superoxide generator), H2O2 and cisplatin 
(Kendig and Tarloff, 2007). In addition, it has been demonstrated in the literature that both 
copper and manganese ions are able to inhibit LDH enzyme activity (Dobryszycka and 
Owczarek, 1981; Xue et al., 2014). If the inhibition observed in the cell systems used here 
is due to release of free metal ions following the dissociation of the compound, then addition 
of EDTA would be expected to eliminate the inhibitory effect under assay conditions. 
Indeed, this is the case with the addition of EDTA leading to a restoration of LDH activity, 
which can be attributed to the sequestration of the metal ions by EDTA (Figure 2.9 and 
Figure 2.10). Using a modified LDH assay method where a molar excess of EDTA is added 
before the start of the LDH assay post compound treatment, it appears that significant 
metabolic effects occur at a much lower concentration than any effects on membrane 
integrity. Similarly as LDH serves as an intermediate link between glycolysis and the TCA 
cycle LDH inhibition either by compound activity or dissociation may serve as yet another 
metabolic mechanism of action.  However while interesting, this line of investigation is 
outside the scope of this thesis. This observation suggests that necrosis may not be the major 
mode of cell death and that other modes e.g. apoptosis are more likely explanations. 
Investigations using erythrocytes as model to test effects on membrane integrity are 
described Chapter 5.  
 
These data are further supported by the significant induction of apoptosis by both CMPD 73 
and 74 following the AnnexinV-FITC Dead Cell apoptosis assay. While some significant 
levels of necrosis were detected, this may be a result of long exposure times allowing 
accumulation of late stage apoptotic bodies rather than direct induction of necrosis, with the 
ratio of apoptosis to necrosis favouring apoptosis for both test compounds and 1,10-Phen. 
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While initially utilised as an apoptotic inducing agent, doxorubicin presented more necrotic 
cell death than apoptotic death.  
 
Doxorubicin has been demonstrated to be a strong anti-tumour drug and inducer of apoptosis 
(Pilco-Ferreto and Calaf, 2016). However as the ratio of late stage apoptotic cells to necrotic 
cells favours necrosis in doxorubicin treated cells at both concentrations, it appears 
doxorubicin may be more indicative of necrotic rather than apoptotic cell death in the A2780 
cell model. Doxorubicin has  been reported to induce necrotic cell death through activation 
of poly-(ADP-ribose) polymerase 1 (PARP1) in HK-2 cells (Shin et al., 2015) and at 
concentrations exceeding 1µM in A2780 cells (Demoy et al., 2000; Fong et al., 2012).  As 
such the data described demonstrating doxorubicin’s effects on necrosis rather than 
apoptosis will be influenced by the concentrations used. Therefore comparing metal-phen 
and phen compounds to doxorubicin at necrotic inducing concentrations supports metal-
phen mediated apoptosis induction over necrosis, as metal-phen cell populations appear to 
flux through apoptosis before entering necrotic/late apoptotic stages of cell death.  Given the 
importance of the metal ligand for the overall structure of the novel compounds tested here, 
examination of the potential involvement of ferroptosis (a metal dependent cell death 
mechanism) will be prudent to rule out its involvement in mediating the effects described 
here (Dixon et al., 2012; Feng and Stockwell, 2018).  
 
Comparison of CMPD 73 with 1,10-Phen supports previous observations that much of 
CMPD 73’s cytotoxicity may be driven by the action of 1,10-Phen, with near identical 
apoptotic and necrotic levels following 24 hr treatment. When present at high concentrations, 
1,10-Phen is known to be a protease inhibitor, due to its ability to chelate metals and it has 
also been widely used as a metal chelator during protein purification processes (Bencini and 
 88 
Lippolis, 2010). Chelation of metals present within cells (or provided via the cell media) has 
been shown to lead to the formation of a mixed population of metal-Phenanthroline 
complexes from 1,10-phenanthroline (e.g. as reviewed McCann et al., 2012), with potential 
cytotoxic activities. This is supported by the similarity of the cytotoxicity profiles of 1,10-
Phen alone and with addition of equimolar amounts of the copper or manganese chlorides 
(Figure 2.7 and Figure 2.8).  
 
In addition, generation of free 1,10-phen due to partial dissociation of the compound may 
lead to chelation of free ions such as magnesium or zinc, with potentially broad impacts on 
metabolic pathways. Magnesium is strongly associated the regulation of multiple enzymes 
of the glycolytic and oxidative phosphorylation pathways (reviewed Pilchova 2017). 
Chelation of magnesium by 1,10-Phen has been shown to alter energy metabolism (Laughlin 
1996). Many transcription factors and gene regulatory enzymes are zinc-binding proteins 
(Nyborg 2004). Events such as this may explain why cell viability assays (Alamar blue) 
detecting a disruption in cellular metabolism are more sensitive at detecting compound 
effects over cytotoxicity assays such as LDH. 
 
The observed impact of EDTA on the LDH assay is further evidence that there is some 
increase in the concentration of free metal ions following treatment with the novel 
compounds. If full dissociation and chelation occur, two moles of ‘alternate’ metal-phen 
complexes could be generated for each one mole of compound, potentially doubling the 
concentration that the cells would be exposed to in this event. Moreover, the typical 
concentration of copper in A549 cells is in the order of 0.1-0.2 mol/106 cells which would 
be of a similar order of magnitude to the highest concentration of 1,10-Phen used (González 
et al., 1999). Intracellular copper content is also known to increase significantly following 
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exposure to CuCl2  (Rupp et al., 2017). In this context it should be noted that the 
concentration of iron is approximately 5-6 times higher than that of copper.   
 
However, the greater efficacy of CMPD73 and CMPD74 compared to treatments including 
free 1,10-Phen support the contention that at least part of the supplied compound remains 
intact and functional. As 1,10-Phen is thought to contribute significantly to the overall 
cytotoxicity of the metal-phen compounds a greater increase in cytotoxicity would be 
expected from compounds containing twice the molar equivalent of 1,10-Phen than 1,10-
Phen alone.  
 
Taken together, these data are consistent with the idea that the observed action of the 
compounds is due to the presence of a mixture of different active agents formed in 
connection with the interaction of the compounds with biological fluids (Figure 2.13). While 
the evidence for this viewpoint is indirect, it should be noted that a very recent paper from 
Nunes et al.,(2020) presented detailed speciation data which supports the viability of this 
viewpoint. In that study, analogous copper-phen compounds decomposed when added mixed 
with cell media during experimental set-up and a variety of different metal-phen complexes 
were observed. This supports the proposed pathway outlined in Figure 2.13 and underscores 




Figure 2.13 Proposed model of pathways of action of metal-phen compounds in cell systems.  1) 
Dissociation of compound outside of cells to produce 1,10-phen, TDDA and the metal ion, 2) 
Chelation of metal (either original or alternate) present in cell medium by 1,10-phen, 3) direct uptake 
of intact compound by cells, 4) direct uptake of 1,10-Phen-metal complex by cells, 5) Dissociation 
of compound inside of the cell to produce 1,10-Phen, TDDA, and the metal ion, 6) Chelation of metal 
(either original or alternate) present within the cell by 1,10-Phen. Overall toxic action would be via 
a combination of various metal-phen complexes, potentially acting via different mechanisms.  
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3. Epigenetic Chemo-sensitisation strategies  
 Epigenetics 
Epigenetics is defined as heritable chemical alterations to DNA and its histone or non-
histone associated proteins, capable of changing the structure of chromatin, resulting in 
modulation of gene expression, without changing the DNA code itself (Rivera and Bennett, 
2010). It has emerged over the last decade as a key process explaining higher levels of 
complexity regarding gene expression by offering an extra highly dynamic layer of 
regulation independent from genes (Cohen et al., 2011). It has been demonstrated as 
essential for embryonic development, maintenance of specific cell lineages, and overall 
homeostasis of gene expression in response to environmental changes and cell signalling 
pathways (Rivera and Bennett, 2010). However it has also emerged as a process deeply 
involved in the initiation, progression, prognosis and potential treatment for many cancers 
(Biswas and Rao, 2017). These discoveries have begun to push epigenetics to the forefront 
of cancer research, acting as a target for the development of novel therapeutics and treatment 
regimes. 
 
Control of gene expression is carried out by combining the effects of altering the structural 
properties of packaged DNA (chromatin) and its interactions with various transcription 
factors through chemical modifications on either the chromatin proteins themselves or the 
DNA it envelopes. These signals can control mRNA production in its initial stages in 
response to cellular and environmental factors, and is mediated by the aforementioned 
processes of chromatin structure alteration, DNA modification and transcription factor 
binding (reviewed by Brkljacic & Grotewold, 2017).  
 
The most well characterised modifications are (i) DNA cytosine methylation, and (ii) Post 
Translation Modification (PTM) of the histone octamer, primarily acetylation and 
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methylation of lysine or arginine residues in the N-terminal tails of histone 3 (H3) and 
histone 4 (H4) (Gibney and Nolan, 2010). DNA methylation and histone modifications 
regulate gene expression by altering chromatin between eu- and hetero- chromatin states. 
They act as transcription factor binding sites, serving as ‘’epigenetic tags’’ for gene 
activation or repression (Rodenhiser and Mann, 2006).  
 
Initially, DNA and histone lysine methylation were associated with gene silencing, while 
DNA demethylation and histone lysine acetylation were associated with gene activation. 
However, it is now recognised that acetylation and methylation of lysine residues can act in 
a synergistic and context dependant manner to either contribute towards gene activation or 
repression, and form what has now been termed as the ‘’Histone Code’’ (Cosgrove and 
Wolberger, 2005). The most dynamic of epigenetic marks that make up this code are histone 
modifications. The ‘’Histone Code’’ is written by either epigenetic writers or erasers, being 
either transcriptionally active or repressive depending on their effects on chromatin structure 
(Morera, Lübbert and Jung, 2016). The dynamic action of the ‘’Histone Code’’ can be 
visualised in Figure 3.1. Of primary interest for this project is the process of histone lysine 




Figure 3.1 Overview of chromatin dynamics.(A) Chromatin (blue and orange circles with extending N-
terminal tails) and DNA structure (in black) in an open configuration as a result of activating lysine 
marks laid down by transcriptionally active epigenetic writers. This specific acetyl, methyl lysine 
modifications along with hypomethylated DNA allow for the access and binding of transcription factors 
to begin transcription. (B) Closed inactive chromatin/DNA structure as a result of removal of activating 
acetyl- lysine modifications by Active Erasers, and the laying down of transcriptionally inactive methyl 
marks by repressive epigenetic Writers. The removal of acetyl groups condenses the chromatin, while 
specific methyl groups on specific lysines found in histone tails and cytosine bases of DNA either 
prevent transcription factors or bind transcriptional repressors. These combined with the closed 
chromatin state prevent any transcription from taking place. This figure was self-generated using 
Microsoft PowerPoint based on the current understanding of knowledge from a multitude of sources. 
• Active erasers 
• Repressive 
writers 
• Active writers 
• Repressive 
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 Histone Lysine Acetylation/De-acetylation: 
Acetylation of H3 or H4 lysine residues is one of the primary drivers of histone associated 
gene regulation. Acetylated and de-acetylated lysine residues can rapidly switch chromatin 
between open and active states, and closed and repressive states, depending on how the 
histone code is incorporated (Dancy and Cole, 2015). HATS transfer an acetyl unit from the 
acetyl-coenzyme A donor to the ε-amino group of the target lysine residue, which confers 
an overall net negative charge to the core histone complex (Allfrey, Faulkner and Mirsky, 
1964). DNA is a negatively charged molecule and so is repulsed by the negative histone, 
leading to the opening of the nucleosome structure into euchromatin. This allows the easy 
access of transcription, replication, recombination and repair factors via bromodomain 
containing proteins that bind acetyl-lysine (Bedford and Brindle, 2012).  
 
The removal of an acetyl group by HDACs diminishes the net negative charge of the histone 
complex and DNA, and causes the nucleosome to revert to a compact and silenced 
heterochromatic state (Rivera and Bennett, 2010). Examples of the most characterised 
acetylation sites that are strongly associated with both activation and repression have already 
been seen in Figure 3.1. In conjunction with targeting chromatin structure, both HATs and 
HDACs can target non-histone protein targets (NHPTs) in the nucleus or cytoplasm. This 
can in turn have further up-stream or down-stream effects on gene expression and cellular 
homeostasis (Wapenaar and Dekker, 2016). 
 
Four classes of HDAC’s are known to exist, and can be divided into zinc dependent (Classes 
I, II, and IV) or NAD+ dependent (Class III) groups (Micelli and Rastelli, 2015). Class I 
HDACs comprise of HDACs 1, 2, 3 and 8 and are localized in the nucleus (Verdone, 2006). 
Class II HDACs are divided into sub-class IIa (HDACs 4,5,7 and 9) and subclass IIb 
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(HDACs 6 and 10) and shuttle between the nucleus and cytoplasm upon certain cellular 
signals and are expressed in a limited number of human tissues (Verdone, 2006). 
 
Class IV contains only HDAC11, while Class III HDACs consist of seven enzymes known 
as sirtuins (Sirt1, 2, 3, 4, 5, 6 and 7) (Delcuve, Khan and Davie, 2012). As a result of their 
dependency on NAD+ over zinc, sirtuins are structurally and mechanistically very different 
from the other 3 classes of HDACs, and are involved in a broader range of cellular processes 
and pathways (Dang, 2014). With regards to disease initiation and progression, it is primarily 
the zinc dependent HDACs (class I, II, IV) which have been studied most extensively, cf 
below.  
 
HATs can be classified into two groups, group A HATs located in the nucleus and group B 
HATs located in the cytoplasm. While these two families play pivotal roles in gene 
regulation and can themselves be a source of disease propagation, they are not a direct line 
of inquiry for this project, and so will not be discussed further.  
 
 Cancer Epigenetics 
Cancer cells were originally thought to arise as a result of genetic mutations which increased 
the function of oncogenic genes and decreased the function of Tumour suppressor genes 
(TSP), resulting in loss of chromosomal stability and uncontrolled cell growth. However, it 
has emerged that genetic alterations to DNA alone do not account for the complexity seen 
in tumour cells, and so epigenetics seems to be the key explanation to this underlying 
problem. The spontaneous mutation rate of a cell is estimated to be 10-10 mutations per 
nucleotide base pair per division, whereas the rate for gaining or losing methylation is 
estimated to be 2 × 10−5 per CpG site per division (Yatabe, Tavare and Shibata, 2001). Since 
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DNA methylation and histone modifications are so closely linked, alteration of one pathway 
will have substantial effects on the other. This indicates that epigenetic dysregulation is a far 
more likely candidate for the initiation of cells to undergo oncogenic transformation than by 
acquiring genetic mutations alone, and aberrant epimutations have been implicated in the 
early stages of initiation and progression of a vast number of cancers (Sharma, Kelly and 
Jones, 2009). 
 
These epimutations primarily manifest as global hypomethylation of gene promoters 
(including many oncogenic promoters) (Feinberg, 2005) and site-specific hyper methylation 
of other gene promoters, primarily in regulatory regions of TSP Genes (Barradas et al., 
2009).  Over 300+ genes have been seen to be altered in various forms of cancer as a result 
of altered methylation patterns and DNA methylation patterns, with 5%–10% of normally 
un-methylated CpG promoter islands becoming abnormally methylated in various cancer 
genomes (Dawson and Kouzarides, 2012). Another epigenetic alteration seen in cancers is 
the dysregulation of histone modifying enzymes, primarily HDACs, as they interact 
intimately with the DNA methylation network, and result in global loss of acetylation 
patterns, and alterations of Histone acetylation patterns (Kanwal and Gupta, 2012).  
 
 Dysregulation of Histone modifications: 
The hallmark changes to histone modifications seen in cancer are primarily global loss of 
acetylated Histone 4 lysine 16 (H4K16ac) and Histone 3 lysine 9 acetylation (H3K9ac) and 
an increase in H3K9 and H3K27 tri-methylation patterns, associated with aberrant gene 
silencing (Sharma, Kelly and Jones, 2009). 
 
The global loss of H4K16ac and other important acetyl histone tags is primarily as a result 
of either HDAC over expression or increased HDAC activity, both causes of which are seen 
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in various cancers (Yixuan and Seto, 2016). A list of class I and class II HDACs and their 
associated cancers can be seen in Table 3.1.  
 
Table 3.1 Association of class I and II HDACs overexpressed in different cancers.  Data from 




HDAC 1 Liver, colorectal, breast, ovarian, prostate, renal, bladder, Acute 
Lymphoblastic Leukaemia (ALL), Chronic Lymphocytic Leukaemia 
(CLL) 
HDAC 2 Liver, pancreas, colorectal, breast, ovarian, prostate, renal, bladder, 
ALL, Cutaneous T-Cell Lymphoma (CTCL), Diffuse Large B-Cell 
Lymphoma (DLBCL) 
HDAC 3 Liver, colorectal, breast, ovarian, prostate, bladder, melanoma, ALL, 
CTCL, DLBCL, Hodgkin’s Lymphoma (HL) 
HDAC 4 Acute Myelogenous Leukaemia (AML), ALL, bladder 
HDAC 5 Colorectal, breast, bladder, ALL, AML 
HDAC 6 Liver, pancreatic, breast, ALL, CLL, DLBCL, CTCL 
HDAC 7 Pancreatic, colorectal, bladder, ALL, CLL 
HDAC 8 Melanoma, bladder, ALL 
HDAC 9 ALL, CLL 
HDAC 10 CLL, cervical 
 
 
De-acetylation of histone and non-histone proteins (e.g. certain transcription factors) results 
in the silencing of various genes, which are involved in the regulation of the cell cycle, 
apoptosis induction or repression, DNA-damage response, metastasis, angiogenesis, and 
other cellular processes (Yixuan and Seto, 2016). How HDACs are targeted specifically to 
this subset of genes is not yet known. 
 
HDAC activity promotes cell cycle progression through G1/S phase of the cell cycle by 
decreasing the expression of various cell cycle regulators such as p21WAF1/CIP1, p27KIP1, 
and p57KIP2(Yamaguchi et al., 2010; Zupkovitz et al., 2010). HDACs regulate apoptosis 
through inhibiting the expression of pro-apoptotic genes such as PUMA, Bax, and Apaf-1, 
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while increasing the expression of anti-apoptotic such as the anti-apoptotic Bcl-2 family of 
proteins (Yixuan and Seto, 2016). 
 
During the DNA damage response (DDR), HDACs facilitate chromatin remodelling and the 
binding of DDR proteins, such as non-homologous end joining (NHEJ) proteins, ataxia 
telangiectasia and Rad3-related protein (ATR), Ataxia-telangiectasia mutated (ATM) and 
BRCA1 (Yixuan and Seto, 2016). An increase in DDR mechanisms allows cancer cells to 
favour repair and survival over apoptosis through suppression of apoptotic signalling and is 
also implicated in the development of resistance of cancer cells towards DNA damaging 
chemo or radiotherapy treatments (Davalli et al., 2018). 
 
Cancer cells exploit the dynamic properties of epigenetic mechanisms such as histone 
acetylation or DNA cytosine methylation to quickly alter their expression profiles to 
generate resistant phenotypes against radio/chemotherapeutics. Examples of this would be 
the de-methylation of the promotor for the Multidrug Resistant Protein (MDR1) (Sharma et 
al., 2010), the aforementioned increase in DDR by HDACs, and HDAC repression of genes 
responsible for maintaining cell lineage, causing de-differentiation and inducing increased 
resistance to chemo/radio therapies (Brown et al., 2014). 
 
 Small molecule epigenetic regulators: 
Over the last decade many small molecule inhibitors targeting either all or specific HDACs/ 
HDAC families have come to the forefront of cancer research, with some gaining FDA 
approval.  The disruption of HDACs and the resulting alterations regarding acetylation levels 
in cancer cells have shown promising results in the treatment of various cancers, primarily 
haematological cancers. HDACi can be broken down into members of four classes of 
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compounds: (i) hydroxamic-acids (hydroxamates), (ii) aliphatic acids, (iii) benzamides and 
(iv) cyclic tetrapeptides (reviewed Stiborova et al., 2012). 
 
Of note for this project is suberoylanilide hydroxamic acid (SAHA), also known as 
vorinostat, belonging to the hydroxymate class of inhibitors, and Valproic acid (VPA), and 
Sodium Phenylbutyrate (SPB), which are aliphatic acids. All three are Zinc dependant 
HDACi, with SAHA being a pan inhibitor targeting classes I, II, and IV of HDACs, and 
VPA and SPB targeting class I and class IIa (Kim and Bae, 2011). The structures of SAHA, 




Figure 3.2 Chemical structures of SAHA, VPA and SPB with (from left to right) 




The effects of HDACi are attributed to re-establishing normal apoptotic, cell cycle, DDR, 
and intracellular regulatory signalling pathways, which is usually as a result of restoration 
of normal NHPT acetylation status which regulate these pathways (reviewed Stiborova et 
al., 2012). An example of this would be the acetylation and stabilisation of the TSP p53, 
which is then capable of increasing the expression of these target genes, as well as inhibiting 
anti apoptotic proteins (Reed and Quelle, 2014).  
 
SAHA, which was FDA approved in 2006, has seen remarkable success in the treatment of 
cutaneous T-cell lymphoma (CTCL), and has been entered into clinical trials for the 
treatment of other cancers such as Acute Myeloid Leukaemia (Mann et al., 2007). SAHA 
has been demonstrated to induce growth and cell cycle arrest in both a multitude of cancer 
cell lines as well as in vivo rodent models, primarily through transcriptional activation of cell 
cycle control and apoptotic genes and transcriptional repression of mitotic genes (Richon, 
2006). SAHA has also been demonstrated to result in an increased production of ROS and 
apoptosis induction in acute myeloid leukaemia cells (Petruccelli et al., 2011) as well as 
increased ROS production accompanied by DNA damage  (Brodská and Holoubek, 2011). 
However SAHA has also been demonstrated to induce the expression of the antioxidant Nrf2 
pathway, indicating that cell type specific effects are likely present (Xu et al., 2018). 
 
Despite initial pre-clinical success in both in vitro and animal models however, data from 
clinical trials using SAHA to treat breast, colorectal, non-small cell lung and other various 
other solid tumours have met with little to no success (Kim and Bae, 2011). This has led to 
the investigation of poly-therapies using SAHA and chemotherapeutic agents as potential 
avenues of treatment for solid tumours. 
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It was demonstrated that treatment with HDACi significantly increased the cytotoxic effects 
of all the anti-cancer agents used, with no added effect seen in non-cancerous cells. This 
demonstrated the potential for combining HDACi with mainstream chemotherapy for 
targeted treatment of cancer cells (Kim et al., 2003). 
 
VPA, FDA approved in 2008 for the treatment of epilepsy, induces differentiation, growth 
arrest, and apoptosis in a broad spectrum of transformed cells through HDAC inhibition 
(Vandermeers et al., 2009). VPA when combined with cisplatin was capable of increasing 
cytotoxicity on both cisplatin sensitive and resistant ovarian cancer cell lines, through 
upregulation of TSP PTEN, DNA repair and apoptotic signaller ATM, and through 
accumulation of ROS (Lin et al., 2008). The re-sensitisation of an otherwise resistant cell 
line to chemotherapy offers HDACi combination therapy as a strong candidate for the 
treatment of chemotherapy resistant tumours. As well as inhibiting HDACs, VPA can act as 
an inhibitor of voltage gated sodium channels and can affect metabolic enzymes and 
processes such as the tricarboxylic acid cycle (Ghodke-Puranik et al., 2013). 
 
Sodium phenylbutyrate, while not yet having FDA approval, has been seen to demonstrate 
very similar results to VPA due to shared structural similarities. SPB as a monotherapy has 
been demonstrated to suppress both proinflammatory molecules and ROS as well possessing 
HDACi properties (Roy et al., 2012). A study conducted that used both in vitro and in vivo 
models investigating interaction between SPB and cisplatin, found that combined treatment 
increased cisplatin’s cytotoxic effect in HeLa cells, and increased the survival of albino mice 
transfected with Ehrlich ascites tumour. SPB treatment was also seen to cause hyper 
acetylation of H4 in regions of heterochromatin, and was associated with the reactivation of 
apoptotic control genes (Koprinarova et al., 2010).  
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The value of combined epigenetic therapies as novel cancer treatments has been clearly 
demonstrated by almost a decade of experimentation. However acquired resistance to 
chemotherapy persists, despite the progress of some epigenetic combinatorial treatments. As 
highlighted previously the ability of cytotoxic metal-based drugs to mediate cell death in 
cisplatin resistant cell systems supports the notion that novel metal-based drugs can 
circumvent mechanisms of resistance. Combinatorial treatment with such drugs and 
epigenetic regulators may provide a novel mechanism to potentiate drug efficacy. This is the 
subject of the current work. 
 
 Aims 
This chapter reports the results of experiments that aim to investigate whether the metal-
phen compounds of interest are available for epigenetic chemosensitisation with three 
different HDACis SAHA, VPA and SPB. As these compounds are hypothesised to target 
DNA as a primary mechanism of action it would be expected that chromatin relaxing agents 
such as HDACi would sensitise cells to DNA damaging drugs by allowing greater access to 




 Combinatorial treatments of HDACi and metal-phen compounds 
To determine the presence of potential epigenetic enhancing effects in combination with 
novel metal-based anti-cancer drugs, cell viability assays were used to screen epigenetic 
regulators and novel metal-based drugs against CS and CR mesothelioma cells. HDACi have 
been demonstrated to reverse chemo-resistant phenotypes to sensitive states (Vandermeers 
et al., 2009; Diyabalanage, Granda and Hooker, 2013) and as such these isogeneic cells 
offered an extra point of comparison regarding novel metal-based compound efficacy against 
resistant cancer cells. A2780 (ovarian) and A549 (lung) cancer cells lines were also used in 
certain circumstances to further investigate epigenetic effects in different cell lines. 
 
HDACi which appeared to enhance test compound cytotoxicity were then the focus of 
further investigation. Optimised resazurin reduction assays, as described in section 2.5.1 
above were used to estimate the IC50 for compounds in the presence and absence of various 
epigenetic modulators (SAHA, SPB, VPA). Fold change in IC50 value was used to evaluate 
impact of treatment.  
 
The treatment protocol for each experiment can be seen in Figure 3.3. Screening of HDACi 
was conducted as both co-treatments and pre-treatments (4hrs) with CMPD 73, 74, and 
CMPD 19 (described in Chapter 1 and by (Kellett et al., 2011; Slator et al., 2017). Control 
experiments utilising cisplatin and HDACi were conducted over a 72hr timescale, in 
accordance with the timescale cisplatin was seen to become active in mesothelioma cell lines 





Figure 3.3 Treatment protocols for novel metal-based drugs and cisplatin with HDACi epigenetic 
regulators 
 
 Western Blot 
To determine that HDAC inhibition had taken place in response to specific inhibitors, 
western blot analysis on purified histones from cells treated with SAHA and VPA was 
conducted. Due to the government restrictions in response to the Coronavirus outbreak and 
university closures investigating SPB using western blot was no longer possible. Histone 4 
Lysine 16 acetylation (H4K16ac) levels were used as a biomarker for HDAC inhibition, as 
increased levels of H4K16ac have been associated with open chromatin states and increased 
gene expression (Shogren-Knaak et al., 2006). 
 
Briefly A549 cells were plated in duplicate in 6well plates and treated with SAHA (5µM) 
and VPA (5mM) for 24hrs. Cells were then lysed, and histones purified by acid extraction 
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as per protocol from Shechter et al., (2007). Histone concentration was then determined 
using the Bradford assay. 
 
20µg of histones were then loaded in triplicate wells of a 15% SDS gel and electrophoresed 
at 130V for 90mins and transferred onto nitrocellulose membrane (BioRad, 0.45µm) using 
a BioRad Turbo Blot semi-dry transfer system (25V, 7mins). The membrane was then 
blocked for 1hrs using 5% Non-Fat dry milk (NFDM). Membrane was washed once 
following blocking with TBST and incubated with Rabbit Anti- H4K16ac antibody (Merck-
Millipore 07-329) 1:10,000 dilution in 2.5% NFDM overnight at 4°C under constant 
rotation.   
 
The membrane was washed for 10mins (x3) with TBST and incubated with anti-rabbit goat 
secondary antibody (Sigma) 1:5000 in 2.5% NFDM for 1hr under constant rotation. The 
membrane was washed for 10mins (x3) with TBST, and then incubated with ECL buffer for 
3mins and chemi-luminescence was analysed.   
 
Histone loading concentration was optimised before experimentation to ensure optimal 
image output and prevent over saturation of the membrane blot. Total Protein Normalisation 
(TPN) was done using SDS-PAGE bromophenol blue staining of the SDS gel post transfer 
and calculated using ImageJ software. TPN using the PonceauS stain was conducted 
however was not used for normalisation due to issues with sensitivity. Combined signal of 
histones H3, H2B, H2A and H4 bands were used for TPN.  
 
Briefly, background signal was subtracted from the combined signal intensities of H3, H2A, 
H2B and H4 for each lane. These were then normalised according the highest signal intensity 
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to determine differences in protein loading onto the SDS gel. Signal intensity for bands 
apparent in western blot images were subjected to the same background subtraction 
methodology as histone bands from SDS gel images. Each western blot band was then 
normalised to its corresponding SDS histone bands, which were then averaged to calculate 
the average change in acetylation levels relative to conditions. 
 
 Statistical analysis 
All data was analysed using GraphPad Prism Version 5.0.0. and Microsoft excel. Statistical 
analysis was conducted using students T-Tests and expressed as a P Value < 0.05, 0.01, 






 Treatment with CMPD 19 and epigenetic regulators: 
CS meso and CR meso, A549 alveolar and A2780 ovarian cancer cells were exposed to 
CMPD19 with or without the addition of SAHA (5µM), VPA (5mM) or SPB (5mM) for 
24hrs to generate IC50 values (Table 3.2). SAHA reduced cell viability by 11% in CS Meso. 
cells and by 27% in CR. Meso cells. VPA increased cell viability by 7% in both cell lines, 
with SPB increasing viability by 24% also in both cell lines. 
 
Table 3.2 Estimated IC50 Values for CMPD19 combined with HDACi with 24h treatment  
Compound 
Mean IC50 M  
(95% CI) 

















* Significantly different from compound control, P<0.05.  
 
Co-treatment with SAHA or SPB had no effect in any of the cell systems tested, indicating 
that there is no obvious complementary effect between CMPD19 and these HDACi 
compounds under the conditions used. There is a modest but statistically significant (P<0.05) 
decrease in IC50 value in the presence of 5mM VPA, which may indicate a possible 
relationship between CMPD 19 and VPA. Treatment with SAHA in A549 lung 
adenocarcinoma cells also failed to yield an effect, as did VPA treatment in A2780 cells. In 
some experiments, a four-hour pre-treatment of SAHA and VPA was carried out in CS meso. 
and CR meso cells, with little or no additional effect on IC50 values (results not shown). 
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 Treatment with CMPD 73 and epigenetic regulators 
In similarity with the conditions noted in 3.4.1 above, CS meso and CR meso, A549 alveolar 
and A2780 ovarian cancer cells were exposed to CMPD73 with or without the addition of 
SAHA (5µM), VPA (5mM) or SPB (5mM) for 24hrs to generate IC50 values (Table 3.3). 
SAHA reduced cell viability by 11% in CS Meso. cells and by 27% in CR. Meso cells. VPA 
increased cell viability by 7% in both cell lines, with SPB increasing viability by 24% also 
in both cell lines. 
 
Table 3.3 Estimated IC50 Values for CMPD 73 combined with HDACi with 24h treatment 
Compound 
Mean IC50 M  
(95% CI) 

















* Significantly different from control, P<0.01. 
 
No significant change in IC50 values is observed following treatment of any cell system with 
SAHA. However, significant decreases (approximately one order of magnitude) in IC50 were 
noted in CS Meso. cells following treatment with the aliphatic acids VPA (5mM) or SPB 
(5mM) and CMPD73. In contrast, there is no effect in CR Meso. cells which suggests a 
mechanistic link between mechanisms of cisplatin resistance and sensitivity to HDACi 
chemo sensitisation. Treatment with SAHA in A549 lung adenocarcinoma cells also failed 
to yield an effect, as did VPA treatment in A2780 cells. These data suggest that CMPD73 
may be a candidate for epigenetic chemo sensitisation approaches. 
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 Treatment with CMPD74 and epigenetic regulators 
In similarity with the conditions noted in 3.4.1 above, CS meso and CR meso and A549 
alveolar cancer cells were exposed to CMPD74 with or without the addition of SAHA 
(5µM), VPA (5mM) or SPB (5mM) for 24hrs to generate dose response curves and IC50 
values (Table 3.4). SAHA reduced cell viability by 11% in CS Meso. cells and by 27% in 
CR. Meso cells. VPA increased cell viability by 7% in both cell lines, with SPB increasing 
viability by 24% also in both cell lines. 
 
Table 3.4 Estimated IC50 Values for CMPD74 combined with HDACi with 24h treatment. 
Compound 
Mean IC50 M  
(95% CI) 


















No significant change in IC50 values is observed following treatment of any cell system with 
any of the HDACi compounds. This may be explained by the already low IC50 for CMPD74.  
In some experiments, a shorter eight-hour treatment was carried out in CS meso. and CR 
meso cells (Table 3.5) There is no enhancement of cytotoxicity under these conditions. 





Table 3.5 Estimated IC50 Values for CMPD74 combined with SAHA with 8h treatment. SAHA 
reduced cell viability by 8% in both cell lines. 
Compound 
Mean IC50 M  
(95% CI) 










Taken together these data suggests that CMPD74, while highly active, does not appear to be 
suitable for epigenetic chemo sensitisation using HDACi. This may be due to an already 
highly effective cytotoxic action.   
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 Treatment with 1,10-Phen and VPA 
Given the data described above CS Meso. cells were exposed to 1,10-phen in combination 
with VPA (5mM) for 24hrs to investigate potential increases in cytotoxicity.  CS cells and 
VPA were chosen due to previous responses with VPA in this cell line using CMPD19 and 
CMPD73. No significant alteration in the IC50 values were observed following treatment 
with 1,10-Phen (IC50 276M) or 1,10-phen with VPA (304M), indicating that VPA does 
not potentiate the action of one of the component parts of CMPD19 or CMPD73. 
 
 Treatment with cisplatin and HDACi 
CS and CR mesothelioma cells were exposed to Cisplatin with or without SAHA (2.5µM) 
and VPA (5mM) for 72 hrs. In some experiments, A2870 cells were exposed to cisplatin and 
HDACi for 48 hrs. SAHA reduced cell viability by 11% in CS Meso. cells and by 20% in 
CR. Meso cells. VPA had no effect on cell viability in CS Meso. cells and reduced viability 
by 17% in CR cells.  
 
Table 3.6 Estimated IC50 Values for cisplatin combined with HDACi following 72h treatment 
Compound 
Mean IC50 M 
(95% CI) 













* Significantly different from control, P<0.05 
 
A modest, but significant, reduction in IC50 values is observed in CS Meso. cells following 
treatment with VPA but not with SAHA. In contrast, the IC50 for CR Meso. cells were 
 112 
moderately influenced by SAHA (approximately two-fold reduction) while the impact of 
VPA is much greater (approximately ten-fold reduction). Intriguingly, the IC50 value 
obtained for CR Meso. cells treated with cisplatin and VPA is almost identical to that for CS 
Meso cells only treated with cisplatin (Table 3.6). These data suggest that VPA may be able 
to sensitise the CR Meso. cells to cisplatin, via mechanisms which involve epigenetic 
regulation. A2780 cells displayed modest (approximately two-fold decreases) in IC50 when 
co-treated with either SAHA (IC50 2.7M) or VPA (IC50 3.1M) when compared to cisplatin 
control (IC50 6.6M).  
 
 Western blot analysis of H4K16ac expression in response to HDACi 
Purified histones from A549 cells treated with SAHA (5µM) and VPA (5mM) for 24hrs 
were assayed using Western Blot staining with the global histone acetylation marker 
H4K16ac antibody to detect increased acetylation levels in response to HDAC inhibition. 
Figure 3.4 and Figure 3.5 (A) demonstrates a significant increase in acetylated histone levels 
in response to SAHA (≈ 9-fold increase) and VPA (≈ 6.5-fold increase) treatments, 
compared to purified histones isolated from non-treated controls. Figure 3.5 (B) also displays 
SDS gel stained post-transfer, showing stained purified histones H3, H2B, H2A and H4, 





Figure 3.4-Increased expression levels of acetylated H4K16 in response to treatment with HDACi  
SAHA and VPA compared to non-treated controls (Results expressed as relative fold increases ± 1 
standard deviation of a representative sample) (a P<0.001 compared to control, b P<0.001 
compared to SAHA). 
  
Figure 3.5-(A) western blot of purified histones from A549 cells treated with SAHA and VPA  
demonstrating an increase in H4K16 acetylation in response to treatment with HDACi. (B) SDS gel 
of purified histones stained post-transfer displaying histones H3, H2B, H2A and H4 which were 





 Discussion  
The mixed results of the novel metal phen compounds with HDACi can likely be attributed 
to their inherent mechanisms of action and the effects of the HDACi used. As reported by 
Kellet et.al (2011) and as will be seen in Chapter 6 of this thesis, CMPD19, CMPD73 and 
particularly CMPD74 all display nuclease capabilities and so would have been expected that 
some form of epigenetic enhancement would have been seen, particularly when compared 
to increased cytotoxicity using cisplatin as a positive control for HDACi therapy.  
 
However CMPD 74 was not seen to interact with any HDACi used, while the manganese 
containing CMPD 19 and CMPD 73 appeared to experience an increase in cytotoxicity 
following treatment with aliphatic acids VPA and SPB. Following western blot analysis 
however this interaction between Mn-phen compounds and the aliphatic acid HDACi was 
determined to likely be a result of alternate cellular HDACi targets rather than their effects 
on DNA. As such it is speculated that DNA may not be a primary target of the metal-phen 
compounds in question. 
 
Although generally reacting in a weak to modest fashion, and with the exception of SAHA 
in CS mesothelioma cells, cisplatin did react with HDACi SAHA and VPA to increase the 
cytotoxic effects of the drug in sensitive and resistant cancer cells. This can be attributed to 
cisplatins’ known DNA damaging capabilities, combining with chromatin relaxation in 
response to HDACi treatment, and so supports the hypothesis that cancer cells can be 
epigenetically sensitised to DNA damaging drugs. Differences in reactivity between 
anticancer drugs and HDACi can be attributed to cell type specificity and may be an 
explanation for cisplatin’s lack of response with SAHA in CS cells. 
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However contrary to our original hypothesis, it may be the case that the mechanism of 
cytotoxicity is not exclusively by direct DNA damage. The subtle differences between how 
cisplatin and the novel metal-phen compounds react with the HDACi may be telling of the 
intra-cellular targets on which they act.  
 
The inability to observe an effect between SAHA and any of the compounds may be the 
most suggestive result to support this. The mechanism through which SAHA primarily exerts 
its effects is attributed to HDACi and the effect this has on chromatin compaction and 
increased acetylation status of cellular proteins (Richon, 2006). Indeed SAHA generated the 
strongest increase in acetylated histones when investigated using western blot. The inability 
of these compounds to react at all with a potent HDACi further supports the contention that 
cellular DNA is not the primary target of the drugs.  
 
It would certainly seem that in the case of CMPD 74, its rapid levels of cytotoxicity may 
suggest that it is not available for epigenetic enhancement, as it may already begin degrading 
DNA and killing the cells before the HDACi can fully take effect. If CMPD 74 were to target 
cellular DNA, it would outpace the effects of HDACi, which are reported to take effect up 
to 4hrs during treatment. 4hr pre-treatment (data not shown) and 8hr co-treatment with 
SAHA and CMPD 74 were conducted to identify any potential rapid responses. However, 
no such response was observed. If CMPD 74 were to act so rapidly on cellular DNA, it 
would have been expected that either pre-treatment or a narrower exposure time would show 
this. It is may be however that despite significant nuclease capabilities, CMPD 74 exerts its 
effects elsewhere from cellular DNA and that it may have other nucleic acid targets. Again, 
this is further supported by a lack of interaction with SAHA despite being observed as the 
strongest HDACi demonstrated by western blot. SAHA has also been demonstrated to 
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increase the expression of Nrf2 the cells master genetic regulator of the antioxidant defence 
system (Xu et al., 2018). This class of compounds are typically found to be redox active as 
such upregulation of the antioxidant defence system may counter act the primary cytotoxic 
mechanism of the metal-phen compounds. Details on the investigation of the redox 
properties of these compounds are described in the next chapter. 
 
Regarding positive effects seen with VPA and CMPDs 19 and 73, this could be attributed to 
more ‘off target’ and unintended interactions of VPA with the compounds, other than 
epigenetic related effects. VPAs primary use is as an anticonvulsant treatment for epilepsy 
and is also used to treat bi-polar disorder and migraine headaches, among many other 
neurological disorders. As well as inhibiting HDACs, it can act as an inhibitor of voltage 
gated sodium channels and can affect metabolic enzymes and processes such as the 
tricarboxylic acid cycle (Ghodke-Puranik et al., 2013). It may be that the increased cytotoxic 
effect induced by CMPD 19 and in particular CMPD 73 are a result of interactions with one 
of the many altered pathways induced by VPA treatment, and not primarily a result of HDAC 
inhibition as originally hypothesised.  
 
Specifically it has been reported that VPA, particularly in mesothelioma cells, is capable of 
producing ROS as one if its primary mechanisms of cell death when combined with cisplatin 
or pemetrexed (Vandermeers et al., 2009). As reported by Kellet 2011 and as will be 
demonstrated later in this thesis, both CMPD 19 and 73 exhibit ROS production as a key 
mechanistic event. It could be the case that it is a crossover between ROS production and 
not HDAC inhibition which is the driving force behind the increase in cytotoxicity seen 
between VPA and the manganese-based compounds. Manganese cytotoxicity has been 
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reported to be a result of GSH depletion, and so the addition of ROS-producing VPA may 
explain the increase in cytotoxicity.  
 
This could further be supported by the lack of response seen in CS cells treated with 1,10-
Phen and VPA. It would have been expected that 1,10-Phen, a known DNA intercalator, 
would experience an increased effect in response to VPA. However, the inability to observe 
an effect using this combination may hint that many of VPAs effects are in fact not driven 
by its HDACi capabilities. However, this may also indicate that while possessing DNA 
intercalative capabilities, 1,10-Phen may also not act on cellular DNA as its primary 
mechanism of action. 
 
Furthermore, despite sharing structural similarities and belonging to the same family of 
aliphatic acid HDACi, SPB did not elicit the same response as VPA with either CMPD 19 
or 73. This again may play into the mechanism of ROS generation reported by VPA. In 
contrast to VPA, SPB has been reported to suppress the generation of ROS in murine models 
(Roy et al., 2012), and so it could be a loss of target specificity that explains why SPB did 
not affect the cytotoxicity of the manganese compounds. This again supports the notion that 
it may be the generation of ROS and not HDACi that enhances the effect of the manganese 
phen compounds when combined with VPA. However, CMPD 73 did appear to experience 
a significant increase in cytotoxicity with SPB in CS mesothelioma cells, but not in CR cells. 
 
The increase in cytotoxic action seen between CMPD 73 and SPB in CS meso cells may 
therefore be a result of HDACi, since there have been no reports of ROS generation by SPB 
to date. While western blot analysis of SPB treated cells was unavailable to fully determine 
increased levels of histone acetylation, its shared structural similarities with VPA and 
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positive effects on cell viability, which have been reported in literature indicate the presence 
of cellular effects. SPB has been seen to prematurely push the cell from the G1 stage of the 
cell cycle into S phase before cell cycle checkpoints such as DNA damage surveillance have 
been completed. This allows the progression of damaged DNA which is later detected in G2 
phase and initiates apoptosis (Koprinarova et al., 2010; Kusaczuk et al., 2016). These effects 
have been attributed to the synergy observed between SPB and DNA damaging drugs such 
as cisplatin (Koprinarova et al., 2010), and may explain as to why both mesothelioma cell 
lines experienced an increase in viability in the absence of a DNA damaging agent, as both 
cell lines may experience a premature push through the cell cycle but lack sufficient DNA 
damage to undergo apoptosis. 
 
While a relaxed chromatin state may be responsible for these effects it is likely previously 
discussed “off target” effects which are being targeted by SPB, again supported by no 
observable effect with SAHA. SPB has been demonstrated to positively interact with cell 
cycle control and apoptotic pathways that may be responsible for the increased effects with 
CMPD 73 which has been demonstrated to initiate apoptosis (Digiuseppe et al., 1999; Witzig 
et al., 2000). Increased levels of apoptotic signalling can easily synergise with a vast number 
of different cellular injuries, such as oxidative stress, a common feature of these compounds.  
 
As it is becoming more likely that these novel metal phen compounds do not appear to 
primarily affect cellular DNA, pursuing the potential additive or synergistic effects of CMPD 
73 and SPB are likely beyond the scope of this investigation, which is primarily focused on 




4. Investigation of ROS  
The lack of interaction between metal-phen compounds and HDACis is indicative of an 
alternate mechanism of action as previously hypothesised. As both CMPD 73 and 74 are 
presumed to be redox active, identifying their potential ROS generating capabilities, and 
which species may be involved is likely to prove a fruitful avenue of investigation.  
 
 Oxidative stress and cancer  
While oxidative stress can be cytotoxic to the cell, it is the mutagenic potential of oxidised 
DNA that has detrimental effects regarding the initiation of oncogenesis. High levels of 
either chronic inflammation or chronic exposure to sub-lethal oxidants (cigarette smoke, UV 
radiation, industrial pollutants) have been implicated in the somatic mutation of many genes 
and transcription factors responsible for controlling cell growth and division (Yang et al., 
2018). Either the overexpression or silencing of these transcription factors can result in the 
initiation of oncogenic transformation. Aberrant cell signalling in response to ROS and 
oxidative stress has been implicated in a vast number of cancers, such as prostatic, 
pancreatic, breast, liver, colon and ovarian cancers (reviewed Afanas’ev, 2011). Oxidative 
stress has been demonstrated to interact with all three stages of the cancer process: initiation, 
promotion and progression (Reuter et al., 2010). Overexpression of antioxidant defence 
genes has also been implicated in facilitating cancer cell survival and progression 
(Sznarkowska et al., 2017). 
 
During the initiation stage, a high oxidant environment can trigger mutations within genes 
responsible for balancing the cell control mechanisms. This can lead to the promotion of 
oncogenesis through abnormal cell signalling such as alterations to second messengers, 
increased levels of cell cycle proteins and decreased levels of apoptosis (Reuter et al., 2010; 
Sosa et al., 2013; Galadari et al., 2017). Oxidative stress can further promote oncogenesis 
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through dysfunctional redox signalling as well as by initiating mutagenesis within specific 
gene promotor regions (Hegedűs et al., 2018), as will be discussed using H2O2 as a primary 
model. 
 
As noted previously in Chapter 1, H2O2 has already been discussed as the primary ROS 
implicated in normal cell signalling processes, owing to its stability and low reactivity with 
biomolecules. Therefore, under elevated levels of oxidative stress, increased concentrations 
of H2O2 can also contribute to the dysfunction of normal intracellular signalling processes. 
H2O2 has been seen to play a dual role in oncogenic activation. It has been demonstrated to 
induce activating mutations in the human Ras oncogene, while also being implicated in 
mutagenic inactivation of the tumour suppressor p53 (Xu, Trepel and Neckers, 2011; He and 
Simon, 2013). H2O2 can induce Ras signalling by oxidising the cysteine thiol groups of the 
tumour suppressor and regulator of Ras PTEN, causing its inactivation (Brewer et al., 2015). 
Activation of Ras can then initiate the activation of the PI3K, Akt, mTOR, MAPK/ERK 
(phosphatidylinositol 3-kinase, Akt, mammalian target of rapamycin, mitogen protein 
activated kinase/extracellular signal regulated kinase) signal transduction pathway 
responsible for growth factor signalling (Zenonos, 2013). This in turn can propagate further 
ROS production, as Ras activation has been seen to increase ROS levels, and p53 
inactivation has been linked with an increase in cytokine production capable of adding to 
inflammation and oxidative stress (Galadari et al., 2017). The implication of oxidative 
regulation of Ras and its potential contribution towards oncogenesis have been demonstrated 




ROS induced silencing of PTEN can further aid cancer cell survival by causing the increased 
expression of Akt. Akt serves to facilitate tumorigenesis by stabilising cell cycle proteins 
such as cyclin D1 and c-Myc while destabilising and causing the degradation of cell cycle 
control proteins such as cyclin-dependent kinase inhibitor protein p27Kip1 (Prasad et al., 
2015). Akt also serves to negatively regulate and inactivate pro-apoptotic proteins such as 
caspase 9, Bad, and BH3 (Sangawa et al., 2014). 
 
Finally, high levels of H2O2 are capable of degrading IƙBα, the suppressive regulator of the 
transcription factor NF-ƙB, responsible for cytokine production and cell survival (Hoesel 
and Schmid, 2013). Nitrosative stress has also been implicated alongside oxidative stress to 
play a role in oncogenic initiation, with both oxidative insults capable of activating Activator 
Protein 1 (AP-1), a redox-sensitive transcription factor involved in cell proliferation and 
transformation (see references 139 and 162 Reuter et al., 2010). S-nitrosylation can also 
cause premature activation of Ras in response to high levels of RNS (Ortega, Mena and 
Estrela, 2010). ROS plays a role in cancer progression by facilitating further mutagenesis to 
allow rapid response to adaptive pressures, and to allow cancer cells to metastasise or 
undergo angiogenesis (Reuter et al., 2010).  
 
To survive in high ROS environments, cancer cells implement a new redox balance between 
higher levels of ROS and antioxidant systems (Sosa et al., 2013). This allows the cells to 
maintain higher levels of ROS and oxidation than normal cells to maintain both oncogenic 
signalling and mutagenesis required for growth and adaptation, while still being afforded the 
protection from detrimentally high levels of ROS which would be cytotoxic (Gill, 
Piskounova and Morrison, 2016). One of the main antioxidant defence pathways seen to be 
upregulated in oncogenic cells is the Nuclear factor erythroid 2-related factor 2 (Nrf2), also 
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known as nuclear factor erythroid-derived 2-like 2 (Nguyen, Nioi and Pickett, 2009). Nrf2 
is a cytosolic transcription factor that in humans is encoded by the NFE2L2 gene and is a 
master regulator of the cellular antioxidant response, controlling the expression of genes that 
counteract oxidative and electrophilic stresses, alleviating oxidative stress (Dodson, Castro-
Portuguez and Zhang, 2019). Under normal conditions, Nrf2 is kept in the cytoplasm by its 
associated regulatory protein Kelch like-ECH-associated protein 1 (Keap1). Keap-1 is a 
ubiquitin ligase, ubiquitinating Nrf2 causing its degradation. Under homeostatic conditions 
Nrf2 has a half-life of only 20 minutes (Kobayashi et al., 2004). However, as Keap-1 is a 
cysteine rich protein (27 cysteine residues in humans), it is sensitive to high oxidant 
environments (Kansanen et al., 2013).  
 
When a cell experiences oxidative stress, the high ROS environment oxidises Keap-1, 
inducing conformational change and releasing Nrf2. Nrf2 is then translocated to the nucleus, 
where it recognises specific promoter sequences known as Antioxidant Response Elements 
(ARE), within specific genes responsible for the antioxidant response (Jaramillo and Zhang, 
2013). Examples of genes possessing an ARE are Glutathione-S Transferase (GST), 
glutamate-cysteine ligase (GCL, required for GSH synthesis), Glutathione Peroxidases 
(GPx), Heme oxygenase-1 (HMOX1) responsible for controlling iron metabolism, genes 
responsible for NADPH regeneration, thioredoxins, and multi-drug resistance proteins 
(MDR) responsible for efflux of GSH conjugated xenobiotics, such as cisplatin (Ma and He, 
2012; Tonelli, Chio and Tuveson, 2018).  
 
As the master regulator of the antioxidant defence systems Nrf2 overexpression confers a 
distinct survival advantage to cancer cells to prevent lethal amounts of oxidative damage 
(Zimta et al., 2019). Overexpression of Nrf2 is generally a result of either somatic mutation 
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of the Nrf2 gene or an inactivating mutation/methylation within the promoter of Nrf2s 
inhibitory regulator Keap-1 (Kitamura and Motohashi, 2018). Nrf2 expression can also be 
positively regulated by c-myc and Ras signalling, as well as resulting from PTEN 
inactivation (as described) (Rojo et al., 2014; Panieri and Saso, 2019). In conjunction with 
its role in maintaining transformed cancer cells, Nrf2 also plays a significant role in the 
development of acquired resistance towards chemotherapy.  
 
The upregulation of the antioxidant defence system allows cancer cells to adapt to oxidative 
stress induced by xenobiotic compounds such as ROS generating chemotherapy agents 
(cisplatin, carboplatin, oxaliplatin, and doxorubicin) (Yang et al., 2018). Detoxification of 
these compounds and repair of oxidative damage is a key mechanism through which Nrf2 
overexpression and signalling is used by cancer cells to acquire chemo resistant mechanisms 
to survive treatment with various chemotherapeutics (Kitamura and Motohashi, 2018). For 
example, GCL the rate limiting enzyme required for GSH synthesis, possesses an ARE 
within its promoter (Mani et al., 2013) therefore increasing the intracellular pool of GSH 
available to detoxify ROS generating compounds (Bansal and Celeste Simon, 2018). 
Enzymatic inactivation of drugs such as cisplatin by GST enzymes has also been seen to 
contribute significantly to drug-resistance (Allocati et al., 2018). 
 
 Mesothelioma: 
Malignant Mesothelioma (MM) is an example of a rare and highly aggressive form of cancer 
whose initiation has been directly attributed to a high ROS environment and chronic 
inflammation (Matsuzaki et al., 2012). MM is a cancer of the mesothelial cells lining the 
pleura of the lung, and is predominantly caused by the inhalation of carcinogenic asbestos 
fibres (Tipu, Ahmed and Ishtiaq, 2013). Asbestos is a term referring to six fibrous silicate 
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minerals naturally found in rocks and soil, which was used extensively in building and 
industrial processes as a fire retardant and insulator up until the 1970s when its hazardous 
effects became apparent (Nynäs et al., 2017). When handled asbestos fibres are easily 
inhaled and become trapped within the smallest bronchial tubes and alveoli, where it is a 
source of major irritation and can cause MM (Nishimura et al., 2013).    
 
MM generally has a dire prognosis, with median survival rates of just a year from diagnosis. 
It is estimated to kill 43,000 people worldwide each year, with 3,000 deaths occurring in the 
U.S. and 5,000 in Western Europe (Boyer et al., 2018). The world Health Organisation 
(WHO) has recognised asbestos as one of the most important occupational carcinogens and 
declared asbestos-related diseases to be eliminated (Galateau-Salle et al., 2015). The 
development of MM can be a very slow process taking years to manifest, with the interval 
between exposure to asbestos fibres and the diagnosis of MM between 30-40 years (Røe and 
Stella, 2015). Therefore the global mortality rate of MM is expected to rise, as generations 
born in the 1940’s and 50’s who have been exposed to asbestos before tight governmental 
regulations were implemented will reach the peak age for MM incidence and mortality (La 
Vecchia et al., 2000). Many cases are expected to arise in developing countries, such as 
India, where the regulation of asbestos in construction is either not tightly controlled or is 
non-existent (Cavone et al., 2019). 
 
The WHO estimates that up to 125 million people worldwide are still exposed to asbestos in 
their homes or workplace (Stayner, Welch and Lemen, 2013). MM is also notoriously hard 
to diagnose requiring expertise in specific histochemical staining to distinguish it from other 
lung cancers such as adenocarcinomas (Bianco et al., 2018). Both the long latency period 
and difficulty in diagnosis significantly contributes to MMs high mortality rate, with poor 
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treatment responses and limited treatment options further contributing (Tomasson et al., 
2016).    
 
Asbestos can initiate oncogenesis of pleural mesothelial cells both directly and indirectly, 
both of which are facilitated by chronic oxidative stress and inflammation (Afaghi et al., 
2015). Insoluble asbestos fibres are engulfed by mesothelial cells causing chronic irritation 
and initiating lung fibrosis (Norbet et al., 2015). Asbestos fibres possess a high iron content, 
and so could significantly increase ROS production (H2O2, O2
•-, OH•) through Fenton-like 
chemistry following ingestion. Asbestos has also been seen to induce the expression and 
activity of nitric oxide synthase (NOS) in alveolar macrophages and mesothelial cells. High 
NOS activity would result in higher levels of RNS production, which alongside ROS, could 
cause mutagenic alterations in genomic DNA resulting in the initiation of oncogenesis 
(reviewed by Benedetti, Nuvoli, Catalani, & Galati, 2015). DNA damage and genotoxicity 
may also be caused by direct interference of asbestos fibres with DNA, particularly during 
chromosome segregation during mitosis (Carbone and Yang, 2012). 
 
The irritation caused by asbestos fibres also serves to recruit immune cells (such as nearby 
alveolar macrophages) in order to try and remove both the foreign body fibres and the 
mesothelial cells which have engulfed them (Maeda et al., 2010). The presence of immune 
cells and resulting inflammation further contributes to the high oxidant environment capable 
of initiating mutagenesis (Hasselbalch, 2013).  However immune cells, particularly 
phagocytic cells, are unable to break down the insoluble asbestos fibres, causing immune 
cell death via necrosis and the release of inflammatory cytokines, such as Tumour Necrosis 
Factor α (TNFα), Tumour Necrosis Factor β (TNFβ) and Interleukins 1β, 6 and 8 (IL-1β, IL-
6, IL-8) (Hillegass et al., 2010). The release of inflammatory cytokines, ROS, and un-
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degraded asbestos fibres are then able to react with neighbouring cells further propagating 
chronic oxidation and inflammation, further contributing towards DNA damage, mutations, 
and oncogenic transformation (Benedetti et al., 2015). 
 
Like all cancers, prolonged exposure to DNA damaging agents such as ROS and chronic 
inflammatory responses will result in the activation of various oncogenes and the 
inactivation of tumour suppressor genes. Many of the cell signalling pathways dysregulated 
in MM have already been discussed, as initiation of neoplasia in MM is attributed to ROS 
signalling. The PI3K/Akt/mTOR (Wilson et al., 2008) and MAPK signalling pathways 
(Hylebos et al., 2016), as well as NfƙB, have all been demonstrated to be activated in MM 
(Nishikawa et al., 2014). Increased signalling through activated receptor tyrosine kinases 
has also been documented (Zhou et al., 2014). MMP expression has also been seen to be 
upregulated in MM, contributing to metastasis (Yoon et al., 2002). One of the hallmarks of 
MM is the inactivation of the tumour suppressor’s p16INK4a and p14ARF which are inactivated 
in ≈ 70% of MM, owing to homozygous deletions or missense/nonsense mutations within 
their genes (Hylebos et al., 2016). Both p16INK4a and p14ARF are cell cycle regulators and 
interact with p53 tumour suppressor pathways, meaning their loss of activity would 
significantly influence oncogenic transformation (Ohtani et al., 2004; Ko, Han and Song, 
2016).   
 
Current treatments for MM are very limited. The most successful treatment is surgical 
removal of the tumour, however since most MM is diagnosed at advanced stages, most cases 
of MM are unresectable, and therefore radiotherapy or chemotherapy is implemented 
(Carbone and Yang, 2012). First line treatment for MM is usually a combination of cisplatin 
and pemetrexed, which can increase median survival rates by ≈ 3-4 months (Vogelzang et 
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al., 2003). However in most cases MM has a rate of high recurrence with a high prevalence 
of multi drug resistant phenotype (Vandermeers et al., 2009). Contributing factors towards 
acquired resistance have been attributed to MM cells displaying increased expression of the 
antioxidant Mn-SOD and catalase enzymes capable of detoxifying further oxidative insult 
from ROS generating cisplatin (Kahlos et al., 1998). As discussed in previous sections high 
ROS environments can act to signal an increase in antioxidant defence systems to mitigate 
potential cytotoxic levels of ROS. Another factor is the prevalence of Cancer Stem Cell 
(CSC) populations within MM tumours, which possess inherent chemo resistant properties 
and are capable of repopulating a depleted tumour population following what appears to be 
a successful round of chemotherapy (Cortes-Dericks et al., 2014). The current limitations of 
treatment options and prevalence of resistance demonstrates the need for novel therapies 
capable of improving the poor survival rate associated with MM.  
 
  ROS and chemotherapeutics: 
Despite resetting the landscape of redox homeostasis to their own advantage, cancer cells 
exist in a state of high ROS sensitivity (Liu and Wang, 2015). Increased antioxidant defence 
systems may facilitate higher levels of oxidative stress to allow oncogenesis, but certain 
thresholds exist within the cell regarding how much oxidative stress they can tolerate 
(Ogundele et al., 2017). This phenomenon has formed the basis for many chemotherapeutics 
in order to target cancer cells (Moloney and Cotter, 2018). As discussed in previous sections, 
ROS generating chemotherapeutics (cisplatin, carboplatin, and doxorubicin) are 
implemented in the treatment of many cancers. However the prevalence of acquired 
resistance to these compounds is significant. To combat this, many novel redox active metal 
compounds are also in development in order to exploit these processes and are designed with 
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the hopes of overwhelming antioxidant defence systems of both chemo sensitive and chemo 
resistant cancer cells. 
 
 Metal-based drugs and redox homeostasis 
Many metal-phen compounds are able to generate ROS, with the formation of various ROS 
typically linked with the mechanism of action of the compound(s). As CMPD 73 and 74 are 
next generation analogues of CMPDs 19 and 22, which have already been demonstrated 
as potential ROS generating compounds (Kellett et al., 2011), it is likely that the current 
compounds will demonstrate analogous biochemical behaviour.  
 
The generation of ROS following treatment of cells with CMPD 73 and CMPD 
74 is anticipated to be a likely mechanistic event in their cytotoxic effect. Whether ROS 
generation is a key mechanistic event utilised to cleave cellular DNA or whether DNA 
damage results indirectly by ROS produced elsewhere in other organelles of the cells, is yet 
to be determined. It may be the case that these compounds have other targets than DNA 
within the cell and utilise ROS to target these, as highlighted in Chapter 3. Figure 4.1 
displays core pathways involved in the clearance of cytotoxic ROS from the cell, and 




Figure 4.1 Pathways for the elimination of key ROS species in cells, highlighting inhibitors of GSH 
and Catalase pathways. This figure was self-generated using Microsoft PowerPoint based on the 
current understanding of knowledge from numerous sources. (SOD, superoxide dismutase; CAT, 
catalase, GSH, reduced glutathione; GSSG, oxidised glutathione; GPx, glutathione peroxidase; GR, 
glutathione reductase; GS, glutathione synthetase; GCS, glutamate–cysteine ligase, G6PDH, 
gluscose-6 phosphate dehydrogenase). 
 
In order to confirm this, spatiotemporal dynamics of ROS production in cells was 
investigated using CMPDs 73 and 74 in A549 and A2780 cells. This was carried out using 
ROS-specific organelle dyes and inhibitors of intracellular antioxidant pathways as well as 




This chapter describes the results that were aimed at clarifying potential ROS generating 
capabilities of CMPD 73 and 74 using ROS-sensitive intracellular chemical fluorescent 
probes, and also the use of both targeted inhibitors of the cells antioxidant pathways and 
ROS specific scavengers to determine the species of ROS generated and if that species is 
biologically relevant to the cell death process observed in Chapter 2. 
 
 Methods:  
 Fluorescent staining of intracellular ROS generation 
To investigate whether CMPD 73 and CMPD 74 can cause an increase in intracellular ROS 
levels, A2780 and A549 cells were stained with 2’, 7ʹ-Dichlorofluorescin Diacetate 
(DCFDA). CS and CR meso. cells were not included in this study as their primary use was 
to investigate responses to epigenetic therapies with metal-phen compounds. DCFDA can 
be assayed using both flow cytometry and fluorescent microplate reader and as such both 
techniques were implemented. 
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For analysis using flow cytometry 2.5x106 cells (A2780, A549) were stained with 5µM 
DCFDA in PBS for 30mins at 37°C, washed thrice with PBS and exposed to 100µM 
concentrations of CMPD 73, 74 and 1,10-Phen for 40mins again at 37°C. 100µM H2O2 was 
used as a positive control. 100µM concentrations were used to ensure that any changes in 
fluorescence were not overlooked as a result of low fluorescent signals from low 
concentrations. Fluorescence was then read in a Beckman Coulter Cytoflex flow cytometer, 
using FL1/FITC channels. Dead cells and cellular debris were removed by selective gating 
based on forward and side scatter data, and a positive response was selected by gating events 
with a higher fluorescent intensity than that of the non-treated control. Data was analysed 
using CytExpert software, and histogram plots were generated using FlowJo version 10.6.1. 
 
Analysis using a fluorescent microplate reader cells were plated in sextuplet wells of a black 
96 well plate at a density of 2x104cells/well and allowed to attach for 24hours. Cells were 
then stained with DCFDA (1µM) in PBS for 40mins at 37°C. Cells were then washed thrice 
with PBS, and exposed to CMPDs 73, 74 and 1,10-Phen at concentrations of 10nM, 100nM 
and 1µM and incubated at 37°C. The use of these specific concentrations was to ensure a 
broad spectrum of potential compound activity could be detected. H2O2 was used as a 
positive control at matched concentrations. Fluorescence was measured at 15min intervals 
for a total of 90mins using a fluorescent spectrophotometer at 485nm excitation/535nm 
emission. Results are expressed as fold changes compared to non-treated control cells with 




 Fluorescent staining of mitochondrial hydrogen peroxide: 
To investigate this A549 cells were stained with MitoPY1 (as per protocol (Dickinson, Lin 
and Chang, 2013)) and exposed to CMPDs 73 and 74. Cells were plated in duplicate in 6 
well plates at a density of 5x105 cells/well and allowed to attach for 24hours. Cells were then 
stained with MitoPY1 (5mM) in PBS for 90mins at 37°C. Cells were then washed thrice 
with PBS, detached using citric saline solution and transferred to a 1.5ml Eppendorf tube. 
Cells were then exposed to ROS generating compounds for 45mins at 37°C, with 100µM 
H2O2 being used as a positive control. CMPDs 73 and 74 were used at a concentration of 
100 µM. Concentrations of 100µM were used as per Dickinson and colleagues (2013) as an 
effective concentration of H2O2 in order to generate a robust response. As such CMPD 73 
and 74 were used at identical concentrations as a point of comparison to the positive control 
and to ensure sensitivity towards low compound concentration was not an issue. 
 
Following incubation cells were again washed 3 times with PBS and read in a Beckman 
Coulter Cytoflex flow cytometer, using FITC channels. Dead cells and cellular debris were 
removed by selective gating based on forward and side scatter data, and a positive response 
was selected by gating events with a higher fluorescent intensity than that of the non-treated 
control. Due to difficulties in sourcing commercial material, MitoPY1 was no longer 
available for use with A2780 cells and so this cell line was not investigated.   
 
 Selective inhibition of cellular antioxidant pathways: 
Indirect profiling of intracellular ROS generation was detected using a potent glutamate 
cysteine ligase (rate limiting enzyme in glutathione synthesis) inhibitor, Butathione 
Sulfoximide (BSO) (Sigma), and a catalase inhibitor, 3-Amino-1, 2, 4-Triazol (A.T.) 
(Sigma). BSO has been demonstrated primarily to sensitise cells to oxidative insult and has 
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been tested in combination with many ROS generating chemotherapeutics (Rocha et al., 
2014; Tagde et al., 2014). A.T. has been demonstrated to inhibit heme synthesis as well as 
catalase enzymes and has also been implicated in effecting metabolic processes (Bayliak et 
al., 2008; Nunes-Souza et al., 2020). 
 
Suspected ROS-generating compounds present in antioxidant deficient cells should 
experience an increase in cytotoxic potential as a result of unchallenged ROS generation. An 
increase in cell cytotoxicity in response to antioxidant deficiency demonstrates generation 
of ROS by the compounds of interest. Multiple cell lines were used for this study to minimise 
cell type specific variables and to highlight possible differences or sensitivities between CS 
mesothelioma and CR mesothelioma cell lines. 
 
Isogeneic mesothelioma and A549 cells were pre-treated with 1mM of BSO and 1mM of 
A.T. for 24hrs and exposed to concentrations of CMPDs 73, 74, and H2O2 control in the 
same co-treatment methodologies as described in methods Chapter 2 page 68, Alamar blue 
assay, and displayed in Figure 4.2. Isogenic mesothelioma cells were included in this 
particular study to fully determine effects of both BSO and A.T. across multiple cell lines. 
A2780 cells were also treated with 1mM of A.T. for 24hrs and exposed to concentrations of 
CMPDs 73 and 74, and H2O2 control. The molar concentrations (1mM) and pre-incubation 
times (24hrs) for both BSO and A.T. were determined to be the optimal conditions to observe 




Figure 4.2 Treatment protocols for novel metal-based drugs with inhibitors of GSH and Catalase 
antioxidant pathways 
 
 Selective inhibition of compound cytotoxicity using ROS scavengers 
Intracellular profiling of reactive species responsible for cytotoxic action of CMPD 73 and 
74 was detected using a H2O2 specific scavenger Sodium Pyruvate (NaPy) (Sigma) and a 
superoxide specific scavenger Tiron (Sigma). Suspected ROS produced by metal-phen 
compounds should cause a decrease in cytotoxic potential of CMPD 73 and 74 when 
scavenged by their corresponding scavenger compounds. A decrease in cytotoxicity in 
response to ROS scavengers demonstrates the generation of the specific ROS by the 
compounds of interest.   
 
A2780 ovarian cancer cells were pre-treated for 1hr with 10mM of either NaPy or Tiron, 
and then were exposed to concentrations of CMPDs 73 and 74, 1,10-Phen and H2O2 control 
in the same co-treatment methodologies as described in methods Chapter 2 page 68, Alamar 
blue assay, similar to those displayed in Figure 4.3. A2780 cells were seen to be more 
sensitive to ROS generation as determined using DCFDA fluorescent staining than A549 




Figure 4.3 -Treatment protocols for novel metal-based drugs in the presence of ROS scavengers 
 
 Statistical analysis  
All data was analysed using GraphPad Prism Version 8.3.0. or Microsoft Excel. Statistical 
analysis was conducted using Students T-Test or multiple T-Tests where applicable and 
expressed as a P Value < 0.05, 0.01, 0.001. Where multiple comparisons were made using 
the students T-test the Holm-Bonferroni correction was used. 
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 Results  
 Fluorescent staining of intracellular ROS generation using flow 
cytometry  
Figure 4.4 and Figure 4.5 displays DCFDA staining using A549 cells exposed to 100µM 
concentrations of test compounds for 40mins. CMPD 73 displays significant ROS generating 
capabilities (≈5-fold increase) compared to both control conditions and H2O2 (≈1.3-fold 
increase). CMPD 74 increased ROS production by (≈ 1.6-fold) compared to control 
conditions with 1,10-Phen showing higher ROS production (≈ 3.9-fold increase). H2O2 did 
not appear to be notably different compared to control cells however control conditions did 
demonstrate high levels of background DCFDA fluorescence relative to control conditions 
using the A2780 cell model (Figure 4.6). Initial analysis of this data demonstrated CMPD 
73 to be statistically different compared to control values (non-treated and positive controls) 
and compared to CMPD 74 (significant values for all analysis P<0.05). However following 
Holm-Bonferroni correction for multiple comparisons the data fell short of the corrected 
significance threshold (P<0.01). Despite the lack of statistical significance these notable 
increases in ROS detected are still apparent for the compounds of interest.  These data 
indicate both CMPD 73 and 74 as well as 1,10-Phen as ROS generating compounds as 




Figure 4.4- A549 cells stained with 5µM DCFDA and exposed to 100µM CMPD 73, 74, 1,10-Phen 
and H2O2 control  for 40mins. Representative data of two independent experiments using duplicate 
technical replicates. Dashed line represents gated events indicating increases in fluorescent signal 
relative to control conditions. 
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Figure 4.5- A549 cells stained with 5µM DCFDA and exposed to 100µM CMPD 73, 74, 1,10-Phen 
and H2O2 control  for 40mins. Results are expressed as mean percent increase in fluorescent 
intensity of DCFDA compared to control conditions (± 1 Standard deviation of two independent 
experiments). 
 
Figure 4.6 and Figure 4.7 displays DCFDA staining using A2780 cells exposed to 100µM 
concentrations of test compounds for 40mins. As seen in A549 cells, CMPD 73 displays 
highly notable ROS generating capabilities (≈ 33-fold increase) further indicating it is an 
exceptional ROS catalyst. CMPD 74 appeared to be observably more active in A2780 cells 
than in A549 cells (27-fold vs 1.6-fold). 1,10-Phen appeared to react in a similar fashion 
regardless of cell line used as seen with near identical results in A2780 cells compared to 
A549 cells. 
 
As discussed with regards to A549 cells initial analysis of this data demonstrated CMPD 73, 
74 and 1,10-Phen to be statistically different compared to control values and following inter-
compound comparisons (significant values for all analysis P<0.05). However following 
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Holm-Bonferroni correction for multiple comparisons the data fell short of the corrected 
significance threshold (P<0.01). Significant differences were not detected using 
comparisons to the positive control before corrections were made with all compounds. 
Despite this the notable increases in ROS detected are still apparent. These data suggest 
A2780 cells are a more sensitive cell model to use in further ROS studies. 
 
 
Figure 4.6- A2780 cells stained with 5µM DCFDA and exposed to 100µM CMPD 73, 74, 1,10-
Phen and H2O2 control  for 40mins. Representative data of two independent experiments using 
duplicate technical replicates. Dashed line represents gated events indicating increases in 




Figure 4.7- A2780 cells stained with 5µM DCFDA and exposed to 100µM CMPD 73, 74, 1,10-
Phen and H2O2 control  for 40mins. Results are expressed as mean percent increase in fluorescent 
intensity of DCFDA compared to control conditions (± 1 Standard deviation of two independent 
experiments). 
 
 Fluorescent staining of intracellular ROS generation using fluorescent 
spectrophotometry  
Figure 4.8 displays DCFDA fluorescence in response to metal phen treatment in A549 cells. 
H2O2 control demonstrated little to no increase in DCFDA fluorescence even after 90mins 
at higher concentrations compared to non-treated control cells. As seen in Figure 4.8 (A) 
CMPD 73 displays potent increases in ROS production as seen by maximum ≈10fold 
increases in 100nM (significantly higher than H2O2) concentrations and exceptionally high 
≈ 40-fold increases in 1µM concentrations after 60mins (significantly higher than H2O2 and 
100nM), which appears to become saturated after 90mins as no fold increases were observed. 
No change is seen in cells treated with 10nM concentrations of CMPD 73 at any time point 
compared to either H2O2 control or non-treated control.  
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By comparison CMPD 74 is not seen to be as potent as ROS generator as CMPD 73 (Figure 
4.8 (B)). CMPD 74 displayed moderate ≈2-fold increases at 10nM and 100nM 
concentrations and modest ≈5-fold increases with 1µM concentrations (as seen more clearly 
using a smaller scale of fold change), indicating significant levels of ROS production 
compared to H2O2 and 100nM treated cells but not as pronounced as CMPD 73. 1,10-Phen 
produced very low levels intracellular ROS under these conditions but did not exceed the 
low levels of fluorescence compared to H2O2 control and so were not included in Figure 4.8. 
 
Figure 4.8- A549 cells stained with 10µM DCFDA and exposed to A) CMPD 73 and B) CMPD 74  
for 15-90mins. Results are expressed as mean fold increase in fluorescent intensity ±1 Standard 
deviation of two independent experiments. (a= P<0.001 compared to 100nM or 10nM concentration, 
b= P<0.001 compared to H2O2 control). Inset shows the data for CMPD 74 with enlarged scale. 
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Figure 4.9 displays DCFDA fluorescence in response to metal phen treatment in A2780 cells. 
In contrast to A549 cells H2O2 produced a ≈5-fold increases in fluorescence compared to 
control cells in the A2780 cell line. Similar to A549 cells CMPD 73 demonstrated a ≈20fold 
increase in fluorescence at 100nM concentrations and ≈40-fold increase following 60 and 
90min treatments at 1µM compared to non-treated control cells (Figure 4.9 A). No change is 
seen in cells treated with 10nM concentrations of CMPD 73 at any time point. Initial analysis 
of this data demonstrated CMPD 73 to significantly produce ROS in a concentration and 
time dependent manner and compared to H2O control (P<0.05 for all comparisons). However 
following Holm-Bonferroni correction for multiple comparisons the data fell short of the 
corrected significance threshold (P<0.01). Despite this the notable increases in ROS detected 
are still apparent. Taken with similar results in A549 cells these data indicate CMPD 73 is a 
robust ROS catalyst.  
 
CMPD 74 demonstrated immediate and potent ROS production at 10nM and 100nM 
concentrations (≈3-5-fold increases in fluorescence) in A2780 cells, an event not seen in 
A549 cells at the same concentrations. However while these increases in fluorescence were 
higher than in A549 cells (Figure 4.9 B) they did not exceed the maximum fold increases 
observed by H2O2 control at the same concentrations. CMPD 74 at 1µM increased DCFDA 
fluorescence ≈6-7 fold in A2780 cells, slightly higher than in A549 cells. This increase is 
not statistically significant compared to H2O2 however it is significantly higher than the 
previous 10nM and 100nM concentration. Similar to A549 cells 1,10-Phen did appear to 
produce intracellular ROS but again did not exceed the low levels of ROS detected by the 
H2O2 control and again were not included in Figure 4.9. 
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Figure 4.9-A2780 cells stained with 10µM DCFDA and exposed to A) CMPD 73 and B) CMPD 74  
for 15-90mins. Results are expressed as mean fold change in fluorescent intensity ±1 Standard 
deviation of two independent experiments (a= P<0.001 compared to 100nM or 10nM 
concentration). Inset shows the data for CMPD 74 with enlarged scale. 
 
 
 Fluorescent staining of mitochondrial hydrogen peroxide 
Addition of 100µM CMPD 73 or CMPD 74 to MitoPY1 treated A549 cells did not lead 
to the generation of significant amounts of mitochondrial H2O2 above that of the negative 
control (Figure 4.10). It has previously been reported (Kellett et al., 2011) that treatment 
with analogous compounds lacking the ethereal bridge structure results in a 1.2-fold increase 
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in ROS generation following treatment of cells for 30 minutes and a 4-fold in ROS 
generation after 60 minutes. The current data, when expressed in a similar 
manner is comparable to these data – 45-minute treatment with CMPD74 led to ≈ 2-fold 
increase in mitochondrial-specific H2O2. Treatment with CMPD73 did not result in any 
increase in mitochondrial-specific H2O2 when compared to the non-treated control.  
 
 
Figure 4.10-MitoPY1 staining of A549 cells exposed to 100µM CMPD 73, 74 and H2O2 control  
for 45mins. Representative data of two independent experiments using duplicate technical 




 Selective inhibition of cellular antioxidant pathways: 
H2O2 was used a model compound to evaluate the efficacy of the inhibitors in modifying 
treatment-dependent cytotoxicity, with a 24-hour treatment period. BSO and AT 
are expected to lead to a reduction of intracellular capacity to metabolise ROS and 
H2O2 and thus enhance its ability to cause cell death (Figure 4.11).  As predicted, there were 
significant effects on the efficacy of H2O2 to act as a cytotoxic agent, with cell death 
essentially complete in the presence 50µM H2O2 and BSO or AT (Figure 4.12). 
Individually BSO and AT had no effect on cell viability. These results validate the use of 
BSO and AT as tools to interrogate the importance of H2O2 removal/deactivation 
mechanisms in cells treated with metal-phen compounds.  
 
 
Figure 4.11- Selective inhibition of GSH synthesis pathway using BSO and the catalase H2O2 
detoxification pathway by AT. 
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Figure 4.12 Chemical blockage of cellular antioxidant defences enhances susceptibility to 
H2O2  exposure in A549 cells.  Results are expressed as mean percent viability ± 1 Standard 
deviation of two independent experiments (*** P<0.001 compared to control concentration). BSO 
and AT had no effect on cell viability.  
 
Pre-treatment of A549 cells with BSO or AT for 24 hours before treatment with CMPD73 
resulted in a modest, but significant, enhancement of efficacy with BSO more potent than 
AT (Figure 4.13). This effect is lost at higher concentrations of CMPD73, possibly due to a 
more generalised toxic effect on the cells.   
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Figure 4.13 Effect of CMPD73 on A549 cells pre-treated with BSO and AT. Results are expressed 
as mean percent viability ±1 Standard deviation of four independent experiments. (*** P<0.001 
compared to concentrations of compound control). BSO and AT had no effect on cell viability.  
 
In a parallel experiment with CMPD74, there is a similar potentiation of the action of the 
compound, albeit at much lower concentration (Figure 4.14). There is essentially complete 
loss of cell viability at 5M (P<0.001), a concentration which had no observable impact with 
CMPD73. There is only a modest decrease in viability for CMPD74 following addition of 
BSO. Intriguingly, there is no significant impact following AT treatment, in contrast to the 
analogous situation with CMPD73. In fact, there is an apparent slight increase in viability 
following AT treatment compared to the control.  
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Figure 4.14 Effect of CMPD74 on A549 cells pre-treated with BSO and AT. Results are expressed 
as mean percent viability ±1 Standard deviation of four independent experiments. (*** P<0.001 
compared to concentrations of compound control). BSO and AT had no effect on cell viability.  
 
A549 cells pre-treated with BSO and exposed to concentrations of 1,10-Phen showed modest 
yet significant decreases in cytotoxicity following treatment with 10µM 1, 10-Phen (Figure 
4.15), indicating that 1,10-Phen can kill cells via the production of ROS.  
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Figure 4.15 Effect of 1,10-Phen on A549 cells pre-treated with BSO. Results are expressed as mean 
percent viability ±1 Standard deviation of two independent experiments. (*** P<0.001 compared to 
concentrations of compound control). BSO and AT had no effect on cell viability.  
 
Pre-treatment of CS mesothelioma cells with BSO or AT for 24 hours before treatment with 
CMPD73 resulted in a modest, but significant, enhancement of efficacy with BSO (Figure 
4.16). No enhancement of efficacy is seen in treatments using AT, in contrast to effects noted 
in A549 cells with concentrations of 50M experiencing a modest but significant 
enhancement of activity. This difference may be a result of cell type specificity and 
expression levels of antioxidant enzymes. In further contrast to A549 cells, the effect of BSO 
mediated enhancement continued significantly at higher concentrations of CMPD73, as CS 
































Figure 4.16-Effect of CMPD73 on CS meso cells pre-treated with BSO and AT.  Results are 
expressed as mean percent viability ±1 Standard deviation of four independent experiments. (*** 
P<0.001 compared to concentrations of compound control). BSO and AT had no effect on cell 
viability.  
 
CMPD74 displayed a similar response in CS meso cells as it did in A549 cells (Figure 4.17), 
with significant reduction in cell viability at 5M (P<0.001). A similar comparison can be 
made between CMPD 73 and 74 as in A549 cells, in that potentiation of the CMPD 74 
happens at a much lower concentration than CMPD 73. Similar to CMPD 73, there is no 
significant impact following AT treatment seen with CMPD 74. This result is also similar to 
AT treatment in A549 cells exposed to CMPD 74.  
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Figure 4.17-Effect of CMPD74 on CS meso cells pre-treated with BSO and AT.  Results are 
expressed as mean percent viability ±1 Standard deviation of four independent experiments. (*** 
P<0.001 compared to concentrations of compound control). BSO and AT had no effect on cell 
viability.  
 
Pre-treatment of CR mesothelioma cells with BSO or AT for 24 hours before treatment with 
CMPD73 resulted in a near identical result as CS meso cells treated in similar fashion (Figure 
4.18). No increase in enhancement is seen in cells pre-treated with AT, with significant 
modest increases in enhancement in response to BSO pre-treatment. As CR meso cells are 































Figure 4.18-Effect of CMPD73 on CR meso cells pre-treated with BSO and AT.  Results are 
expressed as mean percent viability ±1 Standard deviation of four independent experiments. (*** 
P<0.001 compared to concentrations of compound control). BSO and AT had no effect on cell 
viability.  
 
Pre-treatment of CR mesothelioma cells with BSO or AT for 24 hours before treatment with 
CMPD74, as seen with CMPD 73, resulted in a near identical result as CS meso cells treated 
in similar fashion (Figure 4.19). No increase in enhancement is seen in cells pre-treated with 
AT, with significant increases in enhancement in response to BSO pre-treatment. As CMPD 
74 does not distinguish between CS and CR meso cells near identical results were expected.  
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Figure 4.19-Effect of CMPD74 on CR meso cells pre-treated with BSO and AT.  Results are 
expressed as mean percent viability ±1 Standard deviation of four independent experiments. (*** 
P<0.001 compared to concentrations of compound control). BSO and AT had no effect on cell 
viability.  
 
A2780 cells were pre-treated with 1mM AT in order to determine whether limited 
enhancement of compound activity is a result of cell type specificity (Figure 4.20). CMPD 
73 experienced no enhancement of efficacy in A2780 cells pre-treated with AT. It would 
appear A549 cells only can be sensitised to AT treatment regarding CMPD 73, albeit 
modestly only at 50M. 
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Figure 4.20-Effect of CMPD73 on A2780 cells pre-treated with AT.  Results are expressed as mean 
percent viability ±1 Standard deviation of two independent experiments. AT had no effect on cell 
viability.  
 
Pre-treatment of A2780 cells with AT and CMPD 74 did show very modest but significant 
increases in specificity at both 500nM and 50µM concentrations (P<0.01) (Figure 4.21). This 
is in contrast to the three other cell lines used where no enhancing effect is seen between 































Figure 4.21-Effect of CMPD74 on A2780 cells pre-treated with AT.  Results are expressed as mean 
percent viability ±1 Standard deviation of two independent experiments. (** P<0.01 compared to 
concentrations of compound control). AT had no effect on cell viability.  
 
After extensive testing using multiple cell lines in can be determined that pre-treating cells 
with BSO significantly increases the cytotoxicity of both CMPD 73 and 74, indicating that 
the GSH antioxidant pathway is involved in compound detoxification. This supports 
previous observations using ROS detecting probes (DCFDA) that ROS generation is a key 
mechanistic event for these compounds. As inhibition of catalase using A.T. did not 
significantly increase the cytotoxic effects of either novel compound, catalase is not 
implicated in the detoxification of these compounds and likely excludes H2O2 generation as 
a key mechanistic event. 
  
 Selective inhibition of compound cytotoxicity using ROS scavengers 
H2O2 was used a model compound to evaluate the efficacy of ROS scavengers in modifying 
treatment dependent cytotoxicity, with a 24-hour treatment period. NaPy and Tiron 
are expected to lead to increases in cell viability in response to treatment with H2O2 and thus 
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decreasing its ability to cause cell death.  As predicted, there were significant effects on 
the efficacy of H2O2 to act as a cytotoxic agent, with cell death essentially reversed in the 
presence 50µM H2O2 and NaPy, and significantly reduced in the presence of Tiron (Figure 
4.22). Individually NaPy had no effect on cell viability, while Tiron reduced cell viability by 
25-30%. These results validate the use of NaPy and Tiron as tools to interrogate the 






























Figure 4.22-Chemical scavenging of H2O2 and superoxide decreases the susceptibility to H2O2 
exposure in A2780 cells.  Results are mean expressed as percent viability ±1 Standard deviation of 
two independent experiments. (*** P<0.001 compared to concentrations of compound control). 
NaPy had no effect on cell viability, while Tiron reduced cell viability by 25-30%.  
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Pre-treatment of A2780 cells with NaPy or Tiron for 1 hour before treatment with CMPD73 
resulted in a significant increase in cell viability in response to Tiron (iSuperox), but not 
NaPy (H2O2) (Figure 4.23). This effect is lost at higher concentrations of CMPD73 and is 




























Figure 4.23-Effect of CMPD73 on A2780 cells pre-treated with NaPy (iH2O2) and Tiron 
(iSuperox).  Results are expressed as mean percent viability ±1 Standard deviation of three 
independent experiments (*** P<0.001 compared to concentrations of compound control). NaPy 
had no effect on cell viability, while Tiron reduced cell viability by 25-30%.  
 
In a parallel experiments with CMPD74, there is essentially a complete rescuing of cells 
from CMPD 74 cytotoxicity seen at 500nM (P<0.001) when cells were incubated with Tiron, 
compared to a 50% drop in viability in control conditions using CMPD 74 (Figure 4.24). A 
significant increase in viability is also seen at 5M (P<0.001) to almost 75%, compared with 
near total cytotoxicity in control conditions. CMPD 74 is also seen to be significantly more 
susceptible to inhibition by Tiron than CMPD 73. NaPy had a more moderate but significant 
increase in cell viability when compared to CMPD 74 control conditions at both 
































Figure 4.24-Effect of CMPD74 on A2780 cells pre-treated with NaPy (iH2O2) and Tiron 
(iSuperox).Results are expressed as mean percent viability ±1 Standard deviation of three 
independent experiments.(*** P<0.001 compared to concentrations of compound control). NaPy 
had no effect on cell viability, while Tiron reduced cell viability by 25-30%.  
 
1,10-Phen displayed an almost identical ROS scavenging profile as CMPD 73 (Figure 4.25). 
No interaction is seen when NaPy is used. However, there is a significantly more 
pronounced, near total rescuing effect seen in response to treatment with Tiron, when 
compared to the same conditions and concentration using CMPD 73. 
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Figure 4.25-Effect of 1,10-Phen on A2780 cells pre-treated with NaPy (iH2O2) and Tiron 
(iSuperox).  Results are expressed as mean percent viability ±1 Standard deviation of three 
independent experiments (*** P<0.001 compared to concentrations of compound control). NaPy 






 Discussion:  
Metal-phen compounds are often redox active and the generation of ROS is typically 
associated with the cytotoxic action of these compounds. So far both CMPD 73 and 74 have 
been demonstrated to possess potent cytotoxic effects towards cancer cell lines with an as of 
yet undefined cytotoxic mechanism. The data obtained from studies involving epigenetic 
chemo sensitisation strategies (Chapter 3) has highlighted potential crossovers between ‘’off 
target’’ effects of HDACi with suspected ROS generating capabilities of both test 
compounds and as such the production of ROS by these compounds has been investigated. 
Both compounds as well as 1, 10-Phen itself were demonstrated to generate ROS, with 
superoxide generation identified as the primary mediator of compound cytotoxicity. 
  
The fluorescent probe DCFDA was used to investigate ROS generating potential of CMPDs 
73 and 74 in A549 adenocarcinoma cells and A2780 ovarian cancer cells, with both cell lines 
indicating notable ROS production by both compounds comparable or comparably higher 
than both H2O2 and analogous CMPD 19 and 22. Following the use of appropriate statistical 
corrections (Holm-Bonferroni correction) to account for Type 1 errors, data which was 
initially statistically significant (flow cytometric analysis of compounds in both cell lines, 
CMPD 73 in microplate setting using A2780 cells) no longer appears to be statistically 
significant. However, the observed impacts of both compounds are comparable between cell 
lines and is interpreted as an authentic biological effect. Biochemical probing for the 
generation of ROS is demonstrated to produce statistically significant results supporting the 
observations made using fluorescent DCFDA staining. As such the loss of significance using 
DCFDA staining to detect ROS generation by metal-phen compounds may be a result of 
strict significant thresholds associated with Bonferroni/Holm-Bonferroni corrections 
coupled with a degree of variability among biological replicates.  
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Interestingly 1,10-Phen is also demonstrated to produce significant amounts of ROS when 
examined using flow cytometry, an event which is not detected using DCFDA in a 
fluorescent spectrophotometric setting. This may possibly be a result of the lower 
concentrations of test compounds which are generally used for fluorescent 
spectrophotometric assays to avoid saturation of the detecting instrument. This data suggests 
that the hypothesis for both CMPD 73 and 74 operating through a redox active mechanism 
of cytotoxicity is correct and that ROS generation can be conducted by either the compounds, 
1,10-Phen or any potential alternate compounds that may arise following compound 
disassociation. However, it should be noted that caution must be taken when examining 
results provided by the DCFDA probe as can be seen when careful examination of CMPD 
19 and 73 is undertaken. CMPD 73 is seen to follow a similar trend to CMPD 19, with 
significant, rapid, and potent generation of ROS even more so than that of CMPD 19. This 
apparent rapid generation of ROS as detected by DCFDA staining however may be an 
artefactual effect rather than a biological one. 
  
Previous studies using the analogous compounds lacking the ethereal oxygens revealed that 
they may be capable of leading to the production of ROS within the cell (Kellett et al., 2011). 
Careful examination of the data related to ROS revealed that the copper containing 
compound (CMPD22, dark grey circles in Figure 4.26) did not promote the formation of a 
greater amount of ROS compared to 1,10-phen alone (average across all concentrations of 
2.2-fold increase in ROS for both CPMD22 and 1,10-phen). In contrast, the manganese 
containing CMPD 19 is reported to induce significant production of cellular ROS with a 20-
fold increase in DCF fluorescence at 1µM (Figure 4.26).  
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CMPD 19 has also been reported to have significant superoxide dismutase and catalase 
mimetic activities. It has been described that DCFDA generates a radical intermediate 
(DCF•−) which is capable of reacting extremely rapidly with O2 to generate superoxide 
(Wrona and Wardman, 2006). The SOD mimetic activity of CMPD 19 would lead to the 
generation of H2O2 from this superoxide in a concentration dependent manner which can, in 
the presence of iron, react with the DCFH2 to generate the DCF•− intermediate. This process 
creates a potential amplification loop for the generation of intracellular ROS, once the SOD 
activity increases sufficiently. Indeed a reanalysis of the data from Kellet et al (2011) reveals 
that up to 500nM of CMPD 19 the increase in ROS almost perfectly follows the expected 
pattern for exponential growth (Figure 4.26, black circles) which is consistent with the 
hypothesis described above. A possible explanation for the decrease observed at the highest 
concentration (1µM) is that the catalase mimetic activity of the compound may become 
sufficient to degrade the H2O2 and block this cycle. Since CMPD 73 is also manganese 
containing with further potential for SOD-mimetic activity the same artefactual reaction 
described for CMPD 19 may explain the rapid increase in apparent ROS production detected 
by DCFDA in both flow cytometric and spectrophotometric settings.   
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Figure 4.26- Extracted data from Kellet et al (2011) re. ROS production of analogous compounds.  
CMPD 22 is the analogous copper compound, while CMPD19 is the analogous manganese 
compound. 
 
As such the apparent potency of ROS generation by manganese-phen compounds may be a 
caveat when using DCFDA staining resulting from potential SOD-mimetic activity, rather 
than that of significant intracellular ROS generation. While the use of DCFDA staining is 
suggestive of ROS production by both CMPD 73 and 74, DCFDA staining may not be the 
most reliable method for ROS detection at least with regards to manganese containing 
compounds. As such other methods are required to overcome these limitations, such as ROS 
specific fluorescent probes that do not undergo artefactual feedback loops. Other limitations 
of DCFDA staining are that only generic ROS generation is detected rather than exact 
reactive species and as such further investigation using ROS specific probes and scavengers 
as well as inhibitors of antioxidant pathways is warranted. The lack of the apparent 
artefactual SOD mimetic activity seen with CMPD 74 and free 1,10-Phen potentially 
validates data obtained for these compounds by DCFDA staining; however speciation of 
ROS detected is required. 
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Using a chemically distinct mitochondrial specific H2O2 probe, MitoPY1, only a very minor 
increase in mitochondrial H2O2 is observed. This is observed in A549 as well as isogenic 
mesothelioma cells (data not shown). The increase is considered to be within the margin of 
error for the method rather than a reflection of intra-mitochondrial production of H2O2.   
 
Although it is not possible to resolve significant changes in mitochondrial ROS 
concentrations following treatment with CMPD73 and CMPD74, pre-treatment of cells with 
BSO or AT (in the case of CMPD 73) significantly enhanced the cytotoxic capacity of the 
compounds. There is no impact of either BSO or AT on the cell viability alone. These data 
indicate that adequate GSH levels and catalase activity are required to limit cell death, 
consistent with an elevation in cellular ROS levels.  
 
In the A549 cell model a greater enhancement in cytotoxic activity is observed following 
BSO treatment than AT, particularly with regards to CMPD74. These data suggest that the 
GSH pathway may be more critical for the elimination of intracellular ROS generated as a 
result of the (direct or indirect) action of the metal-phen compounds. Treatment of CS or CR 
mesothelioma cell lines with CMPD73 under conditions where catalase is inhibited did not 
reveal any enhancement in cytotoxicity. This may be due to the development of 
mesothelioma in a high ROS environment (e.g. asbestos exposure) which promotes high 
level expression of SOD, catalase and other redox defence enzymes and may explain in part 
why the isogenic CS mesothelioma cell line is more tolerant to CMPD 73 than the A549 
cells. Indeed it has been reported that this is in fact the case in malignant mesothelioma 
(Kahlos et al., 1998). This can further be supported by the modest yet significant 
enhancement of CMPD 74 by AT in A2780 cells, indicating that CMPD 74 may indeed 
interact with the catalase pathway, albeit to a very low degree in a cell type specific context.  
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The possibility that CMPD73 has inherent catalase mimetic activity similar to that of CMPD 
19 may also be a reason for the less pronounced effect of AT in the various model systems 
tested. If catalase mimetic activity is taking place, then it would remove H2O2 through its 
inherent biochemical mimetic activity and would therefore not rely on H2O2 production for 
biological activity. 
 
Comparing both CMPD 73 and free 1,10-Phen in A549 cells in response to knockdown of 
GSH (indirectly confirmed by increased cytotoxicity of H2O2 assay control) may again 
demonstrate that compound efficacy is predominantly driven by the action of 1,10-Phen 
rather than the compound as a whole. Both CMPD 73 and Phen appear to respond to GSH 
synthesis inhibition only within the 10-100M range, before the effect experiences a plateau 
at higher concentrations. These similarities further support these previous observations. 
Inhibition of the GSH pathway also supports the notion that the exceptionally high levels of 
apparent ROS generation detected by DCFDA fluorescent staining were likely a result of the 
artefactual reaction described regarding CMPD 73. While highly significant, the levels of 
enhanced cytotoxicity mediated by CMPD 73 in BSO treated cells is much lower than would 
be expected for a compound with the exceptional ROS generating potential demonstrated by 
DCFDA staining. While DCFDA staining is still indicative of ROS generation by CMPD 73 
despite artefactual reactions further experimentation using biochemical probes and 
genetically encoded ROS sensors will be required to validate observations made with the 
current fluorescent probes. 
 
Comparing both BSO/AT treatments with results obtained from ROS scavenging studies 
sheds further light on intracellular redox status induced by both CMPD 73 and 74, in the 
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context of A2780 ovarian cancer cells. The use of NaPy to scavenge H2O2 again 
demonstrates cell type specificity regarding intracellular H2O2 production, as results from 
AT-treated A2780 cells reflects those of NaPy-treated cells. While H2O2 can vary between 
cell types, it does not appear to be a key reactive species in ROS-mediated cytotoxicity of 
either compound. The limited detection of H2O2 may be a result of indirect generation in 
response to the dismutation (randomly by diffusion or by SOD activity) of the large quantity 
of superoxide produced by both compounds. H2O2 may therefore not be as far reaching 
throughout the cell as superoxide appears to be, if produced significantly at all. These data 
also indicate the use of H2O2 scavengers over the inhibition of H2O2 detoxifying enzymes 
for accurately determining the role of intracellular H2O2.  
 
The identification of the superoxide anion as the major species of ROS required for metal-
phen cytotoxicity can serve as a possible link between the modes of cell death already 
established in Chapter 2 for each compound. Superoxide has been implicated as a mediator 
of both mitochondrial and ER induced cell death (Inoue and Suzuki-Karasaki, 2013), as well 
as been implicated as a master regulator of autophagy and therefore autophagic cell death 
(Chen, Azad and Gibson, 2009).   
 
Both CMPD 73 and 74 have been demonstrated to interact significantly with the apoptotic 
pathway, and so superoxide may be the signalling molecule responsible for its activation. 
This may particularly be the case regarding CMPD 74 owing to is apparent high level of 
dependency on superoxide production to mediate cytotoxicity (≈65% increase in viability 
compared to control compound). However, where superoxide is targeting e.g. the 
mitochondria is yet to be determined and doing so should shed light on the exact mechanism 
through which both CMPD 73 and 74 exert their cytotoxic effects. Redox sensitive 
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fluorescent probes such as MitoSOX red, which specifically stains mitochondria and 
fluoresces upon activation by superoxide would likely shed light on the intracellular targets 
of metal-phen generated superoxide, particularly when used in combination with apoptotic 
markers to determine a causal link between the two, as assayed by Mukhopadhyay et al., 
(2007) using flow cytometry-based methods.   
 
Upon further comparison between CMPD 73 to metal-free 1,10-Phen, a very similar ROS 
profile emerges with a key difference being the sensitivity in which Tiron scavenging of 
superoxide protects A2780 cells from either compound, with test cells experiencing near 
total protection from 1,10-Phen, and significant but a slightly less degree of protection from 
CMPD 73. The reasons to this are yet unknown however it could be speculated that the 
higher molar equivalents 1,10-Phen delivered by CMPD 73 are overwhelming the 
cytoprotective effects of Tiron and lower concentrations of CMPD 73 may show similar 
effects (discussed Chapter 2 page 88-89). As such this line of study warrants further 
investigation. As 1,10-Phen is the major contributor to CMPD 73 cytotoxicity, (discussed in 
Chapter 2), shared ROS profiling further supports this hypothesis. The generation of 
superoxide by 1,10-Phen may occur indirectly as a result of SOD1 and 2 inhibition mediated 
by 1,10-Phen chelation. Evidence of 1,10-Phen-associated superoxide generation is 
presented later in this thesis.  
 
An attempt to use DMSO, a hydroxyl radical scavenger, was conducted in order to determine 
whether hydroxyl radical inhibition could have potential cytoprotective effects on the cells 
in response to metal-phen treatments. However, pilot studies using both 1% and 10% DMSO 
in RNA degradation studies determined that only 10% DMSO is capable of hydroxyl radical 
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inhibition. DMSO at 10% concentration is seen to be highly cytotoxic itself and was 
unsuitable for this investigation. 
 
SOD mimetic activity of metal-phen compounds has been a point of investigation for many 
previous analogues, CMPDs 19 and 22 from Kellet (2011) a prime example. However the 
data described may be telling that SOD mimetic activity, at least regarding CMPD 73 or 74, 
may not be as biologically relevant as originally hypothesised. SOD mimetic activity has not 
yet been directly determined for CMPD 73 or 74, however the data obtained from DCFDA 
staining are highly suggestive of SOD mimetic activity regarding CMPD 73. This coupled 
with the larger effect of the superoxide scavenger compared to H2O2 scavenger (none for 73 
and minimal for 74, Figures 4.21 and 4.22) indicate superoxide is quite likely not being 
dismutated by either compound, at least at a level of any biological significance. Taking this 
into account SOD mimetic activity may not be a fruitful avenue for probing potential 
cytotoxic mechanisms and may only be relevant as a caveat when using fluorescent ROS 
probes as discussed above. Catalase mimetics have also been demonstrated for previous 
analogues (CMPD 19 and 22 respectively Kellet et.al 2011). However the low reliance on 
H2O2 production for cytotoxicity again likely renders this avenue of investigation redundant.  
 
Taken together these data provide significant evidence to the ROS-dependent cytotoxic 
nature of both CMPD 73 and 74 metal-phen based compounds, and that superoxide 
generation is the ROS critical for these toxic effects. Further studies will be required to fully 
determine the intracellular targets of generated superoxide, and if it is the key mediator of 
previously determined apoptotic cell death pathways induced by both compounds.  
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5. Investigating Ferroptosis as a mechanism of cell death 
 Introduction 
As discussed in Chapter 4 cell injury as a result of oxidative stress can manifest in many 
different forms. One potential route for metal-phen compounds, and in particular CMPD 74, 
to target cells via oxidative stress is through the generation of peroxyl radicals and toxic lipid 
peroxides. As the main component of cellular membranes, lipids have an indispensable role 
in maintaining the structural integrity of cells, as well as acting as signalling molecules (Fahy 
et al., 2011). Lipid peroxidation is defined as the oxidative degeneration of lipids, and so 
extensive peroxidation alters the physical properties of cellular membranes and can cause 
covalent modification of proteins and nucleic acids (Gaschler and Stockwell, 2017).  
 
 Lipid peroxides 
Lipid peroxides are formed by the oxidation of lipids containing carbon-carbon double 
bonds, in particular polyunsaturated fatty acids (PUFAs) (Newcomer and Brash, 2015). 
Lipid peroxidation consists of three distinct steps, initiation, propagation, and termination.  
In the initiation step, pro-oxidant molecules such as the hydroxly radical (OH•), peroxyl 
radical (ROO•), singlet oxygen (1O2), or peroxynitrite (ONOO
-) extract allylic hydrogen 
forming a carbon-centred radical forming a lipid radical (L•). In the propagation step, L• 
reacts with oxygen forming lipo-peroxyl radicals (LOO•), which can in turn extract another 
hydrogen from its neighbouring lipid molecule, yielding another L• and a lipid hydroperoxide 
(LOOH). This will manifest as a cascade of continuing oxidation of neighbouring lipid 
molecules within the membrane (reviewed Ayala, Muñoz, & Argüelles, 2014). The 
propagation step will continue until terminated by chain breaking antioxidants such as lipid 
soluble Vitamin E, found within cell membranes (Niki, 2015). The steps of initiation, 




Figure 5.1-Initiation and propagation of lipid radicals and generation of lipid peroxides  
(Freinbichler et al., 2011). 
 
Lipid peroxides, non-radical intermediates of lipid oxidation, are moderately more stable in 
contrast to highly reactive lipid radicals (L•, LOO•) (Shahidi and Zhong, 2010). As a 
hydroperoxide, lipid peroxides behave similarly to H2O2, with their relative stability 
allowing them to transverse cell membranes and permeate the cell much further from their 
point of origin than other peroxidation products (Girotti, 1998). They are also vulnerable to 
further reduction by Fenton like chemistry by free iron or copper, as well as by other lipid 
radicals breaking down into more reactive intermediates, predominantly aldehydes such as 
hexanal, 4-hydroxynonenal (HNE) or malonaldehyde (MDA) (Barrera, 2012). HNE is the 
most intensively studied aldehyde produced by lipid peroxide reduction, as it is known as a 
second messenger of free radicals and is a major biomarker for lipid peroxidation (Ayala, 
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Muñoz and Argüelles, 2014). MDA is also an important lipid metabolite as it can form 
covalent adducts with deoxyguanine and deoxyadenine in DNA (Marnett, 1999), adding 
another layer of potential oxidative damage attributed to lipid peroxidation. 
 
Lipid peroxides are known to be produced in an iron-dependent manner within cells, either 
enzymatically or non-enzymatically (Kristinova et al., 2014). Non-enzymatic peroxidation 
occurs in response to oxidative stress via the Fenton reaction in response to increased iron 
and the production of free radicals such as OH• (Carlsen, Møller and Skibsted, 2005). Other 
non-enzymatic oxidation can result from lipid photo-oxidation as a result of high energy 
radicals produced by UVA light (sunlight), such as 1O2, or by spontaneous auto-oxidation 
resulting from the reaction of oxygen with traces of transition metals (iron)and PUFAs (Sun 
et al., 2011). 
 
Enzymatic lipid oxidation is carried out by a family of iron-dependent Lipoxygenases 
(LOX), which catalyse the dioxygenation of long chain PUFAs containing 2-6 double carbon 
bonds, such as linoleic, arachidonic, and docosahexaenoic acids (Gaschler and Stockwell, 
2017). They are non-heme containing, iron-dependent oxygenases heavily involved in cell 
signalling via production of eicosanoids such as prostaglandins (Mashima and Okuyama, 
2015), and the inflammatory response by producing leukotrienes (pro-inflammatory 
molecules), or lipoxins (anti-inflammatory molecules) (Chandrasekharan and Sharma-Wali, 
2015). Lipoxygenases are classified as 5-, 8-, 12, and 15-lipoxygenases according to their 




The deleterious effects of cytotoxic lipid peroxides (loss of membrane integrity, DNA 
damage) if left unresolved will result in induction of either apoptotic, autophagic or necrotic 
cell death pathways (Su et al., 2019). However, in recent years it has been shown that another 
form of iron regulated programmed cell death, known as ferroptosis, can occur in response 
to lipid peroxidation (Dixon et al., 2012). 
 
 Ferroptosis  
Ferroptosis is defined as an iron-dependent regulated form of necrotic cell death, 
characterised by the accumulation of lethal lipid peroxides (Dixon et al., 2012). It is 
mechanistically distinct from other regulated forms of cell death such as apoptosis or 
autophagy (Gaschler and Stockwell, 2017). In ferroptosis, release of cellular pools of iron 
from degraded ferritin via autophagy (termed ferritinophagy) results in uncontrolled 
production of lipid ROS, which in turn initiates the generation of toxic lipid peroxides, which 
can either disrupt membrane integrity or become incorporated incorrectly into membrane 
lipid bi-layers, disrupting homeostatic function and membrane protein signalling, causing 
membrane disruption, loss of function of membrane bound organelles and cell death 
(Latunde-Dada, 2017). Ferroptosis is distinct from apoptosis in that it is not caspase 
dependent and does not exhibit the same structural changes such as chromatin condensation 
or membrane blebbing. Ferroptotic cells tend to present as rounded and detached, with 
shrunken mitochondria devoid of cristae (Xie et al., 2016). 
 
The cause of ferroptosis is primarily dependent on the repletion and depletion of iron and 
GSH within the cells causing uncontrolled production of lipid peroxides. This can be 
triggered via oxidative stress from exogenous or endogenous agents, resulting in the 
inhibition of both GSH synthesis and the GSH dependent enzyme Glutathione Peroxidase 4 
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(GPx4) (Su et al., 2019). GPx4 has been identified as the primary enzymatic antioxidant 
responsible for detoxification and removal of lipid peroxides from the cell (Ighodaro 2018). 
The role that iron plays in ferroptosis is two-fold, either through ferritinophagy in response 
to cysteine deprivation, or acting as a co-factor in the iron-dependent LOX family of 
enzymes (Newcomer and Brash, 2015; Lei, Bai and Sun, 2019). High levels of free iron are 
available to degrade H2O2 via Fenton like reactions to produce the hydroxyl and peroxyl 
radicals, which in turn can oxidise membrane PUFAs and either initiate or propagate lipid 
peroxide production. LOX enzymes experience an increase in activity in response to elevated 
levels of cellular free iron, uncontrollably generating higher levels of lipid peroxides within 
the cell (Gao and Jiang, 2018). The primary species of PUFA identified as the main 
ferroptotic death signals are phosphatidylethanolamines (PE) containing both arachidonoyl 
(AA) and adrenoyl (AdA) fatty acyls.  Bis-allylic PEs containing these fatty acyls are subject 
to oxidation by 15-LOX to generate lipid hydroperoxides, which then initiate ferroptosis 
(Feng and Stockwell, 2018). 
 
Lipid peroxidation can also result from the inactivity or inhibition of GPX4, either by direct 
inhibition by an exogenous agent, or indirect inhibition resulting from reduced synthesis of 
GSH, the critical co-factor for GPX4 activity. GPX4, a phospholipid hyrdroperoxidase, is 
the primary antioxidant enzyme tasked with detoxifying lipid peroxides and maintaining 
membrane fluidity and integrity. It exists in 3 isoforms, cytosolic, mitochondrial and nuclear 
forms. GPX4 uses reduced GSH as a cofactor to reduce oxidised PUFAs, preventing further 
propagation of lipid oxidation. The resulting oxidised GSSG disulphide is then reduced by 
GSH reductase (reviewed Seibt, Proneth, & Conrad, 2019).  
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GSH synthesis is dependent on System Xc
-, a plasma membrane bound cystine/glutamate 
antiporter responsible for importing cystine, the oxidised form of cysteine required for GSH 
synthesis (Dixon et al., 2014). Cysteine and glutamate are then incorporated into the active 
GSH molecule by glutamate cysteine ligase (GCL). Both the importation of cysteine and the 
subsequent GSH synthesis are two of the most vulnerable sites within the ferroptosis 
pathway which are subject to inhibition by ferroptosis inducing drugs (Zou et al., 2019). 
Erastin and BSO target System Xc- and GCL to cause a decrease in GSH synthesis and 
availability, while RSL3 and RSL5 directly targets GPX4 activity essential for ferroptosis 
induction, with Erastin-mediated inhibition further capable of activating ferritonphagy 
releasing iron from ferritin increasing cellular labile iron pools (Wang et al., 2018; Lu et al., 
2018; Sato et al., 2018). Therefore, it is generally seen that it is the downregulation of GSH 
and GPX4 activity that is the primary mechanism mediating ferroptotic cell death, and that 
labile iron pools are a downstream factor responsible for the final execution of the process 
(Dixon, 2017). 
 
Inhibitors of ferroptosis tend to be lipid antioxidants capable of terminating iron or lipid 
oxidation reactions (e.g. Ferrostatin-1 chelates iron, Liproxstatin-1 and α-tocopherol 
scavenge lipid ROS) (Skouta et al., 2014). Ferrostatin-1 and Liproxstatin-1 are lipophilic 
amines/imines that are thought to accumulate within the cell at high concentrations, and 
furthermore in acidic intracellular compartments such as lysosomes and peroxisomes 
(Stoyanovsky et al., 2019). Trolox, a water-soluble form of Vitamin E, has also been 
implicated as an inhibitor of ferroptosis, as it acts as a chain-breaking antioxidant for lipid 
peroxide generation (Cao and Dixon, 2016). The ferroptotic pathway, its inducers and its 
inhibitors can be seen in Figure 5.2. 
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Figure 5.2-Mechanisms of Ferroptotic cell death.  Inducers of ferroptosis are represented in red 
(arrows, inhibitory bars) while inhibitors of ferroptosis are represented in green (inhibitory bars). 
Inhibition of system Xc- by Erastin or BSO prevents GSH synthesis and reduces GPX4 activity. 
Excess importation of transferrin-associated iron increases labile iron pools which serve to increase 
LOX activity and Fenton like chemistry to generate lipid peroxides capable of inducing ferroptosis. 
Ferroptosis can be inhibited by GPX4 and Fer-1 or Lipro-1 which prevent accumulation of lipid 
peroxides. This figure was self-generated using Microsoft PowerPoint based on the current 
understanding of knowledge from a multitude of sources. 
 
Ferroptosis has been implicated in numerous human pathologies (neurodegenerative 
diseases, ischemic perfusion injury), but a normal physiological function for ferroptosis has 
not been identified (Feng and Stockwell, 2018). However, ferroptosis has recently been 
investigated as a novel target for potential chemotherapeutic agents (Xu et al., 2019). Cancer 
cells, as a result of metabolic reprogramming, are often more sensitive to ferroptosis than 
that of their non-cancerous counterparts (Friedmann Angeli, Krysko and Conrad, 2019). The 
activation of Ras-mitogen-activated protein kinase (MEK) signalling in certain cancers has 
been seen to be responsible for increasing iron abundance in activated cancer cells, by 
increasing the expression of both the transferrin receptor and ferritin (Mou et al., 2019). 
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One such example is the state of chronic inflammation that cancer cells tend to exist in, as 
well as relying on inflammation for oncogenic transformation to begin with. Cancer cells in 
an environment of chronic inflammation have been shown to depend on GPX 4 activity to 
regulate the activity of LOX and other eicosanoid synthesising enzymes (cyclooxygenases) 
to tip the balance in favour of sustaining cell growth (Pang, Hurst and Argyle, 2016; Zou et 
al., 2019). 
 
Metal-phen compounds, particularly copper based CMPD 74, may be available to induce 
ferroptosis. As copper is capable of initiating Fenton-like chemistry in similar fashion to 
iron, it is plausible hydroxyl radical production may be capable of producing large quantities 
of lipid peroxides. The significant increases in cytotoxicity demonstrated by both 
compounds support this proposal. While CMPD 73 and free 1,10-Phen may not be available 
to partake in Fenton-like chemistry, their potential to induce oxidative stress and therefore 
cause GSH depletion, may sensitise the cells to undergo ferroptosis, and so further 
investigation is warranted.  
 
 Aims  
This chapter describes the results of experiments that were aimed at clarifying if these 
compounds interact with iron-mediated ferroptotic cell death in response to treatment with 
ROS-generating CMPD 73 and 74. Multiple ferroptosis inhibitors will be used to investigate 




 Methods  
 Indirect measurement of Ferroptosis using Ferroptosis inhibitors 
A549 alveolar carcinoma cells were incubated with both Ferrostatin-1 (Sigma), Liproxstatin-
1 (sigma) and Trolox (sigma), a water-soluble form of vitamin E/α-tocopherol between 4-8 
hours, and then treated with metal-phen compounds for 24hrs. Where 24hr pre-treatment 
was used, cells were exposed to ferrostatic agents during plating, allowed to attach for 24hrs, 
and then exposed to both metal-phen and ferrostatic agents. FeCl2 was used as a potential 
positive control for iron overload, alongside BSO, a suspected inducer of ferroptosis (Feng 
and Stockwell, 2018). All pre-treatments and incubations were conducted at 37°C. 
Following 24hr incubation with suspected ferroptosis-inducing agents, cell viability was 
assessed using the Resazurin based Alamar Blue assay, as stated in previous sections. Where 
24hr pre-treatment with BSO was also used, it again was added to the cells during cell 
plating. A positive result would present as an increase in cell viability as Ferroptotic cell 
death is inhibited. 
 
 Detection of red cell haemolysis 
Loss of membrane integrity in response to lipid peroxidation, ferroptotic or otherwise, was 
investigated as a potential mechanism of cell death for CMPD 73, 74, and free 1,10-Phen. 
Red Blood Cells (RBC) offer a unique model as they are inherently delicate to both 
mechanical and chemical stress, but also lack many cell organelles otherwise found in human 
cells. e.g. nucleus, mitochondria, Golgi apparatus, lysosomes and the smooth and rough 
endoplasmic reticulum (Moras, Lefevre and Ostuni, 2017). A such, they offer a model for 
determining cytotoxic mechanisms of novel compounds, as loss of target organelles such as 
DNA/RNA or mitochondria may manifest as an absence of toxic effect. On the other hand, 
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the delicacy of these cells means that if haemolysis occurs, it could easily be attributed to a 
membrane attack mechanism causing haemolysis, ferroptotic or necrotic. 
 
The lysis of intact RBC can be detected via the absorbance of released free oxyhaemoglobin 
(Hb) at 540nm. Agents capable of causing haemolysis should cause an increase in 
absorbance at this wavelength over time as Hb is released into the extracellular space. 
 
Briefly, 250µl of 25% (v/v) horse blood (Cruinn) (diluted with 0.9% saline) was plated into 
a clear flat-bottomed 96-well plate and incubated with CMPD 73, 74, free 1,10-Phen, and 
1% Triton-X (total lysis control) at 37°C for 0, 1, 2, and 16hrs. At each incubation time, the 
plate was spun at 300rpm for 5mins, and 50µl of supernatant was sampled and read at an 
absorbance spectrum ranging from 500-600nm, recorded at 10nm intervals. Haemolysis was 
then expressed as a percent of Triton-X control at 540nm. 25% total horse blood was 
determined to be the optimal concentration of total blood that gave the highest absorbance 




 Results  
 Indirect measurement of Ferroptosis using Ferroptosis inhibitors  
Known inhibitors of ferroptosis were utilised in both mono and combinatorial therapies 
against FeCl2, metal-phen and free 1,10-Phen compounds, in order to investigate ferroptosis 
as a potential mechanism of cell death in A549 cells. As a Cu2+ containing compound, 
CMPD 74 is predicted to interact with the ferroptotic pathway and experience inhibited 
activity in response to cytoprotective inhibitors. Surprisingly this is not the case, as 
demonstrated in Figure 5.3 A-D. 
 
FeCl2 was employed as a potential positive control as iron overload has been suggested to 
initiate ferroptosis (Dixon et al., 2012). FeCl2 did not appear to be cytotoxic towards the cells 
at any concentration used (nM, µM or mM) and therefore did not interact with ferroptosis 
inhibitors (data not shown). However, assays employing both a combination of Ferrostatin 
and Liproxstatin and 24hr pre-treatment of both inhibitors demonstrated a significant 
reduction in A549 cell viability when compared to FeCl2-only control (data not shown). 
 
A549 cells pre-treated for 8hrs with increasing concentrations of Trolox (Vitamin E) 
demonstrated no change in cell viability after the addition of CMPD 74 (Figure 5.3 A). As 
Trolox is known to inhibit ferroptosis by scavenging lipid radicals within lipid membranes, 
this indicates that lipid peroxidation is likely not a key process in CMPD 74s initiation of 
cell death. Figure 5.3 B-D, showing both mono and combinatorial, and co and pre-treatment 
therapies utilising Ferrostatin and Liproxstatin -1 displayed near identical results, and further 




Pre-treatment assays using both BSO and Ferrostatin/Liproxstatin inhibitors were also 
pursued, in order to investigate whether ferroptotic inhibitors could prevent BSO 
sensitisation of cells to CMPD 74. No difference is seen between CMPD 74/BSO treatments 
and the same treatments employing ferroptotic inhibitors (data not shown). This extensive 
testing demonstrates that CMPD 74 does not interact with the ferroptosis pathway, and that 
increased cytotoxic effects seen in response to BSO treatments are a result of lowered 









Figure 5.3-CMPD 74 in response to titrations of ferroptosis inhibitors.  A) Trolox B) Ferrostatin-1, 
C) Liproxstatin-1, and D) combinations of Ferro- and Liprox-statins, co-treated or pre-treated for 
24hrs (± 1 Standard deviation of two independent experiments). Trolox caused a reduction of 2-8% 
A549 cell viability. Ferrostatin and Liproxstatin reduced cell vaibilty 10-15%. Ferrostatin and 
Liproxstatin combined reduced cell viability by 40%. 
 
Ferroptotic mechanisms were also investigated for CMPD 73 and free 1,10-Phen, as both 
compounds demonstrated modest increases in cytotoxicity in response to GSH inhibition by 
BSO. Although likely lacking Fenton like capabilities of copper or iron, it may be plausible 




oxidative stress or GSH depletion, as opposed to direct activation of lipid peroxides seen 
with iron. Further to lacking Fenton-like abilities, it is assumed that direct production of lipid 
peroxides is not within the capabilities of either compound and so treatments using Trolox 
were not employed.  
 
Similar to CMPD 74, neither CMPD 73 nor 1,10-Phen demonstrated any increases in 
cytotoxicity in the presence of ferroptosis inhibitors, indicating no interaction with the 
pathway. However, both compounds did appear to undergo a similar enhanced cytotoxic 
effect as FeCl2 when a combination of Ferro and Liproxstatin were employed as a 24hr pre-
treatment (Figure 5.4 A&B). 
 
Both Ferrostatin and Liproxstatin inhibited cell growth between 10-15% in A549 cells, while 
a combination of both is capable of causing up to 40% reduction in cell viability, particularly 
following 24hr pre-treatment. Pre-treatment with combinations of Ferrostatin and 
Liproxstatin above 10µM proved to be lethal to the cells. Pre-treatment with Trolox had 




Figure 5.4-CMPD 73 and 1,10-Phen in response to ferroptosis inhibitors.  A) CMPD 73 in response 
to ferroptosis inhibitors Ferrostatin-1 and Liproxstatin-1, alone and in combinations of Ferro- and 
Liprox-statins, co-treated or pre-treated for 24hrs. B) 1,10-Phen in response to ferroptosis inhibitors 
Ferrostatin-1 and Liproxstatin-1, alone and in combinations of Ferro- and Liprox-statins, co-treated 
or pre-treated for 24hr. (± 1 Standard deviation of two independent experiments). Ferrostatin and 
Liproxstatin reduced cell vaibilty 10-15%. Ferrostatin and Liproxstatin combined reduced cell 
viability by 40%. 
 
 Detection of red cell haemolysis 
Table 5.1 displays the results of RBC lysis assay measuring the release of free Hb in response 




free phen compounds caused any significant increase haemolysis, compared to the Triton-X 
control. A small percent of haemolysis is detected for both CMPD 73 and 1,10-Phen at 1mM 
concentrations (2-3%) however this is likely resulting from disruption of the RBC pellet 
following centrifugation and contamination of supernatant with RBCs. As such the detected 
haemolysis is likely artefactual.  
 
This supports the previous observation that lipid radicals and loss of membrane integrity are 
not key features of metal-phen cytotoxicity. Interestingly, these results may shed light on 
which cell organelles these compounds are targeting. The lack of haemolysis in response to 
metal and free phen compounds indicates that a loss of target specificity has occurred, and 
focus should now be turned towards investigating these subcellular organelles as candidates 
required for cytotoxic action.    
 
Table 5.1- Percent haemolysis of RBC incubated with Triton X control, CMPDs 73 and 74, and 




CMPD 73 CMPD 74 1, 10-Phen 
0 0 (± 0) 0 (± 0) 0 (± 0) 
10 0 (± 0) 0 (± 0) 0 (± 0) 
250 0 (± 0) 0 (± 0) 1 (± 0.02) 
500 0 (± 0) 0 (± 0) 1 (± 0.01) 
1000 2 (± 0.04) 0 (± 0) 3 (± 0.05) 





 Discussion  
Through extensive testing utilising 3 different inhibitors of ferroptosis it can be determined 
conclusively that neither of the novel metal-phen compounds nor free 1,10-Phen itself can 
interact with the ferroptotic cell death pathway. The data described is somewhat surprising 
as copper and iron share some mechanistic similarities, as both can undergo Fenton like 
chemistry capable of producing the hydroxyl radical to induce lipid peroxidation. However 
upon further investigation, it has been reported that copper, while mimicking iron in Fenton 
like chemistry, does not appear to sensitise cells to ferroptosis which have been further 
sensitised with Erastin, a ferroptosis inducer (Dixon et al., 2012). This disparity has since 
been attributed to the regulated nature of ferroptotic cell death and the role of iron-dependent 
LOX enzymes (Shintoku et al., 2017).  
 
The high reactivity and non-specific nature of hydroxyl radicals (copper or iron produced) 
do not fit within the confines of a highly regulated process such as ferroptosis, and as such 
the high levels of oxidative stress are not thought to be a driving factor of the process. 
Coinciding with this Percival et al., 1992 demonstrated that 5- LOX is sensitive to inhibition 
by low micromolar levels of H2O2 and appears to undergo irreversible inhibition by even 
lower levels of Cu2+. This likely supports previous observations that compound dissociation 
may be occurring, as seen when the LDH cytotoxicity assay is employed (Chapter 2 pages 
77-78). It is thought instead that the iron-dependence of LOX enzymes inducing lipid 
peroxidation is the predominant factor (Yang and Stockwell, 2016). 
 
It is interesting to note however that FeCl2, an assumed positive inducer of ferroptosis (data 
not shown), demonstrated a significant drop in viability in response to ferrostatic 
compounds, as opposed to FeCl2 on its own, displaying no effect on cell viability. While no 
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change in effect could be explained in a similar fashion to CMPD 74 i.e. a reliance on LOX 
enzymes rather than ROS produced by redox metals themselves, drastically increasing the 
cytotoxic effect of an otherwise non-toxic compound is completely unprecedented.   
 
This however may be explained by the nature of both Ferrostatin and Liproxstatin-1. Zilka 
et al., (2017) have described both inhibitors as radical-trapping antioxidants (RTAs), 
preventing the propagation of lipid peroxidation. This phenomenon only occurred when both 
inhibitors were added together as a pre-treatment before the addition of FeCl2, and so it may 
be the case that the combination of both RTAs at higher concentrations is causing them to 
adopt a pro-oxidant role as opposed to antioxidant one. 
 
This process has been seen with other antioxidant molecules e.g. ascorbic acid when used at 
high concentrations (Chen et al., 2008). Indeed, studies from later chapters have shown 
ascorbic acid to be essential for the chemical nuclease capabilities of all compounds under 
investigation, when used at high enough concentrations. Experiments conducted in this lab 
attempting to utilise ascorbic acid as an antioxidant to protect cells from metal-phen 
compounds were unsuccessful as even concentrations in the low micromolar range were 
enough to kill all test cells before ROS-inducing agents were added.  
 
CMPD 73 and free 1,10-Phen equally do not interact with the ferroptotic pathway similar to 
CMPD 74. However, they did appear to undergo a similar enhancing effect as FeCl2 control 
at higher concentrations, particularly CMPD 73 at 50 and 500 µM. This again may be due 
to high concentrations of antioxidant molecules switching to pro-oxidant roles. While 
intriguing, this phenomenon of pro-oxidant reversal is beyond the scope of this investigation 
and is therefore deemed to be an artefactual event. 
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Analysis of both lipid peroxide inhibition (Trolox) and RBC integrity assays demonstrated 
that none of the compounds operated through lipid peroxide generation, and that plasma 
membrane autolysis/haemolysis is not a direct mechanism of action for the compounds. This 
supports previous observations from Chapter 2 that necrotic mechanisms of action are likely 
not present. However, this result indicates that both metal-phen and free 1,10-Phen operate 
through alternate mechanisms targeting intracellular organelles as opposed to nonspecific 
necrotic autolysis of the cell membrane.   
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6. Investigating the Chemical nuclease potential of 1,10-
Phen and novel metal phen compounds. 
 Introduction 
Oxidative cellular processes are important for multiple nucleic acid pathways, such as 
synthesis, repair, regulation of transcription factors and epigenetic control of gene expression 
(Luo et al., 2010). As abundant molecules within the cell, nucleic acids are also targets for 
oxidative attack by ROS and lead to the formation of many different mutagenic products. 
 
Despite many cancers arising due to DNA damage and formation of mutagenic products, 
induction of DNA damage has been the target of a variety of chemotherapeutics to date 
(Povirk, 2012; Jekimovs et al., 2014). A list of DNA damaging chemotherapeutics, the DNA 
damage they induce, and the cancers they treat can be seen in Table 6.1. 
 
Table 6.1- DNA damaging chemotherapy drugs and their corresponding types of DNA damage and 
cancers they treat.  (Adapted from Woods & Turchi, 2013). (NSCL Non-Small Cell Lung Cancer, 
SCLC Small Cell Lung Cancer). 
Chemotherapy Agent Type of Damage Cancers treated 
Cisplatin Intra and inter strand Crosslinks 
SSB 
DSB 
Testicular, NSCL, Mesothelioma 
Carboplatin Ovarian, Lung 
Oxaliplatin Colon 










 Oxidative Processes in nucleotide synthesis 
Several enzymes involved in nucleotide synthesis depend on redox catalytic strategies to 
carry out their biochemical function. Ribonucleotide reductase (RNR) catalyses the de novo 
synthesis of deoxyribonucleotides (dNTPs) from ribonucleotides, which are required for 
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DNA synthesis. RNR is thus an essential enzyme conserved across all forms of life (Chen et 
al., 2019). RNR employs redox chemistry to reduce the C2′-OH bond of ribonucleotides, 
forming dNTPs (Torrents, 2014). Zn2+ and Mn2+ dependent-deoxyribozymes such as 
10MD9, 10MD1, 10MD14, and 10MD5 (Chandra, Sachdeva and Silverman, 2009), 
responsible for hydrolytic cleavage of the DNA sugar phosphate backbone during replication 
and repair processes in vitro, also make use of redox dependent reactions (Fekry and Gates, 
2009). DNA primase,  required for the synthesis of the RNA primer used at the replication 
of DNA daughter strand during DNA synthesis, operates via iron-dependent cluster co-
factors to catalyse redox control over binding of the DNA template and synthesise the RNA 
primer, allowing DNA replication to take place (O’Brien et al., 2018).  
 
 Oxidative Processes in the Response to DNA damage 
The DNA damage response (DDR) pathway acts to detect and repair DNA from the constant 
barrage it faces in response to both endogenous sources of ROS (metabolic) and exogenous 
sources of ROS (UV radiation, xenobiotics) (Ciccia and Elledge, 2010). Several of the DDR 
pathways are redox active themselves, for example the base excision repair (BER) enzyme 
apurinic/apyrimidinic endonuclease 1 (APE1). APE1 is involved in both BER and redox 
regulation of transcription factors responsible for the expression of DDR genes, such as AP-
1, NF-B, CREB and p53 (Luo et al., 2010). An overview of these DDR pathways, the 
damage they repair, and their mechanism of repair can be seen in Table 6.2. 
 
DNA is subject to epigenetic modification via methylation of cytosine bases by DNA methyl 
transferases forming 5-methylcytosine (5-mC) which blocks the access of transcriptional 
machinery and is a repressive marker of transcription (Breiling and Lyko, 2015). Cytosine 
demethylation is catalysed by the iron (II) dependent ten-eleven translocation (TET) family 
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of dioxygenase enzymes (Zheng, Fu and He, 2014). TET enzymes convert 5-mC to 5-
carboxycytosine (5-caC) via multiple oxidation steps and cytosine intermediates (for greater 
mechanistic details see Scourzic, Mouly and Bernard (2015). 5-caC is ultimately recognised 
by the BER system, reforming un-methylated cytosine (Kohli and Zhang, 2013). 
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Excision of damaged base adducts 
by NER enzymes 
New bases added by DNA 
polymerase 







Single strand scission of incorrect 
base 
Polymerisation new bases and 
ligation 








Removal of damaged base by 
DNA glycosylases 
Abasic site repaired by 
polymerase 






Removal of single stranded tails at 
break by endonuclease 
Broken ends of DNA strand 
ligated by DNA Ligase 








Singe-stranded DNA generated at 
site of break 
Neighbouring complementary 
strand used as template for broken 
strands 
Regeneration of original strand  
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 Oxidative processes in DNA damage 
While controlled redox reactions play a critical role in nucleic acid homeostasis, pathological 
oxidation of nucleic acids (NA) can dramatically alter their structure and function. Oxidation 
of NA can promote mutagenic alterations to the genetic code and disrupt transcriptional and 
translational machinery by targeting RNA (Collins, 2009). As a result, oxidative damage of 
NA by ROS or RNS is considered to be central to various significant pathologies (e.g. cancer, 
Alzheimer’s and Parkinson’s disease (Gonzalez-Hunt, Wadhwa and Sanders, 2018)). 
However, not all species of ROS or RNS are capable of inducing significant damage to NA 
(ibid). Rather, they serve as intermediates leading to the generation of potent reactive species, 
such as free radicals including the hydroxyl (OH•) and peroxynitrite (ONOO-) radicals 
(discussed in Chapter 1 section 1.2.5-1.2.10). The OH• radical in particular is implicated in all 
known mechanisms of NA damage, as its oxidative potential is so high that it can react with 
both nucleotides and sugar phosphate backbone (Cadet et al., 2012). 
 
Multiple forms of DNA damage may occur including damage to the sugar phosphate backbone, 
nucleotide base oxidation and the formation of inter-strand cross links with the opposing DNA 
strand, and covalent crosslinking with associated histone proteins (Chatterjee and Walker, 
2017). Each form of insult employs a specific mechanism to cause damage to DNA in response 
to different oxidants, resulting in mutagenic alterations or induction of regulated forms of cell 
death, such as apoptosis.  
 
 Attack on sugar phosphate backbone  
The sugar moiety of the phosphodiester backbone of DNA is subject to oxidation by strong 
oxidising molecules, primarily the OH• or hydroxyl-like radical produced by peroxynitrite. For 
example, iron has been seen to increase DNA damage and induce the DNA damage response 
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in endothelial cells, with damage attributed to production of OH• or hydroxyl-like radicals 
(Mollet et al., 2016). The sugar moiety of DNA is considered to be highly stable against 
hydrolysis under most physiological conditions, with an estimated half-life of 30 million years 
(Gates, 2009). However, OH• radicals can react with the sugar moiety of DNA at near diffusion 
rates (1010 M–1 s–1) (Kalyanaraman, 2013). Hydrogen abstraction from each sugar carbon 
results in the formation of five carbon-centred radicals which in turn undergo further complex 
oxidation reactions, leading to the loss of the phosphate group and complete hydrolysis of the 
sugar moiety. It is generally accepted that hydrogen abstraction at C3 and C5 is responsible for 
heterolytic cleavage and strand scission (reviewed Dizdaroglu & Jaruga, 2012). This will result 
in the formation of DNA strand breaks, abasic sites and consequently the release of unaltered 
DNA bases (Evans, Dizdaroglu, & Cooke, 2004). The specific carbon targeted by the OH• for 
H abstraction is dictated by its steric accessibility, with steric accessibility following the trend 
of H5′ > H4′ ≫ H3′  H2′  H1′ (Balasubramanian, Pogozelski and Tullius, 1998).  
 
Single stranded (SSB) and double strand breaks (DSB) are the most serious forms of DNA 
damage (Zhdanov, 2016). While strand breaks do occur naturally as a consequence of 
topoisomerase activity, this occurs under tightly controlled conditions and such breaks are 
immediately repaired by the topoisomerases themselves (reviewed Povirk, 2012). Generation 
of SSB or DSB can result in serious consequences for the cell, primarily various 
rearrangements in the genome, deletions, and chromosomal translocations, fusions or breaks 
(Chakarov, Petkova, Russev, & Zhelev, 2014). When they occur at low frequency both SSB 
and DSB can be repaired by DDR enzymes, such as NER and BER for SSB (Abbotts and 
Wilson, 2017) and HR on NHEJ for DSB (Gursoy-Yuzugullu, House and Price, 2016). 
However, when breaks occur at a very high frequency, they can be difficult to repair, in 
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particular DSB. The inability to repair all of the strand breaks may result in the initiation of 
apoptotic signalling to remove the damaged cell (Mondal et al., 2018). 
 
 
 Mechanisms of DNA Nucleotide oxidation 
Oxidation of nucleotides can result in many different modifications and is dependent on the 
nucleotide base in which is targeted. This can happen at specific carbon or nitrogen sites within 
the base, resulting in either base modification or hydrolysis of the nucleotide/deoxyribose bond 
(Sachdeva et al., 2014). The most characterised mechanistic examples are found the formation 
of abasic sites, deamination and methylation of cytosine, and the oxidation of guanine. These 
are discussed in detail below.  
 
 Formation of abasic sites 
Oxidation of DNA bases can take the form of abasic sites, sites void of a nucleotide base but 
with an intact sugar phosphate backbone (Gates, 2009). The glycosidic bond between the 
nucleotide base and sugar phosphate backbone is more susceptible to hydrolytic cleavage and 
represent a weak point in the nucleic acid structure (ibid). The formation of abasic sites occurs 
as part of DNA repair mechanisms, where BER DNA glycosylases remove oxidised, damaged 
or mismatched nucleotides which are quickly replaced with the correct base (Krokan and 
Bjoras, 2013). Apurinic sites are one hundred times more likely to occur than apyrimidinic 
sites, as they are more susceptible to nucleophilic substitution and hydrolysis (reviewed 
Greenberg, 2014). While the sugar phosphate backbone remains intact following the formation 
of abasic sites, these sites are extremely reactive and sensitive as they are highly electrophilic 
and chemically unstable to further oxidation (e.g. by OH•) resulting in the formation of a SSB 
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(Sczepanski et al., 2010). Abasic sites also block the normal processes of transcription and 
synthesis (Greenberg, 2014). 
 
 Deamination 
Oxidation reactions centred on cytosine or 5-mC can result in the hydrolytic deamination (loss 
of amino group) and the formation of uracil or thymine, respectively (Yonekura et al., 2009). 
Deamination may cause transition mutations, as DNA polymerase may base pair a 
corresponding adenine over a guanine during DNA replication, causing a C→T transition 
(Giglia-Mari, Zotter and Vermeulen, 2011). While targeted deamination plays significant roles 
in fostering immunologic processes such as antibody maturation, uncontrolled transitions 
following oxidative deamination can be deleterious (Nabel, Manning and Kohli, 2012). Such 
transitions are the most common forms of mutations seen in cancer and deamination is the most 
common accumulated mutational signature in cancer after aging (Greenman et al., 2007; Alsøe 
et al., 2017). The mispairing of G:U cause G:C to A:T transition mutations which if not repaired 
are pro-mutagenic. The presence of uracil over thymine is also a major source of endogenous 
abasic site formation through BER, further increasing damage susceptibility and mutagenic 
potential (Yonekura et al., 2009). 
 
As 5-mC is a regulatory epigenetic mark involved in gene silencing oxidative deamination has 
been implicated as a primary source of epigenetic-based alterations which disrupt normal 
regulation of the genome and therefore promote oncogenesis (Lewandowska and Bartoszek, 
2011). Furthermore as 5-mC is deaminated into thymine it is generally not recognized as a 
DNA lesion and is therefore harder for repair enzymes to detect increasing its mutagenicity 
(Nabel, Manning and Kohli, 2012). 
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 Oxidation of nucleotide bases 
Guanine is the nucleotide with the highest oxidation potential and so is the primary nucleotide 
targeted by most forms of ROS (OH•, ONOO-, 1O2) (Niles, Wishnok and Tannenbaum, 2006; 
Agnez-Lima et al., 2012; Hirakawa, 2018). The two main products of guanine oxidation in 
DNA are 8-hydroxydeoxyguanosine (8-oxodG) and 2,6-diamino-4-hydroxy-5-formamido-
pyrimidine (FapyG) (Sova et al., 2010). 8-oxodG is the most common form of DNA lesion 
resulting from oxidation by ROS and can be formed through the initial addition of OH• to C8, 
generating 8-hydroxy-7,8-dihydroguan-8-yl radicals (Dizdaroglu and Jaruga, 2012; Xu et al., 
2019). In addition, 8-oxodG can base pair with adenine as well as cytosine causing transversion 
mutations of A:T to C:C or G:C to T:A (Kino et al., 2017). Unlike larger DNA lesions, 8-
oxodG nucleotides can be incorporated into the nascent DNA strand by DNA polymerase 
without significantly affecting DNA synthesis or transcription, further compromising the 
newly synthesised daughter strand with a mismatch mutation of G to T and C to A substitutions 
(Ishii et al., 2018). 8-oxodG is used as a biomarker for oxidative stress and DNA damage 
(Malayappan et al., 2007; Ock et al., 2012). 
 
FapyG is formed from the ring opening of 7-hydro-8-oxyguanine and, in similarity to 8-oxodG 
lesions, can also initiate mutations such as G to T conversions (Jena and Mishra, 2013). Unlike 
8-oxodG however, FapyG does block DNA synthesis and transcriptional machinery and is 
therefore considered to be cytotoxic (Jena, 2012). Somewhat paradoxically, however, it is 
generally observed that -oxodG rather than FapyG is more likely to initiate mutagenic driven 
oncogenesis. This is because cytotoxic damage such as FapyG will be lost upon cell death, 
whereas 8-oxodG can continue after incorporation into daughter strands following DNA 
synthesis (Gates, 2009; Cadet and Wagner, 2013). RNS such as peroxynitrite may also lead to 
the formation of 8-nitroguanine (8-NO2G) which has been reported to be highly cytotoxic. 
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Moreover it can result in the formation of G to A mutations or the generation of apurinic sites 
(for further details on 8-NO2G see Niles, Wishnok, & Tannenbaum, 2006).  
 
Although adenine can also undergo oxidation it possesses lower oxidation potential than the 
other nucleotide bases and is not as readily oxidised (Dizdaroglu and Jaruga, 2012). Oxidation 
of adenine leads to the formation of 8-oxo-7, 8-dihydroadenine (8-oxodA) and 4,6-diamino-5-
formamidopyrimidine (Fapy-Ade), analogous to the guanine counterpart. Both 8-oxodA and 
Fapy-Ade have been shown to form tandem lesions and abasic sites (Cadet et al., 2012). 
However, the low oxidative potential of adenine generally results in the transfer of radical 
species to neighbouring guanine bases, formation of clustered guanine lesions and the 
formation of guanine radical cations (Cadet and Wagner, 2013). 
 
Finally, the oxidation of thymine can result in the production of thymine adducts with 
neighbouring bases, initiation of strand breaks by hydrogen abstraction by thymine radical 
intermediates or oxidation of thymines own methyl group forming the 5-(uracilyl) methyl 
radical (Robert and Wagner, 2019). This in turn can react with methyl groups on neighbouring 
cytosines forming intra- or inter-strand crosslinks. 
 
 Intra- and Inter Strand DNA crosslinks 
Generation of DNA lesions can result in the formation of intra or inter-strand crosslinks, either 
between adjacent or complementary DNA strands or covalent binding with amino acid residues 
in associated histone, transcriptional, or DNA related proteins (Huang and Li, 2013). However, 
any protein in proximity with DNA has the potential to become cross-linked (Stingele, Bellelli 
and Boulton, 2017). Cross-linked DNA adducts are highly detrimental to cell viability as they 
are generally large and bulky in nature and will sterically hinder interaction of DNA with other 
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protein factors. This serves to stall normal chromatin-based processes involving DNA such as 
transcription, DNA unwinding and synthesis (Shoulkamy et al., 2012). Many examples of 
DNA lesions susceptible to intra- and inter-strand crosslinks involve guanine. This is generally 
a result of either tandem lesions involving adjacent 8-oxodG at sites of multiple damage or 
between guanine and uracil produced by the deamination of cytosine (Jena, 2012). Other forms 
of crosslinks can arise from linking between oxidised purine bases, abasic sites, and between a 
nucleotide base and the sugar phosphate backbone, due to hydrogen extraction from ROS, such 
as OH• (Huang and Li, 2013).  
 
Similar to intra- and inter-strand DNA crosslinks, DNA-Protein crosslinks occur in response 
to various oxidising agents or UV radiation. The mechanism involves the addition of a DNA 
base radical to an aromatic amino acid of a nascent or nearby protein, or the addition of DNA 
base radical with an amino acid radical. Examples include thymine-tyrosine crosslink caused 
by exposure to formaldehyde, metal ions, H2O2, and carcinogenic compounds (Altman et al., 
1995; Evans, Dizdaroglu and Cooke, 2004), and crosslinking between 8-oxodG and lysine 
residues within the N-terminal tails of associated histone octamers (Johansen et al., 2005). 
 
The formation of DNA adducts and crosslinks has been a mechanism for chemotherapy 
directed cytotoxicity for many decades. Cisplatin, along with its carboplatin and oxaliplatin 
analogues induce the formation of DNA adducts and protein crosslinks with histones as one of 
its many mechanisms of action (Florea and Büsselberg, 2011). Indeed many other mainstream 
chemotherapy drugs such as the topoisomerase inhibitors doxorubicin and camptothecin, act 
via promoting covalent linkage between DNA topoisomerases and DNA (Stingele, Bellelli and 
Boulton, 2017).  
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 RNA oxidation: 
The oxidation of RNA and its effects within the cell has received relatively little attention 
compared DNA oxidation. However the role of RNA oxidation in the process of aging and 
neurodegenerative diseases has recently begun to demonstrate its significance as a chronic 
pathological process (Calabretta, Küpfer and Leumann, 2015). In diseases such as Alzheimer’s 
disease, atherosclerosis and even cancer, RNA oxidation has been identified as a likely early 
event in disease progression, rather than as an indication of cellular decay (Küpfer and 
Leumann, 2014). Like DNA, the oxidation of RNA can result in scission of the sugar phosphate 
backbone causing strand breaks, modification of nucleobases or the formation of abasic sites, 
resulting in deleterious effects regarding transcription or translation (Li et al., 2014).  
 
However, RNA is far more vulnerable to oxidative damage than its DNA counterpart. As RNA 
is single stranded in structure, it is devoid of protective hydrogen bonding seen in double 
stranded DNA, potentially allowing greater access of oxidant species to alter nucleotide bases 
or cause strand scission (Kong et al., 2008). RNA is further devoid of yet another layer of 
protection as a result of its lower association with cellular proteins, a protection offered to DNA 
by its tight association with, and protection by, highly condensed histone proteins. RNA is also 
four times more abundant by weight than DNA and is generally concentrated in the cytosol of 
the cell nearer to the mitochondria, where it may be more exposed to oxidant species, such as 
mitochondrial generated ROS (Fimognari, 2015). DNA being harboured in the nucleus, is 
offered yet another layer of protection from cellular oxidants  (reviewed Yan & Zaher, 2019).  
 
As noted above, DNA possesses multiple complex mechanisms dedicated to its repair which 
can remove oxidised nucleobases or repair SSB or DSB. As of yet no such mechanisms of 
RNA repair have been identified and much of the oxidised RNA is removed from the functional 
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RNA pool via degradation (Sugiyama et al., 2019). It is thought that depletion of the functional 
RNA pool is a causative factor of cellular injury or death in response to RNA oxidation (Ishii 
et al., 2018). It has been demonstrated by several studies that RNA can experience up 10-20 
times more oxidative damage than DNA, and that treatments with oxidant generating drugs 
such as doxorubicin or H2O2 significantly damage RNA more than DNA (Hofer et al., 2006). 
Certain classes of RNA have also displayed iron binding properties, with Ribosomal RNA 
(rRNA) having a higher affinity to iron over both transfer-RNA (tRNA) and messenger RNA 
(mRNA) (Fimognari, 2015). Iron Response Elements (IREs) within mRNA transcripts specific 
to iron regulatory genes have also been identified. In response to iron starvation, iron regulatory 
proteins bind IREs and post transcriptionally regulate mRNA expression either negatively 
through translational repression or positively through mRNA stabilisation (Campillos et al., 
2010). This affinity towards iron may increase the susceptibility of certain transcripts to 
oxidative damage through iron-catalysed OH• production via Fenton and Haber Weiβ reactions 
(Poulsen et al., 2012). 
 
Similar to DNA, a significant biomarker of RNA oxidation is the oxidised form of guanine, 
known as 8-oxo-7, 8-dihydro-2’-deoxyguanosine (8-ox-dG) in DNA and 8-oxo-7,8-
dihydroguanosine (8-oxo-rG) in RNA (Shan, Tashiro and Lin, 2003). As a result of RNAs 
abundance compared to DNA, 8-oxo-G is detected almost 20-fold more than 8-oxo-dG in DNA 
under normalised conditions (Fimognari, 2015). 8-oxo-G levels increase by 5-fold compared 
to base levels when mammalian cells are exposed to oxidative stress and are 10-25 times higher 
than 8-oxo-dG, implying that 8-oxo-G is a reliable biomarker of RNA oxidation (Calabretta, 
Küpfer and Leumann, 2015). However, while 8-ox-dG is considered to be highly mutagenic 8-
oxo-rG can stall translation resulting in little to no protein miscoding (reviewed Yan and Zaher, 
2019). Thus 8-oxo-rG is not seen to be as mutagenic as its deoxyribose counterpart (Simms et 
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al., 2014). Other oxidised RNA bases include 8-oxo-7,8-dihydroadenosine (8-oxo-rA), 5-
hydroxyuridine (hm5U) and 5-hydroxycytidine (hm5C), all with much the same function to stall 
translation and cause RNA degradation (Küpfer and Leumann, 2014). 
 
Overall, the main consequences of RNA oxidation appear to be i) ribosome dysfunction 
resulting in stalled translational machinery and when damage is sufficiently high, ER stress, ii) 
protein miscoding altering function and cell homeostasis, and iii) the alteration of the many 
regulatory signalling pathways of micro RNA further altering protein synthesis (Joazeiro, 
2017; Nunomura et al., 2017). The latter could cause the accumulation of inactive or unstable 
proteins, which could either prove fatal to the cell, or it could potentially allow an altered 
protein to continue and have detrimental effects on the functionality of long-living cells, such 
as neurons, potentially contributing to neurodegenerative diseases such as Alzheimer’s or 
Parkinson’s disease (Shan and Lin, 2006).  
 
 Investigation of nuclease mimetics 
Compounds containing 1,10-Phen, or its derivatives, are well known to display nuclease 
mimetic activity (Butler et al., 1969; Sigman et al., 1979; Burkitt et al., 1996). Chemical 
nuclease activity may be readily observed with standard agarose gel electrophoresis using 
appropriate substrates - purified plasmid DNA for the DNAse activity and total RNA for 
RNAse activity.  Nuclease activity is revealed by characteristic changes in the pattern of bands 
as outlined below. 
 
 Agarose gel evaluation of nuclease activity ex cellulo 
Purified plasmid DNA is generally found as a mixture of supercoiled and open circular forms. 
These structures may be observed as distinctive bands after separation by electrophoresis. 
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Cleavage of the DNA leads to the generation of nicks and/or cuts in the DNA, causing de-
compaction of the supercoiled plasmid into a variety of potential forms including nicked/open 
circular plasmid, linear, or single stranded circular configurations (see Figure 6.1), each evident 
as a characteristic band on the DNA gel. Further DNA degradation is demonstrated by the 
formation of multiple bands with full degradation indicated by the presence of a smear of low 




Figure 6.1-Various structural forms of plasmid DNA as they appear on an agarose gel  (excluding low 
Mw smear) (Tirabassi, 2014). 
 
Purified total RNA will appear as three distinct bands, denoted 28S, 18S and 5S RNA which 
represent ribosomal RNA (Figure 6.2). Breakdown of ribosomal RNA leads to the formation 




Figure 6.2-2% Agarose gel electrophoresis of total cellular RNA. The distinctive ribosomal 28S, 18S 
and 5S bands are indicated by arrows. 
 
  qPCR-based evaluation of nuclease activity in cellulo 
To determine if RNAse mimetic activity could affect intracellular RNA, quantitative PCR 
based mRNA integrity assays may be used. The 3’:5’ assay is one such assay which has been 
added to the Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments (MIQE) guidelines, as a form of method validation (Huggett et al., 2013). This 
assay relies on the greater susceptibility of the 5’ end of mRNA towards degradation than that 
of the 3’ end with its poly adenylated tail (Swift, Peyton and MacDonald, 2000). This will 
result in a higher yield of 3’ products over 5’ products when amplified, with resulting in a 3’:5’ 









Figure 6.3-Principle of the 3’:5’ assay.  A) Undamaged and intact mRNA template is reverse 
transcribed from the 3’ end by Reverse Transcriptase (RT) generating a double stranded cDNA 
product of high integrity. A primer pair anchored towards the 5’ end (green) and the 3’ end (red) are 
employed to generate equal amounts of amplicon product following qPCR. B) A damaged mRNA 
strand is reverse transcribed by RT. However the more sensitive 5’ end of the template is inefficiently 
transcribed and retains sites of damage. As such amplification during qPCR will favour the more 
integral 3’ end generating a higher ratio of amplicon products. This figure was self-generated using 
Microsoft PowerPoint based on the current understanding of knowledge from a multitude of sources. 
 
An alternative qPCR-based assay relies on the use of multiple primer pairs, each sharing a 
common 3’ primer with the other primers designed to give rise to amplicons of differing 
lengths. If transcript degradation has occurred, reverse transcription will be interrupted and the 
amplicons closer to the 5’ end will not be reverse transcribed efficiently, if at all. The result 
may be analysed in a similar manner to the 3’:5’ assay, where each amplicon is expressed 
relative to the smallest amplicon (Die et al., 2011). 
 
These PCR based assays have distinct advantages over other types of RNA integrity assays, 
such as the Agilent Bioanalyzer and qualitative agarose gel electrophoresis. Mainly, the 3’:5’ 
assay directly looks at the integrity of the mRNA template that is to be used during qPCR 
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experiments, whereas both the Agilent Bioanalyzer and qualitative electrophoresis detect the 
more abundant ribosomal RNA within an isolated sample. Measuring the integrity of ribosomal 
RNA will likely not reflect the integrity of mRNA. Multiple RNA targets can be probed in 
parallel, reducing the likelihood of false positive results. Finally, these assays can be much 
more cost effective than capillary electrophoretic assays and is available for high throughput 
screening (Die et al., 2011).  
 
 Aims 
It has been reported previously that analogous compounds lacking the ethereal oxygens (i.e. 
CMPD19 and CMPD22) possess the ability to cleave plasmid DNA (Kellett et al., 2011). The 
primary aim of this Chapter is to define the capacity of CMPD73 and 74 to cleave nucleic acids 
under various in vitro conditions (ex cellulo and in cellulo). An additional aim is to investigate 
if any observed activity is dependent on the generation of ROS and, using a similar approach 




 Agarose gel evaluation of nuclease activity ex cellulo 
Plasmid degradation: 
A 5.74 Kbp plasmid (pGlo) was used as the model for DNAse activity, as the exact nature of 
the DNA sequence was not considered critical for the activity. Plasmids were isolated from 
competent BL-21 bacterial cell colonies grown on L.B. agar (Cruinn) using a plasmid 
preparation kit (Sigma). The cleavage assay protocol used was adapted from Molphy et al., 
(2015). 400ng of intact plasmid was incubated (in the dark at 37°C) in cleavage buffer (80 mM 
HEPES, 25 mM NaCl, pH 7.2) and with varying concentrations of novel metal-phen 
compounds for different time periods. Sodium-ascorbate was added to some incubations (final 
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concentration 1mM) to determine if compounds possessed self-cleaving capabilities or if an 
additional reductant was required to facilitate cleavage. Reactions were terminated by addition 
of 60mM EDTA. Samples were run on a 1.2% agarose gel containing ethidium bromide and 
DNA fluorescence was observed using standard image capture protocols. 
 
RNA degradation: 
RNA was isolated from A2780 ovarian cancer cells using Trizol reagent (Invitrogen) and the 
standard protocols. RNA cleavage was tested in the same manner as plasmid cleavage assays 
stated above but using 1µg of total RNA instead of 400ng plasmid DNA. Cleavage products 
were resolved using a 2% agarose gel, all in the presence of ascorbate. Isolated RNA was tested 
against both CMPD 73 and its constituent components, CMPD 74 and its constituent 
components and 1,10-Phen. Reactions were terminated by addition of 60mM EDTA Each 
assay was conducted in triplicate. 
  
Inhibiting Ribonuclease activity using ROS/RNS specific scavengers: 
Isolated RNA (1µg) was treated with both 1,10-Phen and novel copper (CMPD 74) and 
manganese (CMPD 73) compounds in the presence of scavengers for specific ROS and RNS 
in order to determine which reactive species were responsible for ribonuclease activity of test 
compounds. These assays were conducted in identical conditions as in similar RNA 
degradation reactions, with the addition of ROS/RNS scavengers. The names of the scavengers 
used, their ROS/RNS specific targets, and the working concentrations that were used can be 
seen in Table 6.3 (adapted from ThermoFisher Scientific, 2010). This method is a variation of 
similar methods used by Molphy et al., (2015). The results presented are representative data of 
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  RT-qPCR evaluation of nuclease activity in cellulo 
A2780 cells were plated in duplicate wells of a 6 well plate and treated with IC10 and IC25 
concentrations of CMPD 73, 74 or 1,10-Phen for 24hrs. Following exposure to the different 
agents, total RNA was extracted using Trizol reagent, as per the manufacturer's guidelines. 1µg 
of total RNA was reverse transcribed using the Takyon Reverse Transcriptase Core Kit (RT-
RTCK-03, EuroGentec) as per the supplied protocol. For isolated RNA which was to be used 
to standard qPCR gene expression analysis random nonamer primers were used during the RT 
reaction. qPCR reactions were carried out using the Takyon SYBER 2X Master Mix (UF-
LSMT-B0701, EuroGentec), using 100nM cDNA and primer concentrations, as per protocol 
using an Applied Biosystems 7500 Fast Thermocycler set to fast cycling. Cycling conditions 
are seen in Table 6.4. Significance testing for global transcriptional effects was conducted on 
raw Ct values using the Students T-Test.  
 
Table 6.4-Cycling conditions for qPCR assays 
Stage Temperature (°C)  Time (seconds)  
Holding 95 180 
Cycling (x40) 
Denaturing  95 3 
Annealing 60 30 
Melt Curve (x2) 
Denaturing  95 15 
Annealing 60 60 
 
Reference Gene Stability: 
To evaluate metal-phen nuclease activity in cellulo GAPDH, PPIA, 18S, and PGK1 reference 
genes were used to investigate whether stable expression patterns were held in response to 
treatment with metal-phen compounds. RNA was isolated and assayed as per protocol above 
using random nonamer primers for RT. The qPCR primer sets were generated using Primer3 
and can be seen in Table 6.5. Preliminary data using the 18S gene to investigate the effects of 
CMPD 74 on gene expression levels presented with low Ct values of 12-13 indicating a high 
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abundance of 18S expression within the A2780 cell lines. The high abundance of 18S 
expression could potentially mask any effects that the comparatively less potent CMPD 73 and 
1,10-Phen would have on target gene expression. As such for experiments using both CMPD 
73 and 1,10-Phen, dilutions of cDNA samples isolated from A2780 cells exposed to both 
compounds were made using RNase-free water into separate PCR tubes to give higher Ct 
values of  ≈ 30 in attempt to make any effects on gene expression more apparent.  
  
Experiments using 1,10-Phen as the compound of interest had a methanol (MeOH) vehicle 
control equivalent to the IC10 concentration of 1,10-Phen used in order to account for changes 
in gene expression resulting from the solvent used to dissolve 1,10-Phen. As such Ct values for 
gene expression in cells treated with 1,10-Phen were further normalised to MeOH vehicle 
control conditions following initial normalisation to non-treated control conditions. 
 
Table 6.5-Forward and Reverse primers for HKGs 

















3’:5’ RT-qPCR Assay: 
The 3’:5’ assay was adapted to human genes based on a report by Padhi et al (2018), which 
utilised the ubiquitously expressed phosphoglycerate kinase 1 (Pgk1, NM_000291.4) HKG in 
rat samples. Following treatment of cells as noted in section 6.1.4 above, cDNA was 
synthesised using oligo dT primers. Primers against the human PGK1 gene (NM_000291.4) 
were designed using Primer3 and in accordance with the design principles for 3’:5’ assay 
primers, i.e. with approximately 1Kb between the 3’ and 5’ primer sites. The locations of the 
primers are shown in Figure 6.4 and the primer sequences are in Table 6.6. 
 
 
Figure 6.4-Location of primers for the 3’:5’ assay from Primer 3. 
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Table 6.6-Primer sequences used for the 3’:5’ assay 
Primer 
set 
Forward primer Reverse primer Amplicon 
size (bp) 
5’ TGAGAGTCGACTTCAATGT CCATTGTCCAAGCAGAATT 109 
3’ ACTTCTAGGGGCTGCATCAC GTGCTCACATGGCTGACTTT 95 
 
Following qPCR, raw data was normalised to the negative control as follows: 
∆𝐶𝑡 =  𝐶𝑡(𝑇𝑒𝑠𝑡) −  𝐶𝑡(𝐶𝑜𝑛𝑡𝑟𝑜𝑙). 
Each Ct was converted to relative cycles of difference using the following expression 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑐𝑦𝑐𝑙𝑒𝑠 𝑜𝑓 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =  2−∆𝐶𝑡 
The 3’:5’ ratio was then computed using these values and compared to a baseline ratio of 1, 
indicating no damage. 
  
Differential amplicon size assay: 
A differential amplicon assay was designed using the human PGK1 sequence, to provide 
comparability with the 3’:5’ assay described above and was carried out on cDNA samples 
prepared as described above. A series of primers, each sharing a common reverse primer 
anchored at the 3’ end of the gene, were designed to generate amplicons of 115, 292, 497 and 




Figure 6.5- Primer locations for differential amplicon assay form Primer 3. 
 
Table 6.7-Primer sets for differential amplicon assay 
Primer  Sequence Amplicon Size (bp) 
Common 3’ Reverse GTGCTCACATGGCTGACTTT  
115bp Forward AAAGTCAGCCATGTGAGCAC 115 
292bp Forward ACTCGGGCTAAGCAGATTGT 292 
497bp Forward AGAGGGAGCCAAGATTGTC 497 
820bp Forward TCACTTTCCAAGCTAGGGGA 820 
 
Raw qPCR data was initially normalised to the negative control condition as follows: 
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∆𝐶𝑡 =  𝐶𝑡(𝑇𝑒𝑠𝑡) −  𝐶𝑡(𝐶𝑜𝑛𝑡𝑟𝑜𝑙). 
Each Ct was converted to relative cycles of difference using the following expression 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑐𝑦𝑐𝑙𝑒𝑠 𝑜𝑓 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =  2−∆𝐶𝑡 
Each value was then expressed relative to the value of the smallest amplicon, which was 
defined as the reference amplicon, to generate a crude transcript stability score. As above a 




 Nuclease mimetic activity of CMPD73 and CMPD74 
Initial nuclease activity was tested using both DNA and RNA as substrates.  As shown in Figure 
6.6, DNAse activity is observed for each compound tested. However, ascorbate is required for 
activity indicating that none of the compounds possessed self-cleavage activity and is 
demonstrated in Figure 6.7. A time-course revealed that CMPD74 appeared to be significantly 
more active than CMPD73 and can catalyse the almost complete breakdown of the plasmid 
DNA in 30 minutes (Figure 6.6, lane 3). In contrast a 24-hour incubation period with CMPD73 
is required to degrade the plasmid substrate to a similar extent (Figure 6.6, lane 8) with a time 






Figure 6.6- DNAse activity of CMPD73 and CMPD74 in the presence of added ascorbate as a 
reductant for 0.5, 4, and 24hrs at 100µM.  CMPD74 is observed to be highly active as a nuclease, 
leading to the almost complete disappearance of the plasmid DNA with 30 minutes. CMPD73 is less 
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active and took up to 24 hours for significant cleavage to occur. An elevation of open circular DNA is 
observed at 0.5 hrs, with a band in the expected range for single stranded DNA appearing at 4 hrs. 
 
 
Figure 6.7-DNAse activity of CMPD73 and CMPD74 in the absence of added ascorbate as a 
reductant for 24hrs at 100µM. No nuclease activity is observed. 
 
Analogous experiments using RNA as a substrate revealed that both CMPD73 and CMPD74 
possessed significant RNAse mimetic activity (Figure 6.8 and Figure 6.9). The relative 
effectiveness of the nuclease mimetic activity was similar with both DNA and RNA substrates. 
In similarity with the results for plasmid DNA above, incubation with CMPD73 or its 
precursors for 0.5 or 1hr did not lead to observable RNA cleavage at concentrations ranging 
from 10nM to 1M (data not shown). Following a 2hr incubation period cleavage reactions 
were observed at concentrations of 1M, with no significant enhancement of RNA cleavage at 
concentrations up to 100 M. There is no significant activity from any of the precursor 
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compounds tested (Figure 6.8, lanes 7-10). Hydrogen peroxide did not degrade RNA even at 
high concentrations of 100µM when used as a positive ROS control.  
 
 
Figure 6.8 RNAse activity of CMPD73 and its precursors.  Isolated RNA exposed to H2O2, CMPD 73, 
CMPD 69 precursor, and MnCl2 for 2hr in the presence of ascorbate. CMPD73 displayed significant 
capacity to degrade RNA at concentrations as low as 1M. 
 
RNAse mimetic activity of CMPD74 is readily observable at 0.5 hours, a time point at which 
there is no observable activity for the manganese-containing CMPD73. In similarity with 
CMPD73, the RNAse activity of the constituent parts of CMPD74 were investigated (i.e. 1,10-
Phen, the Cu-TDDA salt and CuCl2). Unexpectedly, at sufficiently high concentrations, each 
component part appeared to be capable of causing some RNA degradation (Figure 6.9 lanes 7, 
10 and 12 respectively). These data suggest that the RNAse activity of CMPD74 may be 





Figure 6.9 RNAse activity of CMPD74 and its precursors.  Isolated RNA exposed to CMPD 74, 1,10-
Phen, CuCl2 and CMPD 70 precursor for 0.5hr in the presence of ascorbate. CMPD74 displayed 
significant capacity to degrade RNA at concentrations as low as 1µM, while 10µM concentrations of 
1,10-Phen, CMPD70 or CuCl2 all resulted in RNA breakdown. 
 
The efficacy of CMPD74 and the finding that 1,10-phen also displayed RNAse activity 
prompted the investigation of the kinetics of RNA degradation in the presence of these 
compounds. CMPD74 (1M) and 1,10-phen (10M) were incubated with RNA for varying 
time intervals and breakdown products separated as above (Figure 6.10). Degradation of RNA 
by CMPD74 appeared to occurr very rapidly, with signs of degradation evident after only 15 
minutes and total degradation following 20 minutes (Figure 6.10 compare lanes 6, 8 and 10). 
Degradation also proceeded in the presence of 1,10-phen alone, albeit with less efficacy and at 
a slower rate (Figure 6.10 compare lanes 7, 9 and 11).  
 
The nuclease mimetic activity of 1,10-phen is generally attributed to its chelation of trace 
metals (e.g. iron, copper) in the reaction solution to form DNA/RNA degrading complexes. As 
such the addition of 1mM EDTA to the 1,10-phen reaction was conducted to confirm this 
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property of 1,10-Phen, which indeed resulted in a complete ablation of any RNA degradation 
activity (Figure 6.10, lane 12). This result supports the contention that 1,10-Phen is capable of 
indirect nuclease activity, due to the chelation of free catalytic ions. Direct ribonuclease activity 
would be expected to display degradation of RNA regardless of EDTA treatment. The addition 
of EDTA to reactions where CMPD 73 and 74 was also investigated giving identical results to 
1. 10-Phen, whereby RNA degradation was totally inhibited (data not shown). 
 
Figure 6.10 Kinetics of RNA degradation by 1M CMPD74 and 10M 1,10-Phen in the presence of 
ascorbate.   Lane 1: negative control, Lanes 2-11: time dependent degradation in the presence of 
CMPD74 and 1,10-Phen, Lane 12: 1,10-Phen in the presence of 1mM EDTA. 
 
 Ribonuclease activity in response to ROS and RNS specific scavengers  
It is generally accepted that the nuclease mimetic capabilities of metal-phen compounds likely 
depends on the generation of ROS by redox active copper and manganese (Kellett et al., 2011; 
Molphy et al., 2015). ROS specific scavengers may be used via an inhibitor profiling approach 
to identify the suspected ROS responsible for degradation of RNA. The principle is that if a 
specific ROS (e.g. OH•) is critical for RNA degradation then chemical blockage of that ROS 
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species will inhibit RNA breakdown and the distinctive RNA bands seen in Figure 6.2 would 
remain intact. 
 
Figure 6.11 displays the effects on isolated RNA in response to scavengers of various forms of 
catalytic ROS potentially produced by metal-phen and phen compounds. Following two-hour 
incubation with CMPD 73 (Figure 6.11 A), a notable inhibition of RNA degradation was 
observed following treatment with scavengers of H2O2 and O2•- (lanes 4 and 6 compared with 
non-treated control in lane 1). There is a modest inhibition of CMPD 73 activity by both DMSO 
(lane 3) and sodium azide (lane 5), indicating possible production of both the hydroxyl radical 
and singlet oxygen. There was no obvious effect of Trolox, CarboPTO and uric acid (lanes 7-
9) indicating that peroxyl radical, nitric oxide and peroxynitrite production are unlikely to be 
key mediators of the RNAse activity.  
  
In similarity, CMPD 74 RNAse activity also appears to rely on the production of both H2O2 
and O2
•- as seen by strong inhibition of degraded bands in lanes 4 and 6 following 30-minute 
incubation (Figure 6.11 B). In contrast to CMPD 73, however, the production of the hydroxyl 
radical is seen to be essential for CMPD 74 activity as seen by strong inhibition of RNA 
degradation by DMSO (lane 3). 
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Figure 6.11- ROS inhibitor profiling of RNA degradation. Isolated RNA treated with A) 1µM CMPD 
73 for 2hrs, B) 1µM CMPD 74 for 30 mins and C) 10µM 1,10-Phen for 30mins using scavengers of 
various ROS and RNS in the presence of ascorbate. 
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These data indicate that the copper containing CMPD 74 utilises Fenton-like chemistry to 
degrade RNA. Lanes 5 and 7-9 where sodium azide, Trolox, CarboPTO and uric acid were 
used to inhibit singlet oxygen, peroxyl radical, nitric oxide and peroxynitrite production 
respectively, demonstrated no inhibition. 
  
The activity of 1,10-Phen in response to specific ROS scavengers followed a near identical 
profile to that of CMPD 73 following 30-minute incubation (Figure 6.11 C). The production 
of both H2O2 and O2
•- appear to be critical for its ribonuclease mimetic activity (lanes 4 and 6) 
while hydroxyl radical generation is seen to be moderately involved (lane 3). However unlike 
the modest inhibition of CMPD 73 observed, inhibition of singlet oxygen by sodium azide did 
not appear to inhibit degradation (lane 5). Peroxyl radical, nitric oxide and peroxynitrite 
generation were similarly not detected as seen by an absence of inhibition and total RNA 
degradation in lanes7-9. It could be possible to further quantify the described data using 
densitometry to further analyse the degree of inhibition of test compounds in response to ROS 
inhibitors. 
 
 qPCR analysis of RNA damage 
As an initial step to evaluate the impact of the novel compounds on RNA under in cellulo 
conditions we investigated the expression of a panel of four genes commonly used as 
endogenous controls in qPCR experiments (i.e. housekeeping genes, HKGs). Concentrations 
at the IC10 and IC25 were used to minimise any overt globalised toxic effects. 
 
In general each compound resulted in a reduction in the expression of the four HKGs tested, 
although CMPD 74 was consistently more potent (Figure 6.12). However, some anomalies 
were noted, particularly in relation to the response for CMPD73 and the 18S gene where an 
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elevation, rather than a reduction, in expression was noted at the IC25. In further contrast to 
CMPD 73, CMPD 74 decreased the expression of 18S in a concentration-dependent manner 
with IC10 (P>0.05) and significantly for IC25 concentrations. The significant decreases in 18S 
expression despite high expression levels (control Ct 12) may highly suggest that CMPD 74 
robustly interacts with and degrades ribosomal RNA within the cell, however further 




Figure 6.12- Gene expression analysis of GAPDH, 18S, PPIA and PGK1 HKGs isolated from A2780 
cells, in response to treatment of IC10 and IC25 values of CMPD 73 for 24hrs.  Mean control Ct values 
are present in each HKG. Results expressed as fold-change in gene expression relative to control 
conditions (± range of duplicate wells of duplicate biological replicates) (a= P<0.05 compared to 
control, b= P<0.05 compared to IC10 concentration). 
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PPIA is also observed to decrease in expression in a concentration-dependent manner regarding 
both CMPD 73 and 74. PPIA experiences an initial increase at IC10 CMPD 73; however a 
statistically significant decrease follows at IC25. Neither concentration of CMPD 74 is seen to 
be statistically significant regarding decreases in PPIA expression (P≈0.07 for both 
concentrations); however the apparent biological significance cannot be ignored. Similarly 
PGK1 expression is reduced in a concentration dependant manner following treatment with 
both compounds; however reduction by CMPD 74 is significantly more pronounced. Again, 
despite obvious biologically significant reduction of PGK1 expression neither CMPD 73 (P> 
0.2 both concentrations) nor CMPD 74 (IC10 P<0.08, IC25 P<0.15) is seen to be statistically 
significant.  These data demonstrate that a high degree of caution must be applied to the 
interpretation of studies of these and related compounds unless great care has been given to 
demonstrate stability of HKGs used.  
 
To characterise the impact of the parent 1,10-phen on HGK expression, parallel experiments 
were carried out with 1,10-phen (Figure 6.13). However, these were complicated by the 
requirement for relatively large amounts of methanol to enable solubilisation of the compound. 
On average the presence of methanol resulted in a 1.2 cycle increase in the expression of the 
HKGs. The elevation in GAPDH and 18S expression is likely explainable by these changes. 
Expression of some of the genes, however, appeared to be reduced by 1,10-phen above the 
effects of the vehicle, suggesting that under the right conditions 1,10-phen may be able to 





Figure 6.13- Gene expression analysis of GAPDH, 18S, PPIA and PGK1 HKGs isolated from A2780 
cells, in response to treatment of IC10 and IC25 values of 1,10-Phen for 24hrs.  Mean Ct values for 
control and vehicle control are present beneath each HKG. Results expressed as fold-change in gene 
expression relative to vehicle control conditions (± range of duplicate wells of a duplicate biological 
replicates) (*P<0.05 compared to control Ct, **P<0.01 compared to control Ct). 
 
 
 3’:5’ RT-qPCR assay  
Figure 6.14 displays relative changes in the ratio of 3’ amplicon compared to 5’ amplicon 
following treatment of A2780 cells with CMPD 74 for 24hrs at IC10 and IC25 concentrations. 
CMPD 74 at both IC10 and IC25 concentrations appears to modestly increase the 3’:5’ ratio 
relative to control conditions, which is consistent with degree of RNA damage. The ratio at the 
IC25 dose appears to be slightly lower than IC10’s ratio both concentrations are still observed to 
be above the threshold ratio of 1. Furthermore, as PGK1 expression is significantly decreased 





Figure 6.14- 3’:5’ ratio of PGK1 HKG isolated from A2780 cells in response to treatment of IC10 and 
IC25 values of CMPD 74 for 24hrs.  Results expressed as increase in relative 3’ ratio compared to 
control conditions (dotted line) (± range of duplicate wells of an independent experiment) 
 
  
  Differential amplicon size assay 
The principle of the differential amplicon size assay is that there should be less amplification 
of the larger amplicons from a given gene, due to degradation of the transcript and inability to 
maintain amplification during PCR. Thus, for a degraded sample the relative amount of the 
larger amplicon compared to the smallest (i.e. reference) amplicon, should increase resulting 
in an increase in the ratio of large: small. When cells are exposed to the IC25 concentration of 
CMPD74 there is a clear trend towards greater ratios with larger products, which is consistent 
with partial degradation of the larger transcripts (Figure 6.15 B). To further visualise this we 
plotted the size of the product as an indication of “distance from 3’ end” (Figure 6.15 A). There 





Figure 6.15- Differential amplicon size assay of PGK1 HKG mRNA isolated from A2780 cells treated 
with of IC10 and IC25 concentrations of CMPD 74 for 24hrs.  Both A and B are expressed as fold 





The nuclease mimetic activity of novel CMPD 73 and 74 was assessed. It was determined that 
both compounds are potent nuclease mimetics against both plasmid DNA and isolated RNA, 
and that both tests compounds and 1, 10-Phen itself utilise ROS production to exert their 
mimetic activity. Using molecular based in celluo methods evidence of CMPD 74 mediated 
RNase mimetic activity was also seen in a cellular context. 
 
Chemical nuclease activity is often observed in metal-phen coordination compounds. To 
evaluate the capacity of the current compounds to act as nuclease mimetics a series of 
incubations with RNA and DNA as nucleic acid substrates were completed. Previous data has 
shown that analogous compounds lacking the ethereal oxygens (i.e. CMPD19 and CMPD22) 
can act as chemical nucleases, with CMPD22 able to cleave plasmid DNA in the absence of 
ascorbate (Kellett et al., 2011). The current data shows that both CMPD73 and CMPD74 can 
efficiently cleave and degrade plasmid DNA (Figure 6.6). CMPD74 is the more active of the 
two compounds tested and is able to almost completely degrade the plasmid DNA within 30 
minutes, in contrast to the 24 hours required for CMPD73 for a similar extent of degradation. 
Comparison of these data to that of Kellett et al (2011) indicate that the current compounds are 
significantly more active as DNA nucleases, although an added reductant (i.e. ascorbate) is 
required to support activity (in contrast to the copper containing CMPD22) under in vitro 
conditions.  
 
Given the strong DNA cleavage activity of these compounds it is considered of crucial interest 
to evaluate their potential to degrade RNA, the quantitatively dominating nucleic acid in cells. 
Both CMPD73 and CMPD74 were efficient RNAse mimetics and capable of significant 
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degradation of purified mammalian total RNA within two hours (Figure 6.8 and Figure 6.9). 
Interestingly, although requiring ten-fold greater concentration, CuCl2, TDDA-Cu and 1,10-
Phen (i.e. component moieties of the overall complex) were observed to promote the 
degradation RNA (Figure 6.9). Time-course experiments with CMPD74 and 1,10-Phen 
revealed a rapid impact of CMPD74 and a slower but significant RNAse mimetic activity of 
free 1,10-Phen. The activity associated with 1,10-Phen could be eliminated via addition of 
excess EDTA (Figure 6.10 lane 12) consistent with the observations that 1,10-Phen may be 
‘activated’ via chelation of trace metals in solution (Burkitt et al., 1996). These data support 
previous cytotoxicity results indicating an independent effect of 1,10-Phen, likely due to a 
similar mechanism to that uncovered here with regards to metal scavenging (Figure 2.13 page 
90).  
 
The potential to degrade RNA will have a profound effect on the biology of the cell – damage 
to ribosomal RNA would be expected to lead to deleterious effects on ribosome assembly, 
RNA splicing, silencing or translation, ultimately leading to impaired protein synthesis. In 
rapidly growing cells (such as tumours), this would lead to proteotoxic stress (Madden et al., 
2019). This effect would be exacerbated by direct effects on mRNA levels, further decreasing 
the ability of the cell to respond to the toxic insult mediated by the metal-phen compounds. 
The transcription factor Heat Shock Factor 1 (HSF1) has been shown to be a central regulator 
of the ribosomal stress response (Albert et al., 2019). Intriguingly, previous work has shown 
(Nishimura and Dwyer, 1995) that 1,10-Phen can regulate the expression of selected heat shock 
mRNA and proteins, at least in rat cells. 
 
The resulting degradation of intracellular RNA levels and its effects previously discussed 
(stalled ribosome function, RNA splicing, silencing or transcription) offer lucrative avenues 
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for target identification, e.g. via investigation of ER stress. Profiling of the importance of ROS 
for nuclease mimetic activity was investigated using an inhibitor approach, similar to that 
outlined previously in Chapter 4.  
 
Speciation of suspected ROS produced by CMPD 74 was investigated, and results are shown 
in (Figure 6.11 B). The results of the inhibitor profiling approach indicate that under in vitro 
conditions CMPD74-mediated degradation of RNA occurs via Fenton-like chemistry utilising 
ascorbate as a redox catalyst. The total inhibition of CMPD 74 activity when scavengers against 
H2O2, superoxide and the hydroxyl radical were employed (Figure 6.11 B) supports this 
interpretation. It is likely that hydroxyl radical production is the predominant catalyst of RNA 
degradation, and that H2O2 and superoxide production are the vital intermediate steps involved.  
 
Both H2O2 and superoxide are widely reported to be relatively inert as single agents against 
biomolecules such as nucleic acids, and so support the hypothesis that they drive hydroxyl 
radical formation to cause nucleic acid degradation rather than acting as single agents 
(Kalyanaraman, 2013; Santa-Gonzalez et al., 2016). Indeed, we have noted that H2O2 alone is 
unable to induce any form of RNA degradation unless it is combined with CuCl2 as an oxidising 
agent (data not shown).  
 
The formula by which these Fenton reactions generate hydroxyl radicals utilising ascorbate as 
a reductant can be seen in Figure 6.16 formulas (1) to (5), adopted from Zhou, Zhang (et al., 
2016). Ascorbates ability to cycle Cu (II) to Cu (I) can provide copper in both its cupric and 
cuprous forms to generate both H2O2 and superoxide, allowing the production of the hydroxyl 




Figure 6.16- Reduction of copper in the presence of AA and the generation of ROS (Zhou, Zhang et 
al., 2016) 
 
It is interesting to note the significant role that H2O2 played as a rate-limiting factor in the 
catalysis of RNA by CMPD 74. The use of pyruvate to scavenge H2O2 in a cellular setting did 
not yield any significant effects regarding the cytotoxic activity of CMPD 74 (Figure 4.24 page 
153). It is therefore probable that H2O2 acts as a critical yet short lived intermediate essential 
for immediate catalytic activity, but not directly driving cytotoxicity. This hypothesis likely 
holds true regarding both CMPD 73 and 1,10-Phen. The role superoxide plays in CMPD 74 
mimetic activity supports the previous observation that it is essential for total cytotoxicity 
within the cell. 
 
In contrast to CMPD 74, both free 1,10-Phen and CMPD 73 were seen to have limited activity 
against RNA through production of the hydroxyl radical. These results are somewhat odd in 
that both H2O2 and superoxide are essential for the degradation of RNA by both compounds, 
suggesting that similar to CMPD 74, production of hydroxyl radical through Fenton-like 
chemistry would logically present itself as the direct catalytic mechanism of ribonuclease 
activity.   
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Watts, Sarasa, Loge, & Teel (2005) demonstrated that Mn could generate hydroxyl radicals 
from H2O2 through Fenton-like reactions, but these only occurred at much higher catalytic 
concentrations than its iron counterpart, and at a pH below biological relevance (at pH 6.8 no 
generation of hydroxyl radicals were detected). Mn has also been speculated to be less available 
to undergo Fenton reactions than copper or iron due to its higher reduction potential  (Aguirre 
and Culotta, 2012).  The limited impact of DMSO may be linked to formation of mixed 
subpopulations of 1,10-Phen following exchange of the metal centre with environmental ions 
such as copper or iron, before becoming active against the RNA. Since the RNA degrading 
activity of CMPD 73 appears to be slower acting than free 1,10-phen (2hrs for 73 and 0.5 hrs 
for 1,10-Phen) complex dissociation and capture of other ligand metals by 1,10-phen is a 
plausible explanation for the observed data.  
 
This is in line with initial observations of kinetic replacement reactions of transition metals 
with 1,10-Phen. Hoyler and collaborators (1965) demonstrated that Cu-phen complexes 
possess relatively high formation rate constants higher than that of Mn-phen complexes. Cu(II) 
was also demonstrated to be a suitable decomposing ion for Mn-Phen complexes further 
supporting the notion that Mn-phen complexes require dissociation to become active (Holyer 
et al., 1965). Thus Mn-driven Fenton reactions is a less likely cause of RNA degradation.  
 
Finally the variable nature at which DMSO appears to inhibit hydroxyl radical production by 
CMPD 73 and 1,10-Phen may be a result of experimental design. As is seen in Figure 10.3 in 
the appendix the inhibition of hydroxyl radical-mediated degradation of RNA by CMPD 74 is 
greatest following a 30-60min incubation period prior to compound exposure. Longer pre-
incubation with DMSO before the addition of CMPD 73 or 1,10-Phen may serve to efficiently 
inhibit RNA degradation by the hydroxyl radical and demonstrate similar Fenton-like reactions 
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responsible for CMPD 74 activity. Due to government restrictions in light of the Coronavirus 
pandemic conducting this line of investigation was no longer possible.  
 
Neither MnCl2 nor the phen free precursor to CMPD 73 (Mn-TDDA) displayed RNA 
degradation capacity when tested (shown previously). As both free Phen and CMPD 73 display 
near identical ribonuclease profiles, these data support the hypothesis that the overall nuclease 
activity is a combination of free 1,10-Phen (liberated in the context of the experiment) and the 
intact compound. This is supported by data from cell cytotoxicity discussed previously in 
chapter 2. 
 
The weak inhibition of RNA degradation seen in response to treatment with sodium azide 
(NaN3) and CMPD 73 may indicate that the production of singlet oxygen (
1O2) is a contributing 
factor in the degradation of RNA. While reactions utilising 1,10-Phen did not indicate 1O2 
inhibition as seen in Figure 6.11 (C) initial preliminary experiments did yield similar results to 
CMPD 73 regarding 1,10-Phen and NaN3. This may be telling of the variable nature at which 
1,10-Phen cycles catalytic ions to degrade RNA and further support the notion of a 1,10-Phen 
driven mechanisms for CMPD 73.  
 
1,10-Phen is a Polycyclic Aromatic Hydrocarbon, which in some instances have been shown 
to react with oxygen to release 1O2, indicating 
1O2  production could be plausible for 1,10-Phen 
containing compounds (Aubry et al., 2003; You, 2018). However, while 1O2 is a known free 
radical capable of oxidising nucleobases, it is not capable of causing breaks within the 
phosphate backbone of either DNA or RNA. It could be the case that 1O2 is involved in a cyclic 
mechanism with superoxide and H2O2, whereby it is produced as a by-product of Fenton or 
Haber Weiβ chemistry, alongside the hydroxyl radical. 1O2 may then be recycled back into 
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either H2O2 or superoxide to continue propagating the production of ROS capable of cleaving 
the sugar phosphate backbone. Indeed it has been shown by Kramarenko et.al (2006) that 1O2 
can react with ascorbate to generate H2O2. This can be further supported by Takeshita et.al 
(2000), who reported that 1O2 can produce superoxide or H2O2 in the presence of certain 
biomolecules (Takeshita et al., 2000). Therefore, scavenging of 1O2 by NaN3 may serve to 
dampen but not eliminate RNA degradation, as seen by the partial degradation in Figure 6.11 
(C). 
 
However, NaN3 has been reported to possess some scavenger activity towards the hydroxyl 
radical (Girotti, 1998). As NaN3 inhibition is very similar to inhibition in response to DMSO, 
it may be the production of the hydroxyl radical rather than 1O2 that is being detected. As 
1O2 
is incapable of sugar phosphate backbone scission and the hydroxyl radical is capable of such 
scission it may likely be the case.  The fact that these small inhibitory bands were not seen in 
treatments using CMPD 74 may be a result of the high level of catalytic hydroxyl radical 
production in response to the copper element of CMPD 74. As it is speculated that CMPD 73 
relies on 1,10-Phen for catalytic ribonuclease activity it is likely that the production of hydroxyl 
radicals would be at a slower rate as compound disassociation would be required for 1,10-Phen 
to become catalytically active. This could allow any potential scavenging by NaN3.  
 
At a practical level, RNA cleavage capabilities of both compounds will have downstream 
considerations regarding further experimental planning. As well as potential cellular targets, 
activity of these compounds against RNA (in particular mRNA) will have to be considered for 
any gene expression experiments (e.g. qPCR) that will likely be carried out in future, as part of 
a mechanistic approach to determine compound mode of action.  
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The effect that this ROS-mediated ribonuclease activity may have on gene expression studies 
was investigated. The 3’:5’ qPCR-based assay has been used as a tool to determine the quality 
of isolated mRNA that has been subject to treatment with cytotoxic compounds. It was 
therefore applied to determine whether the ribonuclease activity of metal phen compounds 
could significantly compromise the integrity of mRNA to be used in further gene expression 
studies. CMPD 74 was selected as the most likely candidate to test this hypothesis using both 
the 3’:5’ and the amplicon size assays owing to its rapid and potent ribonuclease mimetic 
activity. 
 
Analysis of both methods yielded conflicting results as the standard 3’:5’ assay demonstrated 
both minimal increases in relative ratios and little difference in CMPD 74 concentration. 
Contrasting this the amplicon size assay to detect difference in expression level yielded little 
to no effect following treatment with IC10 concentrations yet observable changes in relative 
ratio following treatment at the IC25 concentration. The inability to observe a significant effect 
using the standard 3’:5’ assay may be a result of primer design with the 5’ primer pair being 
too close in proximity to the 3’ primer pair thereby creating a sensitivity issue in damage 
detection. It may also be related to the requirement to use a minimally toxic concentration to 
ensure that frank cytotoxic effects do not dominate, thus leading to a sensitivity issue. 
Regarding the amplicon size assay it would appear that expressing multiple amplicon products 
as a ratio of the smallest amplicon product may serve as an accurate measure of mRNA integrity 
in response to RNA damaging compounds e.g. metal-phen. However, it should be noted that 
CMPD 74 does have an impact on the expression of PGK1 which is aligned with the findings 
of the 3’:5’ assay, i.e. damage to RNA and reduction in expression.  
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Further to the effects CMPD 74 had on PGK1 expression observed following the 3’:5’ assays, 
multiple HKGs were analysed to determine which if any could be applicable to qPCR-based 
gene expression studies. Global alterations made to the expression of HKGs may also shed 
light on whether metal-phen compounds are affecting the transcription/translation processes as 
a result of nuclease mimetic activity. This would hold particularly true for changes to ribosomal 
18S expression as it would be a direct target of metal-phen compounds. 
 
Interestingly CMPD 73 is observed to have varied effects on gene expression particularly 
regarding the expression of 18S. While initially seen to reduce the expression of GAPDH, PPIA 
and PGK1 CMPD 73 drastically increased 18S expression at higher concentrations 
contradicting previous assumptions it would cause its degradation in a concentration-dependent 
manner. This may indicate that CMPD 73 is not targeting intracellular RNA as previously 
assumed and that reduced expression of the other three HKGs is a result of an alternate target 
over direct RNA degradation. Despite appearing to share many mechanistic properties CMPD 
73 and 1,10-Phen did appear to diverge somewhat in the context of HKG expression. While 
1,10-Phen did appear to reduce the expression of both PPIA and PGK1 its effect was more 
pronounced than CMPD 73 and it is also seen to increase not decrease GAPDH expression. 
Interestingly 1,10-Phen also resulted in an increase in expression of the 18S gene however in 
contrast to CMPD 73 this happened at IC10 concentrations rather than IC25 concentrations seen 
with CMPD 73. IC25 concentrations were then observed to significantly reduce 18S expression 
again in contrast to CMPD 73. This somewhat paradoxical event may be explained by the 
inherent chelative properties possessed by 1,10-Phen.  
 
Kloubert and Rink (2019) demonstrated that the stability of HKG expression can vary 
depending on the availability of zinc, while Yamagami et al., (2018) also demonstrated that 
weakly-chelated magnesium by amino acids aids in RNA stabilisation and folding. As such the 
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chelative properties of 1,10-Phen may in fact enhance RNA stability over RNA degradation at 
lower concentrations, with the ribonuclease-mimetic activity becoming prominent at higher 
concentrations. This could also likely explain the comparable effects seen regarding CMPD 73 
and increased expression of 18S. Similarly compound kinetics may explain these differences. 
CMPD 73 requires a longer incubation period to efficiently degrade RNA (2hrs) while 1,10-
Phen can degrade RNA within 30mins but at concentrations one order of magnitude higher 
(1µM for CMPD 73 vs 10µM 1,10-Phen). Slower kinetic rates may allow the cell to counteract 
RNA degradation caused by the compounds resulting in significantly increased expression of 
RNA and in particular rRNA. However experimental error must not be excluded as a plausible 
explanation for these unexpected results.  
 
Furthermore, the high concentration of MeOH required as a vehicle for both IC10 (1% v/v) and 
IC25 (2.5% v/v) concentrations of 1,10-Phen are seen to increase the expression of all HKGs 
investigated. The increases in expression observed regarding GAPDH and 18S may be a result 
of vehicle effects rather than compound effects. This indicates certain limitations regarding 
compound delivery and solubility and further potential effects on experimental reproducibility. 
As such the significant effects MeOH as a vehicle for 1,10-Phen may also explain the HKG 
expression profiles observed with 1,10-Phen and difference with otherwise comparable CMPD 
73. Furthermore IC10 and IC25 drug concentrations may not be the optimal concentrations at 
which to investigate these effects for any of the test compounds owing to cytotoxic induced 
variability. Optimising compound concentration and more robust experimental replicates may 
serve to overcome the limitations encountered in this study. 
 
In contrast CMPD 74 is seen to cause significant reduction in gene expression of all four HKGs 
with significant reductions seen in 18S expression despite inherently high expression levels (Ct 
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12). These data appear to support the hypothesis that CMPD 74 is capable of degrading 
intracellular RNA and that it may be a possible mechanism of cytotoxic action. CMPD 74s 
higher potency and rapid degradation of RNA may explain why it can reduce 18S expression 
compared to CMPD 73 or 1,10-Phen. Further investigation using multiple alternate HKGs is 
warranted to ensure that these observations operate on a global level throughout the cell and 
are not limited to these specific HKGs. However the significant reductions in 18S expression 
is suggestive of the presence of this effect. If altered expression levels in the larger panel of 
HKGs is detected this may be telling that the metal phen and phen compounds have global 
effects on mRNA expression. This would validate the original hypothesis that cellular RNA is 
a target of metal phen compounds, and that gene expression studies could be compromised as 
a result.  
 
While certain limitations are noted regarding the data described using qPCR to investigate the 
in cellulo effects of these compounds, the combination of in cellulo and ex cellulo analysis do 
demonstrate that ROS-mediated RNase mimetic activity does persist within the cell in a 
biologically significant manner. This is further supported by the fact that ascorbate as an added 
reductant is not required for the effects measured in cellulo indicating that conditions required 
for RNAse mimetic activity are met within the cell. 
 
As such the ribonuclease mimetic activity of these compounds should not be underestimated 
as a potential mechanism of action, particularly with regards to CMPD 74. While more 
experimentation is needed to fully determine the scope at which these compounds target RNA 
within the cell the data described thus far indicates that careful consideration must be taken 
when utilising gene expression and qPCR-based approaches to avoid artefactual and erroneous 
results.
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7. Potential interactions between metal-based drugs and ER 
stress 
 Introduction  
The processes of transcription and translation represent the canonical pathway for protein 
synthesis in the cell, with translation localised to ribosomes, either free or associated with the 
endoplasmic reticulum (ER) membrane, forming the rough ER (Jackson, Hellen and Pestova, 
2010) (Wilson and Doudna Cate, 2012). Ribosomes are composed of a mixture of ribosomal 
RNA (rRNA) and associated proteins. During translation, transcribed mRNA is shuttled from 
the nucleus to the cytosol, where it becomes encapsulated by the small and large ribosomal 
subunits forming a single complex. Transfer RNAs (tRNA) also found in the cytosol are 
adaptor molecules which bind to free amino acids and become incorporated into the ribosome 
forming a polypeptide chain. As the polypeptide grows it is fed into the ER lumen, where it 
immediately begins to be folded and post-translationally modified to become a functional 
protein (reviewed Bravo et al., 2013). The lumen of the ER is rich in calcium which acts as a 
cofactor for many protein folding chaperons such as calreticulin and is both an energy and 
oxidant rich environment, to favour oxidation of cysteine residues required for disulphide bond 
formation (Carreras-Sureda, Pihán and Hetz, 2018). 
 
The majority of polypeptide chains that enter the ER lumen are not successfully folded, and so 
are targeted for degradation through a process known as ER-associated degradation (ERAD) 
(reviewed Hetz & Papa, 2018). ERAD removes misfolded proteins by exporting them into the 
cytosol to undergo ubiquitin-mediated degradation and recycling in the proteasome. The 
clearance of misfolded proteins is an important process in order to maintain ER integrity and 
prevent the ER from experiencing secretory overload with misfolded and non-functional 
proteins (reviewed Ruggiano, Foresti and Carvalho, 2014). Incorporation of misfolded and 
non-functional proteins into cell structures and pathways could have detrimental effects to the 
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cell. This is seen in many diseases such as Alzheimer’s, diabetes and cancer and underscores 
the need for an efficient mechanism of protein clearance (Scheper and Hoozemans, 2015). 
 
When the cell experiences more severe forms of stress such as hypoxia, oxidative stress, 
starvation, or a loss of calcium homeostasis the resulting accumulation of misfolded proteins 
may overload the ER and induce ER stress. This initiates a separate process of protein clearance 
and is called the Unfolded Protein Response (UPR). The UPR is a dynamic intracellular 
signalling pathway that alleviates ER stress through two distinct mechanisms (reviewed Diehl, 
Fuchs and Koumenis, 2011). Firstly, the UPR causes global translational arrest to prevent 
further overloading of the ER with misfolded proteins, and also increases protein degradation 
through ERAD in order to clear the irregular proteins. Secondly, it initiates a transcriptional 
cascade of hundreds of genes involved in global proteostasis control, such as genes involved 
in maintaining ERAD function, ER chaperone and folding proteins, autophagy, and antioxidant 
defence genes (reviewed Tsai and Weissman, 2010). If the ER experiences prolonged stress 
and is unable to clear the accumulated misfolded proteins, the UPR is then capable of activating 
autophagic and apoptotic cell death to prevent incorporation of irregular proteins into the cell, 
compromising homeostasis. The UPR can therefore be seen as an intersection between adaptive 
and cytotoxic roles within the cell (Sano and Reed, 2013). 
 
Misfolded proteins are typically recognised by a lack of post-translational modifications such 
as glycosylation. Misfolding will also result in the exposure of hydrophobic residues within the 
protein and unpaired cysteines, which are then recognised and bound by quality control 
proteins such as glucose-related protein 78/binding immunoglobulin protein (GRP78/BiP). 
GRP78/BiP is an important ER chaperone which binds misfolded proteins in an attempt to help 
rectify misfolding errors (reviewed Adams et al., 2019). However GRP78/BiP is also the key 
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modulator of the three ER membrane-bound UPR sensory proteins, Inositol requiring enzyme 
1 alpha (IRE1α), Protein kinase RNA-like endoplasmic reticulum kinase (PERK) and 
Activating transcription factor 6 (ATF6). These proteins are negatively regulated by 
GRP78/BiP, which binds their transmembrane receptors found within the ER lumen. 
Disassociation of GRP78/BiP in response to misfolded protein accumulation leads to the 
activation of all three proteins, either through homo/oligo dimerization or translocation from 
the ER (Bergmann and Molinari, 2018; Spaan et al., 2019).  
 
In response to the accumulation of misfolded proteins in the ER lumen, BiP/GRP78 
disassociates from ATF6, IRE1α and PERK UPR regulatory proteins, facilitating activation 
(Casas, 2017). Activated ATF6 translocates from the ER membrane to the Golgi apparatus 
where it is cleaved at specific catalytic sites by serine proteases S1P and S2P releasing ATF6f. 
ATF6f translocates to the nucleus where it regulates the expression of genes involved in ERAD, 
autophagy and ER folding and chaperone proteins (Hillary and FitzGerald, 2018). 
 
Activation of IRE1α results in receptor dimerization and auto trans-phosphorylation. 
Phosphorylated IRE1α dimer possess bi-functional kinase/ribonuclease. The ribonuclease 
domain is capable of alternatively splicing XBP1 mRNA present in the cytosol, removing its 
intron allowing for its translation (Chen and Brandizzi, 2013). The XBP1 protein then 
translocates to the nucleus where it regulates the expression of genes involved ERAD, 
autophagy, ER chaperones and redox homeostasis (Cubillos-Ruiz, Bettigole and Glimcher, 
2016). The ribonuclease domain may also cause what is known as Regulated IRE1-Dependent 
Decay (RIDD) of specific mRNA, rRNA and miRNAs and serves to regulate many important 
biological functions such as UPR signalling itself, inflammation, translation and apoptosis 
(Maurel et al., 2014). The kinase domain of IRE1α is capable of activating apoptotic protein 
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JNK. Sustained activation of JNK by IRE1α signals irreparable ER stress and signals apoptosis 
(Junjappa et al., 2018). Thus JNK activation and RIDD serves as the link between UPR and 
apoptosis (Fribley, Zhang and Kaufman, 2009). 
 
Activated PERK also dimerizes at the ER membrane where it phosphorylates and inhibits 
eukaryotic initiation factor 2 (eIF2α) causing global translational arrest. eIF2α inhibition allows 
for the translation of ATF4 which possesses an upstream open reading frame in its 5’ region 
capable of bypassing translational arrest (McQuiston and Diehl, 2017). Translated ATF4 then 
translocates to the nucleus where it also regulates the expression or ERAD and redox associated 
genes as well as genes involved in autophagy and amino acid metabolism (Pitale, Gorbatyuk 
and Gorbatyuk, 2017). PERK activation has also been seen to promote Nrf2 phosphorylation 
further initiating the antioxidant response network (Cullinan et al., 2003). ATF4 also regulates 
the expression of pro-apoptotic C/EBP Homologous Protein (CHOP). Therefore ATF4 acts in 
similar fashion to IRE1α which under sustained UPR signalling is capable of inducing 
apoptosis (Rozpedek et al., 2016). A full visualisation of the UPR signalling cascade can be 
seen in Figure 7.1. 
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Figure 7.1-Activation of the UPR signalling pathway.  Activation of the UPR signalling pathway. 
Accumulation of misfolded proteins causes BiP/GRP78 disassociation from transmembrane ATF6, 
IRE1α and PERK. Activation of all three UPR signalling pathways results in the increased expression 
of protein chaperones and folding enzymes, as well as autophagy, redox balance. Prolonged activation 
of the UPR pathway will result in IRE1α and PERK-mediated cell death signalling. Self-generated 




Of the three UPR sensory proteins, IRE1α is the most conserved UPR sensor (Hetz and Papa, 
2018). IRE1α is a ubiquitously expressed transmembrane, bi-functional kinase/ribonuclease 
responsible for the expression of the UPRs master regulatory protein, Xbox binding protein 1 
(XBP-1) (Tsuru et al., 2016). 
 
Misfolded proteins in the ER are thought to be subjected to fruitless cycles of aberrant disulfide 
bond formation and reduction, increasing the production of Endoplasmic Reticulum 
Oxireductin-1 (ERO1)-derived H2O2, which would in turn exacerbate ER stress and activate 
UPR signalling. However, the source and nature of ER stress-derived ROS, and whether they 
are ERO1-derived, is not entirely clear (Redza-Dutordoir and Averill-Bates, 2016). 
 
ER stress has been seen to play a dual role in cancer, whereby cancer cells have been seen to 
upregulate the UPR pathway to maintain tumorigenesis by increasing the protein folding 
capacity in response to high proliferative rates (Urra et al., 2016). Cancer cells experience 
higher levels of cellular stress (hypoxia, nutrient depravation, genetic mutations) which can 
often lead to gross accumulation of misfolded and faulty proteins. Therefore cancer cells may 
depend on elevated UPR signalling in order to survive (Kim, Bhattacharya and Qi, 2015). 
Indeed increased UPR signalling and a dependence on PERK, IRE1α and ATF6 signalling has 
been comprehensively reviewed by Walczak et al. (2019). 
 
Furthermore increased UPR signalling may also contribute to chemotherapy resistance by 
initiating cellular stress response and repair pathways clearing damaged proteins or organelles, 
such as the proteasomal or autophagic pathways (Madden et al., 2019). However this state of 
prolonged UPR signalling may sensitise cancer cells overexpressing these pathways to targeted 
intervention/treatment (Ojha and Amaravadi, 2017).  
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Cu-Phen compounds have already been demonstrated to inhibit proteasome function (Zhang et 
al., 2013, 2017), while Mn-Phen have been demonstrated to interact with the autophagic 
pathway (Slator et al., 2017). Proteasome inhibition has been demonstrated to sensitise cancer 
cells to UPR mediated cell death (Amanso, Debbas and Laurindo, 2011), while prolonged 
activation of the autophagic pathway has been known to induce autophagic and apoptotic cell 
death. As such the inherent stress of proteasome inhibition by Cu-Phen compounds and 
induction of autophagy demonstrated by Mn-Phen may be linked by the ribonuclease mimetic 
activity of metal-phen compounds (as discussed in Chapter 6). UPR-mediated cell death may 
therefore be subject to a ‘double hit’ strategy by metal-phen compounds, whereby ribonuclease 
activity induces ribosomal stress and UPR signalling alongside concurrent induction of the 
UPR by proteasome inhibition and autophagic signalling, ultimately favouring UPR-mediated 
cell death (Figure 7.2). 
 
 
Figure 7.2-Potential crosstalk between UPR signalling and inherent metal-phen activity 
 
The UPR pathway can be probed using two well established ER stress inducing agents, the 
antibiotics Anisomycin and Tunicamycin. Anisomycin has been shown to inhibit peptidyl 
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transferase the primary enzyme involved in protein translation which would stall protein 
biosynthesis and induce ER stress mechanisms (Croons et al., 2009).  As well as potent protein 
synthesis inhibition, anisomycin has been shown to induce apoptosis via activation of p38 
mitogen-activated protein kinase pathway in macrophages (ibid).  
 
Tunicamycin is an inhibitor of N-linked glycosylation via inhibition of N-acetylglucosamine-
1 phosphotransferase (Guha et al., 2017). As glycosylation is a major post translational 
modification and is critical for proper protein folding its inhibition will result in the 
accumulation of misfolded proteins in the ER and induction of ER stress. However the effects 
of inhibited glycosylation are not always exclusive to the ER and as such tunicamycin can 
effect multiple pathways reliant on glycoprotein signalling such as cell death (reviewed 




This chapter describes the results of experiments that were aimed at clarifying the downstream 
and intracellular effects of ribonuclease-mimetic CMPD 73, 74 and 1,10-Phen with the UPR 
as a possible mediator of cell death. This will be investigated using the compounds Anisomycin 
and Tunicamycin.  while . Therefore both are well-known inducers of ER stress pathways and 
the UPR. The hypothesis is that if CMPDs 73 or 74 interact with the ER stress/UPR pathways 




 Selective induction of the UPR pathway using UPR inducing compounds 
A549 cells were seeded at a density of 5x103 cells/well and A2780 cells were seeded at a 
density of 1x104 cells/well in a black 96-well plate. For treatments using Anisomycin both 
A2780 and A549 cells were pre-treated for 24hrs with 100nM Anisomycin. Both cell lines 
were then exposed to concentrations of CMPD 73, 74 and 1,10-Phen for a further 24 hrs. Cells 
exposed to Tunicamycin were pre-treated with 5nM for 8hrs before being exposed to 
concentrations of CMPD 73, 74 and 1,10-Phen for 24 hrs. These treatment regimens can be 
seen in Figure 7.3. Both treatments were analysed using the Alamar Blue proliferation assay 
stated in Chapter 2 (section 2.5.1 page 68) and all pre-treatments and incubations were 
conducted at 37°C. 
 
Figure 7.3-Timeline of Anisomycin and Tunicamycin incubation regimes. 
 
 Statistical analysis: 
Data was analysed using Microsoft excel and graphs were generated using GraphPad Prism 
Version 5.00. Statistical analysis was conducted using Students T-Test and are expressed as a 
P Value < 0.05, 0.01, 0.001. for experiments where only one biological replicates were used, 
statistical analysis was conducted using technical replicates of control conditions against 




Pre-treatment of A549 cells with 100nM Anisomycin for 24 hours followed by exposure to 
CMPD73 did not result in any additional cytotoxicity beyond that achieved by the metal-based 
compound alone (Figure 7.4). Anisomycin at a concentration of 100nM reduced A549 cell 
viability by 30%. 
 
Figure 7.4-A549 cells pre-treated with 100nM Anisomycin for 24hrs followed by treatment with 
CMPD 73 for a further 24hrs.  Results are expressed as mean percent viability ±1 Standard deviation 
of a single experiment. Anisomycin at a concentration of 100nM reduced A549 cell viability by 30%. 
 
In contrast, however, a similar experiment with CMPD74, which has potent nuclease activity, 
revealed a significant impact of Anisomycin pre-treatment on cell viability in the high nano 
molar range of CMPD 74. No effect on cell viability is seen by the metal-phen compound 




Figure 7.5-A549 cells pre-treated with 100nM Anisomycin for 24hrs followed by treatment with 
CMPD 74 for a further 24hrs.  Results are expressed as mean percent viability ±1 Standard deviation 
of a single experiment (*P<0.05 compared to control). Anisomycin at a concentration of 100nM 
reduced A549 cell viability by 30%. 
 
Parallel experiments with 1,10-Phen alone revealed a similar effect to that of CMPD74, albeit 
at much higher concentrations Figure 7.6) There is a significant increase in cytotoxicity of 
50µM 1,10-phen in cells pre-treated with 100nM Anisomycin. An observable, but not 
statistically significant effect is noted at the lower 5M concentration of 1,10-Phen.  
 
Figure 7.6-A549 cells pre-treated with 100nM Anisomycin for 24hrs followed by treatment with 1,10-
Phen for a further 24hrs.  Results are expressed as mean percent viability ±1 Standard deviation of 
two independent experiments. (*P<0.05 compared to control, ns=not significant compared to control). 
Anisomycin at a concentration of 100nM reduced A549 cell viability by 30%. 
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Similar experiments using A2780 cells revealed a modest yet highly significant increase in 
cytotoxicity when cells were treated with 500nM and 5µM CMPD73 (Figure 7.7). Anisomycin 




























Figure 7.7-A2780 cells pre-treated with 100nM Anisomycin for 24hrs followed by treatment with 
CMPD 73 for a further 24hrs. Results are expressed as mean percent viability ±1 Standard deviation 
of a single experiment (***P<0.001 compared to control). Anisomycin at 100nM reduced A2780 cell 
viability by 37%. 
 
CMDP 74 also demonstrated a modest yet significant increase in cytotoxicity at a concentration 
of 500nM (Figure 7.8). However a loss of effect is seen at the higher concentration of 5µM 





























Figure 7.8-A2780 cells pre-treated with 100nM Anisomycin for 24hrs followed by treatment with 
CMPD 74 for a further 24hrs.  Results are expressed as mean percent viability ±1 Standard deviation 
of a single experiment (**P<0.01 compared to control). Anisomycin at 100nM reduced A2780 cell 
viability by 37%. 
 
 
A similar pattern is observed with A2780 cells using 1,10-Phen alone with that of CMPD 73 
(Figure 7.9). Modest yet highly significant increases can be seen in both concentrations of 1,10-





























Figure 7.9-A2780 cells pre-treated with 100nM Anisomycin for 24hrs followed by treatment with 
1,10-Phen for a further 24hrs.  Results are expressed as mean percent viability ±1 Standard deviation 
of one experiment. (***P<0.001 compared to control). Anisomycin at 100nM reduced A2780 cell 
viability by 37%. 
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Pre-treatment of A549 and A2780 cells for 8hrs with 5nM Tunicamycin demonstrated similar 
results to Anisomycin pre-treatments. An unexpected increase in viability is observed in 
response to treatment with CMPD 73 indicating modest yet highly significant inhibition by 
Tunicamycin in A549 cells at both 500nM and 5µM (Figure 7.10). Tunicamycin at 5nM 



























Figure 7.10-A549 cells pre-treated with 5nM Tunicamycin for 8hrs followed by treatment with 
CMPD 73 for a further 24hrs. Results are expressed as mean percent viability ±1 Standard deviation 




CMPD 74 experienced a modest yet highly significant increase in cytotoxicity at a 
concentration of 500nM following pre-treatment with Tunicamycin in A549 cells (Figure 




























Figure 7.11-A549 cells pre-treated with 5nM Tunicamycin for 8hrs followed by treatment with 
CMPD 74 for a further 24hrs. Results are expressed as mean percent viability ±1 Standard deviation 
of two independent experiments (*** P<0.001). Tunicamycin at 5nM reduced A549 cell viability by 
40%. 
 
1,10-Phen experienced a similar significant inhibitory effect as CMPD 73 at both 
concentrations used (Figure 7.12). 
 
 
Figure 7.12- A549 cells pre-treated with 5nM Tunicamycin for 8hrs followed by treatment with 1,10-
Phen for a further 24hrs.  Results are expressed as mean percent viability ±1 Standard deviation of 
two independent experiments (*P<0.05, *** P<0.001). Tunicamycin at 5nM reduced A549 cell 
viability by 40%. 
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Parallel experiments using an 8-hour Tunicamycin pre-treatment and 24-hour exposure to the 
CMPD73 revealed a modest yet highly significant increase in cytotoxicity at the 500nM 
concentration in A2780 cells (Figure 7.13). No change in compound cytotoxicity can be seen 
at the 5µM concentration. This is in contrast to the results obtained using the A549 cell model. 



























Figure 7.13-A2780 cells pre-treated with 5nM Tunicamycin for 8hrs followed by treatment with 
CMPD 73 for a further 24hrs.  Results are expressed as mean percent viability ±1 Standard deviation 
of a single experiment. (*** P<0.001). Tunicamycin at a concentration of 5nM reduced A2780 cell 
viability by 35%. 
 
Experiments using CMPD74 demonstrated a small but significant impact on cytotoxicity 
following treatment with 50nM of CMPD74 (Figure 7.14). The magnitude of this effect is 
similar to that of CMPD73. Unexpectedly, at higher concentrations of CMPD74 a significant 
decrease in cytotoxicity is observed in higher concentrations (500nM) of CMPD 74 in 






























Figure 7.14-A2780 cells pre-treated with 5nM Tunicamycin for 8hrs followed by treatment with 
CMPD 74 for a further 24hrs.  Results are expressed as mean percent viability ±1 Standard deviation 
of two independent experiments (*P<0.05, **P<0.01 compared to control). Tunicamycin at a 
concentration of 5nM reduced A2780 cell viability by 35%. 
 
In similarity with the data described above, treatment with 1,10-Phen resulted in an increase in 



























Figure 7.15-A2780 cells pre-treated with 5nM Tunicamycin for 8hrs followed by treatment with 1, 
10-Phen for a further 24hrs.  Results are expressed as mean percent viability ±1 Standard deviation of 
a single experiment (**P<0.01 compared to control). Tunicamycin at a concentration of 5nM reduced 




In a series of pilot experiments, the potential for metal-phen compounds to interact with the 
UPR pathway was assessed. The ability for metal-phen compounds to cause an increase in cell 
cytotoxicity in response to ER stress and UPR inducing drugs Anisomycin and Tunicamycin 
would implicate this stress response pathway as a target for metal-phen compounds. Overall 
these data indicate that CMPDs 73, 74 and 1,10-Phen interact with both UPR-inducing drugs 
to a modest degree and in a cell type-specific manner. While major changes in cytotoxicity 
were not seen, the modest yet significant enhancement of metal-phen compound efficacy 
suggests that the UPR may play a role in the mechanism of action of the metal-based 
compounds, although it may not be the primary mediator of cell death. 
 
Moráň et al., (2019) demonstrated that a mononuclear di-phenanthroline copper compound 
similar to CMPD 74 has reduced cytotoxic potential in the presence of an ER stress alleviating 
drug tauroursodeoxycholic acid (TUDCA). This data supports observations from this study that 
metal-phen compounds (particularly copper-phen) may be targeting the UPR in a significant 
manner and that biochemically targeting the UPR with ER-stress inducing or alleviating drugs 
is a valid experimental approach. 
 
Both CMPD 73 and 1,10-Phen reacted with Anisomycin and Tunicamycin treatment in cell 
type-specific manners.  In A549 cells the efficacy of 1,10-Phen is modestly yet significantly 
enhanced by Anisomycin with a similar trend observed in A2780 cells indicating that 1,10-
Phen likely interacts with the UPR pathway albeit modestly. CMPD 73s interaction with the 
UPR inducing drugs is highly contextual in relation to the cell type analysed. CMPD 73 did 
not interact with Anisomycin in A549 cells yet experienced modest increases in cytotoxicity 
with a high degree of significance in A2780 cells following Anisomycin treatment. 
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Tunicamycin appeared to inhibit both CMPD 73 and 1,10-Phen activity in A549 cells while 
again modest yet highly significant increases in cytotoxicity were observed in A2780 cells. 
Collectively these data indicate that in similar fashion to 1,10-Phen, CMPD 73 does interact 
with the UPR pathway to a modest degree, however the somewhat contradictory results 
observed between A549 and A2780 cells regarding Tunicamycin pre-treatment is somewhat 
perplexing.  
 
At the current state of knowledge, it is difficult to speculate about the mechanisms for this 
increase in viability. It may be a consequence of the experimental set-up with pre-treatment. 
One potential biological reason is that the treatment with a ribonuclease mimetic may reduce 
the flow of mRNA through the translational machinery, reducing the input of new proteins in 
the ER and thus limiting the scale of the UPR. An alternative approach is that the mechanism 
of action of CMPD73 is dependent on one or more glycoproteins, the concentration of which 
are reduced following Tunicamycin treatment in A549 cells but not A2780 cells. Glycans and 
glycoproteins are involved in the complex regulation of cell fate either promoting or inhibiting 
cell death in a context-dependent manner (reivewed by Lichtenstein and Rabinovich, 2013; 
Seyrek, Richter and Lavrik, 2019). As such alterations to glycosylation status of proteins 
involved in regulating cell death pathways by Tunicamycin could have unexpected effects 
regarding cytotoxic insult by metal-phen compounds. However the exact reasons for these 
effects are outside of the scope of the current work but is an avenue of investigation which 
should be followed in more detail.  
 
CMPD 74 is seen to interact with Anisomycin and Tunicamycin in both cells lines and supports 
the notion that this compound interacts with the UPR stress pathway, possibly due to a 
combination of previously reported proteasome inhibition by copper-phen complexes (Zhang 
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et al., 2017) and (ribo) nuclease mimetic activity. Interestingly higher concentrations of CMPD 
74 appeared to experience a cytoprotective effect similar to that of CMPD 73 following 
treatment with Tunicamycin. However, this inhibition is observed in A2780 cells regarding 
CMPD 74 yet CMPD 73 is inhibited only in A549 cells and is enhanced in A2780 cells 
following Tunicamycin treatment. Many of the reasons for these phenomena have already been 
speculated, and this specific instance of compound inhibition may be a combination of both 
cell type specific effects regarding not just Tunicamycin as previously thought but also 
cytotoxic mechanisms of the compounds in both cell lines.  
 
To fully determine the extent the UPR plays in compound cytotoxicity the implementation of 
a multipronged approach would likely be required. Western blot analysis to detect 
translationally-activated XBP-1 protein would further validate the activation of the UPR 
pathway in response to treatment with metal-phen compounds. This would be further supported 
by the use of inhibitors targeting IRE1α and XBP-1 activity, which could determine whether 
their activity is detrimental to cell death signalling in response to treatment with metal-phen 
compounds.  
 
Inhibitors of the autophagic process would also shed light on whether CMPD 73 shares 
similarities with CMPD 19, its analogous compound already shown to induce autophagic cell 
death (Slator et al., 2017). Sequentially combining both UPR inhibitors with inhibitors of 
autophagy could also shed light on the degree of any potential crosstalk between the two 
pathways in relation to signalling cell death following treatment with CMPD 73. A change in 
cytotoxicity in response to one or both inhibitors would likely determine this. This could also 
apply in regard to CMPD 74 which has been demonstrated in Chapter 4 to be significantly 
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dependant of superoxide generation for cytotoxic effect, superoxide being the master regulator 
of autophagy.  
 
Taken together these results, although preliminary, implicate the UPR pathway in mediating in 
part the effects of novel metal-based phen compounds albeit to a modest degree. Given the 
established ribonuclease mimetic activity, in particular that of CMPD74, the UPR remains a 






8. Overall Discussion 
Metal-based compounds remain a mainstay of many cancer therapies, even in an era of 
precision therapies (Ndagi, Mhlongo and Soliman, 2017). However, acquired resistance to 
such compounds and major toxicity issues have prompted the exploration of alternative metal-
based compounds (ibid).  1,10-Phen has proved to be a versatile scaffold for the development 
of such compounds and a broad array of different compounds has been synthesised over the 
last few decades (Thederahn et al., 1989; McCann et al., 1997; Kellett et al., 2011; Thornton 
et al., 2016). The novel water-soluble 1,10-phenanthroline compounds incorporating 
trioxaundecanedioic acid and copper (CMPD74) or manganese (CMPD73) are the focus of this 
thesis (Figure 8.1).  
 
The key findings of this thesis are that compound dissociation is likely prevalent among both 
compounds and contributes significantly towards the overall cytotoxicity of the compounds, 
with a more significant contribution of 1, 10-Phen mediated cytotoxicity also being 
highlighted. The identification of superoxide dependant cytotoxicity for both test compounds 
and 1, 10-Phen highlights both a more focused mechanisms of action and further supports 1, 
10-Phens overall contribution towards compound cytotoxicity. Finally evidence of intracellular 





Figure 8.1- Chemical structures of CMPD 73 and 74 
 
These novel compounds were synthesised as part of an existing programme of research to 
discover compounds with enhanced cytotoxic action. This thesis explored the efficacy and 
biological mechanisms of CMPD73 and CMPD74, gathering evidence that did not support 
initial hypotheses, identifying potential novel mechanisms of action and expanding our 
understanding of the biological effects of 1,10-Phen based compounds. 
 
Experiments designed to evaluate the baseline cytotoxic action of these compounds uncovered 
evidence for compound dissociation and a resulting complex interplay of compound 
components (pages 77-78, 90). These data indicate that the effect observed in cellulo is likely 
to be due to the action of a few different compounds which together lead to the observed 
cytotoxic effect. Importantly, metal-free 1,10-phen generated a clear dose-dependent cytotoxic 
effect and indeed the presence of 1,10-phen was necessary and sufficient for activity (Figure 
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2.7and Figure 2.8 pages 74-76). This is consistent with the known capacity of 1,10-phen to 
chelate metal ions from aqueous environments which is well established as a key mechanism 
when used as a monotherapy (see McCann et al., 2012 for a detailed review). Recent findings 
by Nunes et al., (2020) further support this observation, where analogous copper-phen 
compound activity was determined to be a consequence of compound dissociation and 
formation of alternate metal-phen complexes were demonstrated to be an active part of the 
overall cytotoxic mechanism. 
 
The mode of cell death was explored using tests for apoptosis, necrosis and, due to the metal-
based nature of these compounds, the less well-studied ferroptosis. Data support apoptosis as 
a terminal mechanism for cell death and there was no indication that ferroptosis played any 
significant role in cell death (Chapter 5). In addition, a technical observation in relation to an 
LDH-based necrosis assay suggested that interaction with intermediate metabolism may 
potentially be involved in cell death, although it was outside the scope of the thesis work to 
explore this aspect. 
 
These data thus support the view that dissociation of compounds leads to the generation of 
various bioactive entities, including 1,10-phen and diverse metal chelates of 1,10-phen with 
environmental metals. However, it should be noted that both CMPD73 and CMPD74 were 
more potent than the 1,10-phen, either alone or in combination with other compound 
components (Figure 2.7 and Figure 2.8). This activity was present in multiple cellular models, 
indicating a wide applicability. The observed effects are thus most likely an ‘ensemble effect’ 
of multiple chemical entities that may or may not have overlapping mechanisms of action. 
Despite these complexities, the efficacy of these compounds did not appear to be impaired in 
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cisplatin-resistant cell models. This is a significant advantage of these compounds, but 
additional studies (e.g. in vivo) would be required. 
 
As the chemical nuclease activity of 1,10-phen-based compounds against DNA is well 
described (Kellett et al., 2011; Molphy et al., 2015), and also present in these novel compounds 
(Figure 6.6 page 213), an initial goal was to explore methods to enhance this activity (and hence 
cytotoxicity), mainly via supporting/promoting access of the compounds to the DNA substrate. 
The hypothesis was that if genomic DNA damage were the primary factor in cytotoxic action, 
then compounds that make DNA more accessible (e.g. HDACi) would enhance action of the 
compounds (Figure 8.2). Although the compounds demonstrated clear in vitro DNase mimetic 
activity, pre- and/or co-treatment with different chromatin modifying agents under different 
experimental conditions had minimal impact on observed cytotoxicity. This was in contrast to 
cisplatin, a known DNA damaging agent, where a significant increase of efficacy was noted, 
such that the resistant cells became sensitive to cisplatin (Table 3.6).  
 
These data prompted the investigation of RNA as a substrate for the nuclease mimetic activity 
of the novel compounds. Surprisingly both CMPD73 and CMPD74 efficiently degraded RNA 
under in vitro conditions and, based on initial evidence presented in this thesis, in a cellular 
context. Gel-based degradation assays revealed that CMPD74 was capable of driving 
significant RNA degradation in as little as 20 minutes at 1M concentration, making it 
significantly more active than CMPD73. Using a number of different RT-qPCR strategies, 
modest impact on RNA degradation in cellulo was evident. Previous studies, principally in 
yeast, have shown that 1,10-phen can cause transcriptional inhibition (Adams and Gross, 1991) 
at high concentrations (approximately 500 M). However, the low concentrations used for cell 
experiments argues against this as a primary driver of our observations, although it is not 
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possible to rule out some contribution at the current state of knowledge. Although these 
experiments require further replication, taken together the available data from the 3’:5’ assay 
and differential amplicon size assay and the in vitro gel-based degradation assay indicate that 
RNA is a key substrate of nuclease-mimetic activity in the cell. In addition, a metal-dependent 
RNAse activity of 1,10-phen was also observed under in vitro conditions, although requiring 
higher concentrations than CMPD73 or CMPD74 but observably more rapid than CMPD 73. 
Notably, and in support of the idea that 1,10-phen’s activity is dependent on the presence of 
metal ions, addition of EDTA efficiently abrogated the RNAse activity of 1,10-phen alone 
(Figure 6.10). 
 
Numerous metal-based compounds can generate reactive oxygen species (ROS), including 
analogues of the novel compounds under investigation in this thesis. The generation of 
intracellular ROS and their role in the mechanism of action of the novel compounds was 
investigated using flow cytometry and plate-based assays. Each assay revealed an increase in 
total cellular ROS following treatment with CMPD73, CMPD74 and also with 1,10-phen. An 
inhibitor profiling approach, evaluating the impact of a panel of selective inhibitors/blockers 
of different ROS on cytotoxicity, revealed that superoxide was a key mediator of cell death, 
although some differences were observed between the compounds (Figure 4.23-Figure 4.25 
pages 152-154).  
 
This observation argues against significant intracellular superoxide dismutase mimetic-activity 
by CMPD73 or CMPD74, as this activity would degrade superoxide and form hydrogen 
peroxide. As there was a limited impact of sodium pyruvate, a well-established scavenger of 
hydrogen peroxide and 3-amino-1,2,4-triazol, an inhibitor of catalase, it is evident that any 
such intracellular activity is relatively minor. Parallel ROS scavenger studies of RNAse 
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mimetic activity again revealed the importance of ROS for the RNA degradation activity of the 
compounds. Scavengers of hydrogen peroxide and superoxide blocked RNAse mimetic-
activity of both CMPD73 and CMPD74, while scavengers of the hydroxyl radical had a greater 
impact on the activity of CMPD74 compared to CMPD73. These data are consistent with that 
from Kellett et al. (2011) who studied the DNAse activity of analogous compounds lacking the 
ethereal groups.  
 
Intriguingly, 1,10-phen was also demonstrated to possess RNAse mimetic activity under in 
vitro conditions. This activity was abolished by EDTA co-treatment indicating that the activity 
was dependent on the chelation of trace metal ions present in the reaction solutions. In addition, 
activity was also lost when ascorbate was not used in the experiments. Inhibitor profiling 
revealed a profile almost identical to that of CMPD73, although some minor differences were 
evident. These data again support the partial dissociation of the compound and the formation 
of novel metal-phenanthroline compounds in solution. While somewhat speculative at the 
current state of knowledge, the rate of action of 1,10-phen compared to that of CMPD73 (Figure 
6.6 and Figure 6.10) suggests that a slow or partial dissociation of CMPD73 is followed by 
release of 1,10-phen and formation of new chelates which contributes to the observable RNAse 
activity. In contrast, the very rapid action of CMPD74 is consistent with direct activity as an 
intact molecular entity. This is in line with initial observations of kinetic replacement reactions 
of transition metals with 1,10-Phen. Hoyler and collaborators (1965) demonstrated that Cu-
phen complexes possess relatively high formation rate constants, higher than that of Mn-phen 
complexes. Cu (II) was also demonstrated to be a suitable decomposing ion for Mn-Phen 
complexes further supporting the notion that Mn-phen complexes require dissociation to 
become active (Holyer et al., 1965). 
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The lack of significant effect of chromatin modifying agents, despite demonstrable DNAse 
activity, requires exploration of other targets and mechanisms of action e.g. RNA driven. 
Importantly, the rank order of RNAse activity is consistent with the cytotoxic action – 
CMPD74 is more potent, by both of these measures, than CMPD73. Cytosolic RNA oxidation 
is thus a novel and viable mechanism which may represent one of the initiating factors in cell 
death, e.g. via promotion of ER stress and its sequelae, including autophagy which ER stress 
and oxidative stress are known to promote (Yan et al., 2015).  
 
We carried out initial experiments to test this hypothesis by combining compound treatment 
with two known inducers of ER stress. There was a modest but significant impact on cell death 
with both CMPD73 and CMPD74, although the effects were cell-dependent. 1,10-phen 
dependent cell death was also impacted in these experiments, again indicating a potential role 
of free 1,10-phen in the effects of the compounds. It was not possible to carry out the reverse 
experiment, i.e. to test the effects of a known ER stress rescuer, tauroursodeoxycholic acid, on 
the efficacy of the novel compounds. Recent data from Moráň and collaborators (2019), 
however, demonstrated that tauroursodeoxycholic acid significantly reduced the cytotoxicity 
of a mononuclear, di-phenanthroline copper compound (similar to CMPD 74) (Moráň et al., 
2019). It will be critical to evaluate the impact of tauroursodeoxycholic acid on the efficacy of 
CMPD73, CMPD74 and indeed 1,10-phen.  
 
The action of the site-1 protease (S1P), an ER resident metalloprotease, is critical for the release 
of the membrane bound activating transcription factor 6 (ATF6), a key transducer of the 
unfolded protein response which regulates ER protein folding (Lebeau et al., 2018). As 1,10-
phen is a known metalloprotease inhibitor, inhibition of its activity by secondary to the 
intracellular dissociation of compounds may lead to additional indirect effects. Analogous 
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compounds have been shown to interact with downstream protein removal mechanisms, i.e. 
the proteasome (Zhang et al., 2013) and autophagy (Slator et al., 2017; Song et al., 2017). It is 
noteworthy that the proteasome regulatory particle lid subunit RPN11 is itself a 
metalloprotease and has been reported to be inhibited by 1,10-phen by several authors (Song 
et al., 2016, 2017). These data again highlight the importance of (partial or full) dissociation 
of the compounds and generation of 1,10-phen within the cell. Indeed, in a recent thesis on the 
generation of metal-folate-phenanthroline complexes, evidence was presented that copper(II) 
phenanthroline, derived from the parent complex during cell treatment, was a specific 
proteasomal inhibitor (Crowley, 2019). 
  
Taken together these data provide insight into the mechanism of action of these novel 
compounds, which add to the growing body of evidence that the overall effect of these 
compounds is a combination of a number of diverse effects (summarised in Figure 8.2). These 
results provide data for a plausible mechanistic model that unifies our observations, and those 
of others, and explains the mode of action of these compounds that is initiated by early RNA 
damage, triggering ER stress and ultimately apoptosis. In addition, the data provided here 
supports ‘ensemble’ modes of action with potentially diverse 1,10-phen based compounds 
influencing their targets with different efficacies, but which together give rise to the observed 
holistic cytotoxic effect. This may be advantageous in the context of therapeutic development 
as it may reduce the potential development of resistance and provide a rationale for future drug 
design. These data provide insights into the general mechanisms of 1,10-phen based 
compounds, opening up new avenues of research and potentially accelerating the translation of 
novel metal-based compounds to the clinic. 
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Figure 8.2- Model of forms of cell death associated with metal-phen compounds.   Original cell death 
pathway (black section): CMPDs 73 and 74 were originally hypothesised to target genomic DNA 
initiating oxidative damage resulting in intrinsic apoptosis. Disproven cell death pathway (red 
section): CMPD 73 and 74 were investigated and shown not to interact with necrotic or ferroptotic 
pathways. Novel cell death pathway(s) (blue): both metal-phen compounds, 1,10-Phen and potential 
“alternate”-phen compounds hypothesised to target RNA and autophagy induction simultaneously 
using superoxide. RNA oxidation results in UPR induction which further stimulates autophagy and 
can include intrinsic apoptosis. Cu-Phen compound-mediated inhibition of the proteasome further 
increases UPR activation alongside Mn-Phen induction of autophagy further amplifying UPR-
Autophagy apoptotic signalling. 
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9. Future perspectives 
This study has explored a variety of different mechanisms through which the selected water-
soluble metal-phen compounds are believed to exert their anti-cancer cytotoxicity while also 
highlighting novel mechanisms which require further examination.  
 
To expand the current knowledge highlighted in this thesis elucidating the specific cellular 
targets of these compounds would further aid their potential clinical development. A 
comprehensive mapping using organelle specific, superoxide sensitive fluorescent probes, both 
chemical and genetically encoded sensors, would determine where in the cell the superoxide 
generated by these compounds taking greatest effect. Probing organelles such as the 
mitochondria (MitoSox-Red), the ER (ER-NACP, Xiao 2018) or the lysosome (HKSOX-2L, 
Lu, Jiao and Yang, 2016) would therefore be of critical importance to define a more focused 
model. A multi-pronged microscopy-based approach implementing multiple fluorophores 
simultaneously, and coupled with time-resolved mapping, would be an important tool to 
highlight both the sequence, site and molecular targets of ROS-mediated cytotoxic events. 
 
The ability to circumvent chemotherapy resistance, in this case towards cisplatin, is 
demonstrated as a significant event regarding future compound development and indicates 
alternative mechanisms of action to that of cisplatin. However fully investigating these 
mechanisms is beyond the scope of this current investigation. Further expanding how these 
compounds escape resistant mechanisms would likely prove to be a fruitful avenue of 
investigation. Comparing gene/protein expression profiles of e.g. sensitive versus resistant cell 
lines would support understanding of the mechanism(s) of action and prompt other 
confirmatory experiments. However, as highlighted throughout this study some caution must 
be taken with regards to RNA-based gene expression analysis. Owing to the technical issues 
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described transcriptomic analysis would likely not be suitable with protein-based methods 
more appropriate. Candidates identified in this way could be confirmed via gain and loss of 
function studies using gene knockdowns and thus potentially identifying routes for synergistic 
treatment. 
 
The implication of the ER stress response as a novel pathway involved in the activity of these 
compounds was an intriguing finding which opens up a completely new line of enquiry. Initial 
studies would evaluate the changes in UPR specific targets (such as activated XBP-1), ER 
stress reporter assays and gene knockdown studies using siRNA. Analogous approaches could 
be applied to autophagy and the proteasome to elucidate potential crosstalk between these 
pathways.   
 
As the potential for mixed populations of metal-phen compounds following compound 
dissociation is highlighted in this study further investigation into the characterisation of these 
compounds will be essential. This will be challenging but it is an essential step in definitively 
proving the hypothesis of multiple compounds.  
 
ICP-MS would be an essential tool for the investigation of these complexes. Studies conducted 
in parallel using sub-cellular fractionation coupled with mass spectrometry could further 
identify either intact, disassociated or alternate metal-phen complexes. An alternative approach 
would be to use direct imaging mass-spectrometry, which would provide information on both 
the localisation and identity of compounds. Use of isotope-labelled compounds (including 
individual components) would enable tracking of breakdown of the parent compound and 
formation of new compounds.  
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To further expand this line of inquiry the chelative effects that mixed populations of free 1,10-
Phen or 1,10-Phen alone have on intracellular calcium concentrations could be investigated. 
Calcium is a key regulatory signal involved in multiple cell pathways such as ER homeostasis 
and apoptotic signalling in the mitochondria (reviewed Chernorudskiy and Zito, 2017). 
Calcium-based fluorescent probes capable of tracking calcium flux throughout the cell, 
particularly between the ER and mitochondria (a critical apoptotic event), may also be useful 
for determining intracellular signals contributing towards cell death. 
 
To fully determine the degree to which the selected metal-phen complexes target genomic 
DNA if at all, assays detecting DNA damage such as the γH2AX or COMET assay would need 
to be implemented. However it must be ensured that direct DNA damage by the metal-phen 
compounds is detected as opposed to indirect DNA damage resulting from oxidative stress or 
induction of apoptosis. Time course analysis investigating the induction of DNA damage in the 
presence of apoptotic inhibitors would likely serve to determine direct vs indirect DNA 
damage, although interpretation of these effects is likely to be complex. Gene knockdown 
studies targeting DNA damage response pathways or experiments performed in cells deficient 
in damage repair genes (e.g. NER, SSBR and DSBR pathways) would also serve to determine 
how significant DNA as a target is for compound efficacy. 
 
The ribonuclease activity of metal-phen and 1,10-Phen compounds is both a novel and lucrative 
target for these compounds. As such further expanding the research into cytosolic RNA as the 
primary target of compound ribonuclease mimetic activity would further support this 
observation. While qPCR analysis conducted in this study is suggestive of RNA degradation it 
is limited in that it lacks direct confirmation of damaged RNA. Directly detecting oxidised and 
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damaged bases would definitively determine RNA oxidation as a key mechanistic process of 
these compounds. 
 
To investigate this an ELISA assay probing for 8-hydroxyguanosine (8-OHG), the oxidised 
form of guanosine in RNA would be useful to determine whether oxidation of cytosolic RNA 
is occurring in response to treatment with test compounds. To coincide with this further 
research into the effects of metal-phen compounds on have on reporter mRNA integrity 
required for qPCR analysis could shed further light on the reliability of using this assay to 
determine gene expression analysis in response to metal-phen compounds. Screening a larger 
sample of genes (e.g. via an array or NGS approach) would indicate whether qPCR analysis is 
applicable to studies involving metal-phen compounds and is a necessary first step to identify 
if there are any suitable endogenous control genes.  
 
Furthermore the extent through which ribonuclease mimetic activity could impact on the vast 
number of other species of RNA is yet unknown. Owing to their short strand length and highly 
regulatory nature microRNAs (miRNAs) would be extremely sensitive to degradation by 
metal-phen compounds and degradation could have serious downstream effects regarding cell 
signalling and viability. As miRNAs have been seen to be dysregulated in a variety of cancers 
(Peng and Croce, 2016) investigating their role as a potential target may prove lucrative. 
However certain limitations may arise until qPCR techniques are validated for use with metal-
phen complexes and as such ELISA based approaches similar to assays probing for 8-
hydroxyguanosine (8-OHG) but specific for miRNAs would likely be required. 
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The future perspectives described herein will be fruitful avenues of investigation for years to 
come and likely contribute significantly to the development and understanding of metal-phen 





10.  Appendix 
 
Characterisation of CMPD 73: 
 
{[Mn(3,6,9-tdda)(phen)2]3H2O.EtOH}n 
Molecular Mass: 735.65 g/mol 
Microanalysis (CHN):  
% Calculated: C, 55.5; H, 5.5; N, 7.6 
%Found: C, 52.7; H, 5.2; N, 7.4 
Magnetic moment µeff = 6.0 B.M. 
Infrared spectrum main peaks:  
IR(KBr) Vmax: 3410, 2915, 1625, 1585, 1515, 1425, 1325, 1120, 1075, 845, 730, 635 cm-1  
Solubility: The complex was soluble in water, ethanol and methanol, and insoluble in ethyl 
acetate and acetone. 
 
Characterisation of CMPD 74: 
 
{[Cu(3,6,9-tdda)(phen)2].3H2O.EtOH}n 
Molecular Mass: 744.26 g/mol 
Microanalysis (CHN):  
% Calculated: C: 54.87, H: 5.42, N: 7.53.  
% Found: C: 54.65, H:5.63, N: 7.39  
Magnetic moment µeff = 1.92 B.M. 
Infrared spectrum main peaks:  
IR (KBr) Vmax: 3982, 3415, 3041, 2901, 1989, 1752, 
1618, 1587, 1513, 1421, 1320, 1252, 1221, 1121, 1090, 1077, 1011, 
934, 893, 847, 770, 720, 704, 643, 619, 603, 573, 555, 507, 426 cm−1 
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 Solubility: The complex was soluble in water, ethanol and methanol, and insoluble in ethyl 





Figure 10.1- An example image of Multiple T-Test analysis from GraphPad Prism 8 testing statistical 
significance of each concentration of the intact CMPD 73 vs 1,10-Phen at the same concentration to 
generate a P value. Each combination of CMPD 73 component compounds were then analysed in 
identical fashion to 1,10-Phen to determine individual P values for each concentration tested 




Figure 10.2- An example image of Multiple T-Test analysis from GraphPad Prism 8 testing statistical 
significance of each concentration of the intact CMPD 7 vs 1,10-Phen at the same concentration to 
generate a P value. Each combination of CMPD 74 component compounds were then analysed in 
identical fashion to 1,10-Phen to determine individual P values for each concentration tested 






Figure 10.3- Isolated RNA exposed to CMPD 74 and DMSO at various pre-incubation times (Lanes 
3-4 0min, lanes 5-6 30mins, lanes 7-8 60mins) in presence of ascorbate. Inhibition of CMPD 74 
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